Criteria for the classification of monoclonal gammopath disorders: a report of the International Myeloma Worki

British Journal of Haematology

121, 749-757

DOI: 10.1046/j.1365-2141.2003.04355.x

Citation Report

#	Article	IF	Citations
1	ecancermedicalscience. Ecancermedicalscience, 2013, 7, 331.	0.6	2
2	Diagnosis of multiple myeloma. Seminars in Oncology, 2002, 29, 2-4.	0.8	6
4	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-398.	2.0	374
5	A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thrombosis and Haemostasis, 2004, 92, 1438-1445.	1.8	61
6	PROTEIN PRECIPITATION AS A POSSIBLE IMPORTANT PITFALL IN THE CLINICAL CHEMISTRY ANALYSIS OF BLOOD SAMPLES CONTAINING MONOCLONAL IMMUNOGLOBULINS: 2 CASE REPORTS AND A REVIEW OF THE LITERATURE. Acta Clinica Belgica, 2004, 59, 263-273.	0.5	65
7	Genetics and Cytogenetics of Multiple Myeloma. Cancer Research, 2004, 64, 1546-1558.	0.4	642
8	Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. British Journal of Haematology, 2004, 126, 475-486.	1.2	90
9	Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia, 2004, 18, 1879-1882.	3.3	73
10	Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. European Journal of Haematology, 2004, 73, 402-406.	1.1	114
12	Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein. Annals of Hematology, 2004, 83, 658-60.	0.8	4
13	Pneumococcemia as the presenting feature of multiple myeloma. American Journal of Hematology, 2004, 77, 277-281.	2.0	23
14	Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer, 2004, 101, 558-566.	2.0	170
15	Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years Later. Mayo Clinic Proceedings, 2004, 79, 859-866.	1.4	165
16	Clinical Course of Patients With Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2004, 79, 867-874.	1.4	319
17	Multiple Myeloma. New England Journal of Medicine, 2004, 351, 1860-1873.	13.9	1,291
18	New treatment strategies for multiple myeloma. Seminars in Hematology, 2004, 41, 2-8.	1.8	11
19	Non-secretory Multiple Myeloma with Azurophilic Granules and Vacuoles: An Immunological and Ultrastructural Study. Internal Medicine, 2004, 43, 590-594.	0.3	4
21	SSX Cancer Testis Antigens are Expressed in Most Multiple Myeloma Patients. Journal of Immunotherapy, 2005, 28, 564-575.	1.2	53

#	Article	IF	Citations
22	MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management. Hematology American Society of Hematology Education Program, 2005, 2005, 340-345.	0.9	75
23	Gastric Relapse of Solitary Bone Plasmacytoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 325-326.	0.6	3
24	Radiologic Findings in Primary Pulmonary Plasmacytoma. Journal of Thoracic Imaging, 2005, 20, 53-54.	0.8	11
25	Serum Levels of Free Light Chain before and after Chemotherapy in Primary Systemic AL Amyloidosis. Internal Medicine, 2005, 44, 428-433.	0.3	24
26	Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood, 2005, 105, 4836-4844.	0.6	61
27	The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood, 2005, 106, 167-174.	0.6	172
28	Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival. Leukemia Research, 2005, 29, 665-671.	0.4	11
29	Amyloidosis, not myeloma. British Journal of Haematology, 2005, 129, 158-159.	1.2	2
30	Response to Goodman et al.: Amyloidosis, not myeloma. British Journal of Haematology, 2005, 129, 159-160.	1.2	0
31	Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology, 2005, 129, 776-783.	1.2	378
32	Diagnostic criteria for monoclonal B-cell lymphocytosis. British Journal of Haematology, 2005, 130, 325-332.	1.2	360
33	Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia, 2005, 19, 449-455.	3.3	83
34	Solitary plasmacytoma of the sacrum. Clinical Imaging, 2005, 29, 426-429.	0.8	5
35	Autologous stem cell transplantation in patients with high-risk plasmacytoma. European Journal of Haematology, 2005, 74, 402-406.	1.1	15
36	Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. European Journal of Haematology, 2005, 75, 376-383.	1.1	61
37	Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. American Journal of Hematology, 2005, 78, 288-294.	2.0	71
38	Calcaneus involvement by multiple myeloma. American Journal of Hematology, 2005, 80, 311-312.	2.0	5
39	Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma. Annals of Hematology, 2005, 84, 19-24.	0.8	7

#	Article	IF	Citations
40	Novel therapy in multiple myeloma. Investigational New Drugs, 2005, 23, 411-415.	1.2	7
41	Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. Journal of Pathology, 2005, 205, 92-101.	2.1	124
42			

#	Article	IF	Citations
59	Risk Stratification of Patients with Newly Diagnosed Multiple Myeloma: Optimizing Treatment Based on Pretreatment Characteristics. Clinical Lymphoma and Myeloma, 2005, 6, 200-207.	1.4	6
60	Multiple myeloma: clinical features and indications for therapy. Best Practice and Research in Clinical Haematology, 2005, 18, 553-568.	0.7	59
61	Conventional therapy and approach to management. Best Practice and Research in Clinical Haematology, 2005, 18, 585-601.	0.7	6
62	Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood, 2005, 106, 812-817.	0.6	557
63	Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2006, 355, 2765-2770.	13.9	97
64	Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Expert Review of Anticancer Therapy, 2006, 6, 1769-1785.	1.1	22
65	In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1921-1931.	0.6	11
66	IgM multiple myeloma: Report of four cases and review of the literature. Leukemia and Lymphoma, 2006, 47, 1565-1569.	0.6	22
68	Myelomaâ€Related Disorders in Cats Commonly Present as Extramedullary Neoplasms in Contrast to Myeloma in Human Patients: 24 Cases with Clinical Followâ€up. Journal of Veterinary Internal Medicine, 2006, 20, 1376-1383.	0.6	47
69	Monoclonal Gammopathy of Undetermined Significance, WaldenstrÃ¶m Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment. Mayo Clinic Proceedings, 2006, 81, 693-703.	1.4	181
70	Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma. Mayo Clinic Proceedings, 2006, 81, 889-895.	1.4	100
71	Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays. Mayo Clinic Proceedings, 2006, 81, 1575-1578.	1.4	179
72	Prevalence of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2006, 354, 1362-1369.	13.9	1,135
73	Acute renal failure caused by renal infiltration by hematolymphoid malignancy. Annals of Diagnostic Pathology, 2006, 10, 230-234.	0.6	30
74	Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Annals of Diagnostic Pathology, 2006, 10, 263-268.	0.6	26
75	Biology and Treatment of Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2006, 12, 81-86.	2.0	10
76	Conventional diagnostics in multiple myeloma. European Journal of Cancer, 2006, 42, 1510-1519.	1.3	72
77	State of the art therapy in multiple myeloma and future perspectives. European Journal of Cancer, 2006, 42, 1591-1600.	1.3	30

#	Article	IF	Citations
78	Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. European Journal of Cancer, 2006, 42, 1671-1683.	1.3	60
79	Plasma cell dyscrasias and leukemias. Update on Cancer Therapeutics, 2006, 1, 539-567.	0.9	0
80	Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thrombosis and Haemostasis, 2006, 95, 924-930.	1.8	73
81	Comparison of Serum Beta 2-Microglobulin and 24 hour Urinary Creatinine Clearance as a Prognostic Factor in Multiple Myeloma. Journal of Korean Medical Science, 2006, 21, 639.	1.1	8
82	Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. Hematology American Society of Hematology Education Program, 2006, 2006, 338-347.	0.9	15
85	Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 2006, 107, 4907-4916.	0.6	992
86	Clinical implication of centrosome amplification in plasma cell neoplasm. Blood, 2006, 107, 3669-3675.	0.6	90
87	Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood, 2006, 108, 2013-2019.	0.6	88
88	Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood, 2006, 108, 1661-1667.	0.6	79
90	European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Journal of the Peripheral Nervous System, 2006, 11, 9-19.	1.4	51
91	European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society*. European Journal of Neurology, 2006, 13, 809-818.	1.7	58
92	HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Multiple Myeloma in Endâ€Stage Renal Disease. Seminars in Dialysis, 2006, 19, 329-334.	0.7	17
93	Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. British Journal of Haematology, 2006, 132, 155-161.	1.2	39
94	Guidelines on the diagnosis and management of multiple myeloma 2005. British Journal of Haematology, 2006, 132, 410-451.	1.2	234
95	Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia. British Journal of Haematology, 2006, 133, 301-304.	1.2	23
96	Fracture risk in patients with monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2006, 135, 62-67.	1.2	48
97	Investigation of monoclonal gammopathy of undetermined significance: a single-centre study. International Journal of Laboratory Hematology, 2006, 28, 164-169.	0.2	1
98	International uniform response criteria for multiple myeloma. Leukemia, 2006, 20, 1467-1473.	3.3	2,332

#	Article	IF	Citations
99	Evaluation of a new capillary zone electrophoresis system for the identification and typing of Bence Jones Protein. Clinical Biochemistry, 2006, 39, 152-159.	0.8	12
100	From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. Clinical Rheumatology, 2006, 25, 3-15.	1.0	26
101	Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiology, 2006, 35, 632-640.	1.2	116
102	Multiple myeloma in a murine syngeneic model:modulation of growth and angiogenesis by a monoclonal antibody to kininogen. Cancer Immunology, Immunotherapy, 2006, 55, 797-807.	2.0	12
103	Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Current Treatment Options in Oncology, 2006, 7, 237-245.	1.3	14
104	Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer, 2006, 6, 118.	1.1	164
105	Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vβ2 repertoire. Cancer, 2006, 106, 1296-1305.	2.0	58
106	Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. Hematological Oncology, 2006, 24, 205-211.	0.8	10
107	Pharmacotherapy of multiple myeloma. Expert Opinion on Pharmacotherapy, 2006, 7, 767-781.	0.9	4
108	PET and PET/CT Imaging in Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias. , 2006, , 283-302.		2
109	Serum Free Light Chains in the Diagnosis and Monitoring of Patients with Plasma Cell Dyscrasias. , 2006, 153, 44-65.		17
110	Primary (AL) Amyloidosis in Plasma Cell Disorders. Oncologist, 2006, 11, 824-830.	1.9	28
111	Radiologic Manifestations of Primary Solitary Extramedullary and Multiple Solitary Plasmacytomas. American Journal of Roentgenology, 2006, 186, 821-827.	1.0	89
112	Low CD27 Expression in Plasma Cell Dyscrasias Correlates With High-Risk Disease. American Journal of Clinical Pathology, 2006, 126, 545-551.	0.4	20
113	Hematological malignancies: myeloma. Annals of Oncology, 2006, 17, x136-x143.	0.6	8
114	The Generation and Regulation of Functional Diversity of Malignant Plasma Cells. Cancer Research, 2006, 66, 8608-8616.	0.4	22
115	Multiple Myeloma. Journal of the American Society of Nephrology: JASN, 2006, 17, 2533-2545.	3.0	137
116	Serum Free Light Chains: An Alternative to the Urine Bence Jones Proteins Screening Test for Monoclonal Gammopathies. Clinical Chemistry, 2006, 52, 1743-1748.	1.5	96

#	Article	IF	Citations
117	Non-secretory multiple myeloma with involvement of the hand as initial manifestation. Leukemia and Lymphoma, 2006, 47, 1677-1679.	0.6	1
118	Identification of Two Groups of Smoldering Multiple Myeloma Patients Who Are Either High or Low Producers of Interleukin-1. Journal of Interferon and Cytokine Research, 2006, 26, 83-95.	0.5	41
119	Immunophenotyping of Plasma Cells. Current Protocols in Cytometry, 2006, 36, Unit6.23.	3.7	24
120	Serum Free Light Chain Specificity and Sensitivity: A Reality Check. Clinical Chemistry, 2006, 52, 1638-1639.	1.5	11
121	A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica, 2007, 92, 50-55.	1.7	318
122	Multiple Myeloma: Molecular Imaging with C-Methionine PET/CTâ€"Initial Experience. Radiology, 2007, 242, 498-508.	3.6	105
123	Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Molecular Cancer Therapeutics, 2007, 6, 3256-3262.	1.9	74
124	Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nature Clinical Practice Oncology, 2007, 4, 722-725.	4.3	14
125	Smoldering Multiple Myeloma. New England Journal of Medicine, 2007, 357, 1048-1050.	13.9	0
126	Recommendations for use of Tumor Markers in Monoclonal Gammopathies. Journal of Medical Biochemistry, 2007, 26, 165-172.	0.7	0
127	Monoclonal gammopathy in systemic lupus erythematosus. Lupus, 2007, 16, 426-429.	0.8	50
128	Detection by Immunofixation of M Proteins in Hypogammaglobulinemic Patients With Normal Serum Protein Electrophoresis Results. American Journal of Clinical Pathology, 2007, 127, 746-751.	0.4	16
129	Hyperdiploidy Is a Common Finding in Monoclonal Gammopathy of Undetermined Significance and Monosomy 13 Is Restricted to These Hyperdiploid Patients. Clinical Cancer Research, 2007, 13, 6026-6031.	3.2	39
130	Multiple myeloma: causes and consequences of delay in diagnosis. QJM - Monthly Journal of the Association of Physicians, 2007, 100, 635-640.	0.2	124
131	Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. Journal of Clinical Oncology, 2007, 25, 2434-2441.	0.8	329
132	Body Mass Index, Physical Activity, and Risk of Multiple Myeloma. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1474-1478.	1.1	79
133	Successful Treatment of Extramedullary Plasmacytoma of the Carvenous Sinus Using a Combination of Intermediate Dose of Thalidomide and Dexamethasone. Acta Haematologica, 2007, 117, 20-23.	0.7	15
134	Acquired Fanconi Syndrome with Osteomalacia Secondary to Monoclonal Gammopathy of Undetermined Significance. Internal Medicine, 2007, 46, 241-245.	0.3	11

#	Article	IF	Citations
137	Multiple Myeloma: Most Common End-Organ Damage and Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 170-178.	2.3	15
138	Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood, 2007, 109, 1103-1112.	0.6	154
139	4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4. Blood, 2007, 109, 2089-2099.	0.6	31
140	Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood, 2007, 109, 1228-1232.	0.6	78
141	Treatment for IgG and IgA paraproteinaemic neuropathy. , 2007, , CD005376.		17
142	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings, 2007, 82, 323-341.	1.4	143
143	Chest Pain, Dyspnea, and Fatigue in a 57-Year-Old Man. Laboratory Medicine, 2007, 38, 543-548.	0.8	0
144	Medical management update: Multiple myeloma. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2007, 103, 599-609.	1.6	36
146	Primary extramedullary plasmacytoma in retroperitoneum: CT and integrated PET/CT findings. European Journal of Radiology Extra, 2007, 62, 57-61.	0.1	4
147	Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Biology of Blood and Marrow Transplantation, 2007, 13, 1066-1072.	2.0	40
149	Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Human Pathology, 2007, 38, 1779-1787.	1.1	55
150	Epidemiology of the plasma-cell disorders. Best Practice and Research in Clinical Haematology, 2007, 20, 637-664.	0.7	109
151	Advances in the treatment of multiple myeloma in patients with chromosome 13 abnormalities. Community Oncology, 2007, 4, 137-140.	0.2	0
152	Mieloma no secretor. Gaceta Medica De Bilbao, 2007, 104, 129-130.	0.0	3
153	Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana. Mayo Clinic Proceedings, 2007, 82, 1468-1473.	1.4	142
154	Solitary plasmacytoma of bone in two successfully treated cats. Journal of Feline Medicine and Surgery, 2007, 9, 72-77.	0.6	10
155	Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. New England Journal of Medicine, 2007, 356, 2582-2590.	13.9	740
156	Managing plasma cell leukemia. Leukemia and Lymphoma, 2007, 48, 5-6.	0.6	17

#	Article	IF	Citations
157	Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leukemia and Lymphoma, 2007, 48, 1423-1425.	0.6	31
158	Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Hematology/Oncology Clinics of North America, 2007, 21, 1093-1113.	0.9	49
159	New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood, 2007, 110, 2586-2592.	0.6	447
160	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings, 2007, 82, 323-341.	1.4	155
161	Urine proteomics: the present and future of measuring urinary protein components in disease. Cmaj, 2007, 177, 361-368.	0.9	183
162	Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood, 2007, 109, 2100-2105.	0.6	117
165	Current Treatment Strategies for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, S139-S144.	1.4	8
166	Genetic events in the pathogenesis of multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 571-596.	0.7	154
167	Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation. Best Practice and Research in Clinical Haematology, 2007, 20, 665-680.	0.7	42
168	Monoclonal Proteinuria as a Prognostic Factor for Multiple Myeloma Patients with Intact Immunoglobulin Type. The Korean Journal of Hematology, 2007, 42, 276.	0.7	0
169	Multiple myeloma: A review of the epidemiologic literature. International Journal of Cancer, 2007, 120, 40-61.	2.3	265
170	Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964â€“2003. International Journal of Cancer, 2007, 121, 2260-2266.	2.3	104
171	Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer, 2007, 109, 2285-2290.	2.0	79
172	Epidemiology of multiple myeloma in Taiwan. Cancer, 2007, 110, 896-905.	2.0	92
173	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Reviews, 2007, 21, 255-265.	2.8	54
174	Management of multiple myeloma: The changing landscape. Blood Reviews, 2007, 21, 301-314.	2.8	23
175	Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leukemia Research, 2007, 31, 591-598.	0.4	57
176	A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia, 2007, 21, 2046-2049.	3.3	39

#	Article	IF	Citations
177	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology, 2007, 136, 393-399.	1.2	63
178	Guidelines for the use of imaging in the management of myeloma. British Journal of Haematology, 2007, 137, 49-63.	1.2	93
179	Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance. British Journal of Haematology, 2007, 138, 249-252.	1.2	21
180	Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. British Journal of Haematology, 2007, 139, 730-743.	1.2	98
181	Cytogenetic patterns in multiple myeloma after a phase of preceding MGUS. European Journal of Clinical Investigation, 2008, 38, 53-60.	1.7	5
182	Unusual clinical presentation of amyloidosis: Bilateral stenosis of the external auditory canal, hoarseness and a rapid course of cutaneous lesions. International Journal of Dermatology, 2007, 46, 503-504.	0.5	15
183	Multiple Myeloma: Charging Toward a Bright Future. Ca-A Cancer Journal for Clinicians, 2007, 57, 301-318.	157.7	82
184	Amyloid deposition in knee and ankle joints in the course of multiple myeloma. Joint Bone Spine, 2007, 74, 209-211.	0.8	4
185	Plasma cell growth fraction using Kiâ€67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. European Journal of Haematology, 2007, 79, 297-304.	1.1	31
186	Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma. International Journal of Hematology, 2007, 86, 180-185.	0.7	50
187	PET/CT and MR imaging in myeloma. Skeletal Radiology, 2007, 36, 5-16.	1.2	69
188	Multiple Myeloma Presenting with Malabsorption. Digestive Diseases and Sciences, 2007, 52, 1851-1854.	1.1	2
189	In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrow. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2007, 20, 93-101.	1.1	25
190	Deposition-associated diseases related with a monoclonal compound. Clinical and Translational Oncology, 2007, 9, 777-783.	1.2	1
191	Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy. Clinical Biochemistry, 2007, 40, 351-354.	0.8	14
193	Secondary contributors to bone loss in osteoporosis related hip fractures. Osteoporosis International, 2008, 19, 991-999.	1.3	60
194	Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. Neuroradiology, 2008, 50, 665-674.	1.1	116
195	Cholesterol levels in patients with multiple myeloma. Annals of Hematology, 2008, 87, 223-228.	0.8	58

#	Article	IF	Citations
196	Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Annals of Hematology, 2008, 87, 439-449.	0.8	88
197	ParaproteinÃmien / Multiples Myelom. Wiener Klinische Wochenschrift Education, 2008, 3, 93-105.	0.0	0
198	Thirty patients with primary plasma cell leukemia: a single center experience. Medical Oncology, 2008, 25, 154-160.	1.2	37
199	Extramedullary plasmacytomas in the head and neck region. European Archives of Oto-Rhino-Laryngology, 2008, 265, 1417-1423.	0.8	51
200	Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrology, 2008, 9, 11.	0.8	159
201	Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clinical Pathology, 2008, 8, 13.	1.8	24
202	European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. Trials, 2008, 9, 55.	0.7	90
203	A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer, 2008, 113, 1588-1595.	2.0	163
204	Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma. International Journal of Cancer, 2008, 122, 2871-2875.	2.3	18
205	Solitary plasmacytoma: Is radiation therapy sufficient?. American Journal of Hematology, 2008, 83, 695-696.	2.0	23
206	Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: First reported case. Leukemia Research, 2008, 32, 339-341.	0.4	36
207	Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leukemia Research, 2008, 32, 611-623.	0.4	23
208	Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leukemia Research, 2008, 32, 1153-1156.	0.4	35
210	Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia, 2008, 22, 1767-1772.	3.3	43
211	Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia, 2008, 22, 1651-1657.	3.3	86
212	Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene, 2008, 27, 663-674.	2.6	129
213	Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplantation, 2008, 41, 779-784.	1.3	44
214	The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. Tissue Antigens, 2008, 71, 548-551.	1.0	3

#	Article	IF	Citations
215	More studies are needed to assess the performance of serum free light chain measurement for the diagnosis of Bâ€¢cell disorders in routine clinical practice. British Journal of Haematology, 2008, 143, 143-145.	1.2	25
216	Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal Bâ€¢cell disorder. British Journal of Haematology, 2008, 143, 496-502.	1.2	12
217	Multiple myeloma and systemic amyloidosis. International Journal of Dermatology, 2008, 47, 165-167.	0.5	12
218	Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. European Journal of Haematology, 2008, 80, 503-509.	1.1	4
219	Promoter Hypermethylation of the MEG3 (DLK1/MEG3) Imprinted Gene in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2008, 8, 171-175.	1.4	88
221	IgM-Î» paraproteinemia with associated cutaneous lymphoplasmacytic infiltrate in a patient who meets diagnostic criteria for POEMS syndrome. Journal of the American Academy of Dermatology, 2008, 58, 671-675.	0.6	11
222	In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. Thrombosis Research, 2008, 121, 493-497.	0.8	20
224	Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy. Leukemia and Lymphoma, 2008, 49, 2272-2283.	0.6	13
225	Role of thalidomide in previously untreated patients with multiple myeloma. Expert Review of Anticancer Therapy, 2008, 8, 1569-1580.	1.1	4
226	MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1285-1290.	3.3	235
227	Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. Journal of Clinical Oncology, 2008, 26, 2737-2744.	0.8	193
228	JAK2V617F-Positive Essential Thrombocythemia and Multiple Myeloma with IGH/CCND1 Gene Translocation Coexist, but Originate from Separate Clones. Acta Haematologica, 2008, 120, 177-181.	0.7	15
229	Investigative Tools for Diagnosis and Management. Hematology American Society of Hematology Education Program, 2008, 2008, 298-305.	0.9	11
230	Epigenetic Silencing of the Tetraspanin CD9 during Disease Progression in Multiple Myeloma Cells and Correlation with Survival. Clinical Cancer Research, 2008, 14, 2918-2926.	3.2	46
231	Quantitation of Serum Free Light Chains in Combination with Protein Electrophoresis and Clinical Information for Diagnosing Multiple Myeloma in a General Hospital Population. Clinical Chemistry, 2008, 54, 1823-1830.	1.5	53
232	Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells. Clinical Cancer Research, 2008, 14, 6081-6091.	3.2	32
233	Plasma Cell Myeloma and Related Disorders. , 2008, , 373-396.		0
234	Current Trends in Multiple Myeloma Management. Journal of International Medical Research, 2008, 36, 371-386.	0.4	5

#	Article	IF	Citations
235	Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples. American Journal of Clinical Pathology, 2008, 130, 141-145.	0.4	15
236	Peripheral Blood Dendritic Cell Subsets from Patients with Monoclonal Gammopathies Show an Abnormal Distribution and Are Functionally Impaired. Oncologist, 2008, 13, 82-92.	1.9	21
237	Vertebroplasty in Multiple Myeloma: Outcomes in a Large Patient Series. American Journal of Neuroradiology, 2008, 29, 642-648.	1.2	126
238	The Evaluation of Chronic Axonal Polyneuropathies. Seminars in Neurology, 2008, 28, 133-151.	0.5	13
239	Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica, 2008, 93, 459-462.	1.7	62
240	Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. Haematologica, 2008, 93, 791-792.	1.7	34
241	Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica, 2008, 93, 623-626.	1.7	79
242	Systemic AL Amyloidosis Mimicking Rheumatoid Arthritis. Internal Medicine, 2008, 47, 1133-1138.	0.3	25
243	Long-term Follow-up of Plasma Cells in Bone Marrow and Serum Free Light Chains in Primary Systemic AL Amyloidosis. Internal Medicine, 2008, 47, 1783-1790.	0.3	11
244	Multiple Myeloma and Immunosecretory Disorders. Advances in Anatomic Pathology, 2008, 15, 196-210.	2.4	21
245	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood, 2008, 111, 785-789.	0.6	355
246	SMM: toward better predictors of progression. Blood, 2008, 111, 479-480.	0.6	0
247	AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 2008, 112, 4009-4016.	0.6	73
248	Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood, 2008, 112, 3582-3586.	0.6	170
249	Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood, 2008, 112, 3122-3125.	0.6	90
250	Validation of PDGFRÎ² and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood, 2008, 112, 1346-1356.	0.6	99
251	FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica, 2008, 93, 1269-1271.	1.7	70
252	A 37-year-old Man Presenting with a Chief Complaint of Numbness in Both Hands. The Journal of the Japanese Society of Internal Medicine, 2008, 97, 479-480.	0.0	0

#	Article	IF	Citations
253	Therapeutic Outcome of Cyclic VAD (Vincristine, Doxorubicin and Dexamethasone) Therapy in Primary Systemic AL Amyloidosis Patients. Internal Medicine, 2008, 47, 1517-1522.	0.3	8
254	A 37-year-old Man Presenting with a Chief Complaint of Numbness in Both Hands. The Journal of the Japanese Society of Internal Medicine, 2008, 97, 457-458.	0.0	0
255	DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT OF SOLITARY PLASMACYTOMA. , 0, , 150-163.		0
256	MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND SMOLDERING MULTIPLE MYELOMA. , 0, , 164-181.		0
257	99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS. Nuclear Medicine Communications, 2008, 29, 535-541.	0.5	9
258	The lymphomas and myeloma. , 0, , 347-369.		0
260	A Case of Cardiac Dysfunction Associated with Monoclonal Gammopathy of Undetermined Significance. Journal of Korean Medical Science, 2009, 24, 354.	1.1	1
262	A Case of Multiple Myeloma Associated with Multifocal Osteosclerosis (Multiple Myeloma with) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	2
263	Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance. Haematologica, 2009, 94, 1179-1181.	1.7	14
264	Spontaneous Remission in a Patient With t(4;14) Translocation Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, e194-e197.	0.8	4
265	Serum Free Light Chain Ratio, Total Î¹/Î» Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. Clinical Chemistry, 2009, 55, 1510-1516.	1.5	33
266	Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 5001-5007.	0.8	46
267	Insulin-like Growth Factor-1- and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma: Table 1.. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 282-288.	1.1	37
268	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood, 2009, 113, 5412-5417.	0.6	904
269	Serum Protein Electrophoresis: An Underused but Very Useful Test. Digestion, 2009, 79, 203-210.	1.2	74
270	Bone Marrow. , 2009, , 1536-1593.		0
271	Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation. Clinical Cancer Research, 2009, 15, 3118-3125.	3.2	51
272	Quantitation of serum free light chains does not compensate for serum immunofixation only when screening for monoclonal gammopathies. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1109-15.	1.4	8

#	Article	IF	Citations
273	Serum free light chains: diagnostic and prognostic value in multiple myeloma. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1101-7.	1.4	11
274	Screening Panels for Detection of Monoclonal Gammopathies. Clinical Chemistry, 2009, 55, 1517-1522.	1.5	268
275	Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma. Clinical Cancer Research, 2009, 15, 5369-5378.	3.2	91
276	Autologous Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2009, 361, 1118-1119.	13.9	3
277	Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance. Annals of Medicine, 2009, 41, 547-558.	1.5	4
278	Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Importance of Whole-Body versus Spinal MR Imaging. Radiology, 2009, 252, 477-485.	3.6	113
279	Proposal and Validation of Prognostic Scoring Systems for IgG and IgA Monoclonal Gammopathies of Undetermined Significance. Clinical Cancer Research, 2009, 15, 4439-4445.	3.2	15
280	Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2009, 101, 100-106.	3.0	97
281	Nonsecretory multiple myeloma. Indian Journal of Orthopaedics, 2009, 43, 408.	0.5	17
282	Multiple Myeloma in Chronic Kidney Disease. Nephron Clinical Practice, 2009, 111, c7-c11.	2.3	12
283	Immunophenotype of neoplastic plasma cells in AL amyloidosis. Journal of Clinical Pathology, 2009, 62, 724-730.	1.0	25
284	Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv97-iv99.	0.6	17
285	Unusual Tumors of the Breast. Current Problems in Surgery, 2009, 46, 514-590.	0.6	8
286	Serum concentrations of DKKâ€1 decrease in patients with multiple myeloma responding to antiâ€myeloma treatment. European Journal of Haematology, 2009, 82, 31-38.	1.1	66
287	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. European Journal of Haematology, 2009, 82, 93-105.	1.1	21
288	Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. European Journal of Haematology, 2009, 83, 528-534.	1.1	4
289	Intracranial plasmacytoma mimicking meningioma in a patient with Castleman's disease. American Journal of Hematology, 2009, 84, 195-196.	2.0	10
290	The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. American Journal of Hematology, 2009, 84, 208-214.	2.0	146

#	Article	IF	Citations
291	A possible link between Trousseau's syndrome and tissue factor producing plasma cells. American Journal of Hematology, 2009, 84, 382-385.	2.0	5
292	Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma. American Journal of Hematology, 2009, 84, 809-814.	2.0	23
293	Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. International Journal of Cancer, 2009, 124, 367-375.	2.3	25
294	TGFÎ²R2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. International Journal of Cancer, 2009, 125, 1985-1991.	2.3	48
295	Primary plasma cell leukemia. Cancer, 2009, 115, 5734-5739.	2.0	74
296	Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer, 2010, 116, 84-92.	2.0	18
297	Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes and Cancer, 2009, 48, 624-636.	1.5	65
298	Construction of A Multiple Myeloma Diagnostic Model by Magnetic Beadâ€Based MALDIâ€TOF Mass Spectrometry of Serum and Pattern Recognition Software. Anatomical Record, 2009, 292, 604-610.	0.8	38
299	Multiple Myeloma. Current Problems in Cancer, 2009, 33, 7-64.	1.0	64
300	18F-FDG-PET findings of rare case of nonsecretory plasmablastic myeloma. Annals of Nuclear Medicine, 2009, 23, 807-811.	1.2	3
301	A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: Î²2-microglobulin associated with time to progression. International Journal of Hematology, 2009, 89, 342-347.	0.7	9
302	Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. International Journal of Hematology, 2009, 89, 259-268.	0.7	31
303	Protein-losing gastroenteropathy: unusual presentation of multiple myeloma. Annals of Hematology, 2009, 88, 705-707.	0.8	0
304	Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Annals of Hematology, 2009, 88, 1161-1168.	0.8	120
306	Extramedullary myeloma in an HIV-seropositive subject. Literature review and report of an unusual case. Head & Face Medicine, 2009, 5, 4.	0.8	12
307	Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992â€“2004. British Journal of Haematology, 2009, 144, 86-94.	1.2	220
308	Longâ€term followâ€up of a population based cohort with monoclonal proteinaemia. British Journal of Haematology, 2009, 144, 176-184.	1.2	19
309	AL amyloidosis and progression to multiple myeloma with gain(1q). British Journal of Haematology, 2009, 144, 963-964.	1.2	9

#	Article	IF	Citations
310	UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected Mâ€proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology, 2009, 147, 22-42.	1.2	116
311	Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 2009, 23, 3-9.	3.3	1,000
312	Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia, 2009, 23, 2139-2146.	3.3	38
313	International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia, 2009, 23, 1545-1556.	3.3	428
314	Radiotherapy for Extramedullary Plasmacytoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2009, 73, 789-794.	0.4	86
315	Plasma cell neoplasms. Diagnostic Histopathology, 2009, 15, 134-141.	0.2	2
316	Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leukemia Research, 2009, 33, 1475-1480.	0.4	75
317	The incidental monoclonal protein: Current approach to management of monoclonal gammopathy of undetermined significance (MGUS). Blood Reviews, 2009, 23, 257-265.	2.8	15
318	The impact of extramedullary disease at presentation on the outcome of myeloma. Leukemia and Lymphoma, 2009, 50, 230-235.	0.6	97
319	Amyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 226-231.	1.4	17
320	Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica, 2009, 94, 1599-1602.	1.7	92
321	Whole-body MRI of multiple myeloma: Comparison of different MRI sequences in assessment of different growth patterns. European Journal of Radiology, 2009, 69, 339-345.	1.2	40
322	Imaging in multiple myeloma. European Journal of Radiology, 2009, 70, 401-408.	1.2	77
323	SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. Cancer Letters, 2009, 278, 41-48.	3.2	51
324	Triple MEL100 Therapy in Multiple Myeloma. Transplantation Proceedings, 2009, 41, 3863-3867.	0.3	1
326	IgM Monoclonal Gammopathy of Undetermined Significance and Smoldering WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 17-18.	1.4	50
327	Novel Aspects Pertaining to the Relationship of WaldenstrÃ¶m's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 19-22.	1.4	25
328	Treatment of Multiple Myeloma: A Comprehensive Review. Clinical Lymphoma and Myeloma, 2009, 9, 278-288.	1.4	135

#	Article	IF	Citations
329	Serum Levels of Total-RANKL in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2009, 9, 430-435.	1.4	24
330	Frontal skull craniotomy combined with moderate-dose radiotherapy effectively ameliorate a rare case of non-secretory, multiple myeloma with orbital involvement. World Journal of Surgical Oncology, 2009, 7, 86.	0.8	2
331	The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood, 2009, 114, 4369-4372.	0.6	67
332	Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment. Oncologist, 2009, 14, 276-283.	1.9	62
333	Multiple myeloma. Lancet, The, 2009, 374, 324-339.	6.3	685
334	Presumptive increase in proteinâ€bound serum calcium in a dog with multiple myeloma. Veterinary Clinical Pathology, 2009, 38, 87-90.	0.3	10
335	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clinic Proceedings, 2009, 84, 1095-1110.	1.4	389
336	Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1Î²-Induced Interleukin 6 Production and the Myeloma Proliferative Component. Mayo Clinic Proceedings, 2009, 84, 114-122.	1.4	236
337	Plasma Cell Myeloma. Hematology/Oncology Clinics of North America, 2009, 23, 709-727.	0.9	21
338	Plasma Cell Leukemia Maintaining Complete Remission by Syngeneic Stem Cell Transplantation Combined with Low-Dose Thalidomide Maintenance Therapy. Internal Medicine, 2009, 48, 1833-1835.	0.3	3
339	The significance of monoclonal gammopathy of undetermined significance. Haematologica, 2009, 94, 1641-1644.	1.7	21
340	Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood, 2009, 113, 6386-6391.	0.6	137
341	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood, 2009, 114, 791-795.	0.6	133
342	Hematopoietic Cell Transplantation for Multiple Myeloma. , 0, , 845-859.		0
344	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica, 2009, 94, 1714-1720.	1.7	95
345	Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance. Medicine (United States), 2010, 89, 211-216.	0.4	16
346	Nodal and Extranodal Plasmacytomas Expressing Immunoglobulin A. American Journal of Surgical Pathology, 2010, 34, 1425-1435.	2.1	25
347	A Solitary Pelvic Extramedullary Plasmacytoma. Southern Medical Journal, 2010, 103, 831-833.	0.3	0

#	Article	IF	Citations
348	Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood, 2010, 115, 1185-1193.	0.6	66
349	Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood, 2010, 116, 1056-1059.	0.6	137
350	Kidney disease associated with plasma cell dyscrasias. Blood, 2010, 116, 1397-1404.	0.6	50
351	Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood, 2010, 116, 2019-2025.	0.6	59
352	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood, 2010, 116, 5501-5506.	0.6	308
354	A Rare Masquerader of Lung Cancer: Nonsecretory Multiple Myeloma with Plasmacytoma of Bone Presenting as Acute Kidney Injury. Internal Medicine, 2010, 49, 2133-2135.	0.3	0
355	Myeloma: making sense of a complex blood cancer. British Journal of Nursing, 2010, 19, 1415-1421.	0.3	2
356	PET/CT in primary musculoskeletal tumours: a step forward. European Radiology, 2010, 20, 2959-2972.	2.3	30
357	Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Annals of Hematology, 2010, 89, 391-397.	0.8	50
358	Hyperlipidemic myeloma: review of 53 cases. Annals of Hematology, 2010, 89, 569-577.	0.8	33
359	Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Annals of Hematology, 2010, 89, 579-584.	0.8	14
360	Monoclonal gammopathy of undetermined significance related pyoderma gangrenosum successfully treated with autologous peripheral blood stem cell transplantation. Annals of Hematology, 2010, 89, 823-824.	0.8	7
361	Extramedullary manifestations of multiple myeloma in the thyroid gland and in the lungs: excellent response to therapy. Annals of Hematology, 2010, 89, 1183-1184.	0.8	3
363	Artifactual measurement of low serum HDL-cholesterol due to paraproteinemia. Clinical Research in Cardiology, 2010, 99, 599-602.	1.5	4
364	Antibiotic treatment for bacterial meningitis caused by Listeria monocytogenes in a patient with multiple myeloma. Journal of Infection and Chemotherapy, 2010, 16, 123-125.	0.8	10
366	Methylation status of nine tumor suppressor genes in multiple myeloma. International Journal of Hematology, 2010, 91, 87-96.	0.7	36
367	Uncommon case of chronic myeloid leukemia with multiple myeloma. International Journal of Hematology, 2010, 91, 699-704.	0.7	26
368	Extramedullary plasmacytoma of the dura mimicking meningioma. International Journal of Hematology, 2010, 91, 731-732.	0.7	9

#	Article	IF	Citations
369	Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case. Cancer Genetics and Cytogenetics, 2010, 201, 62-65.	1.0	6
370	New treatments for myeloma. Joint Bone Spine, 2010, 77, 20-26.	0.8	5
371	Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis. Joint Bone Spine, 2010, 77, 120-124.	0.8	23
372	Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. European Journal of Haematology, 2010, 85, 181-191.	1.1	18
373	Betaâ€2â€microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. Cancer, 2010, 116, 2188-2200.	2.0	41
374	Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cellâ€related disorders. Cytometry Part B - Clinical Cytometry, 2010, 78B, 239-252.	0.7	109
375	Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2010, 78B, 338-347.	0.7	28
376	Prevalence, clinical aspects, and natural history of IgM MGUS. Cytometry Part B - Clinical Cytometry, 2010, 78B, S91-7.	0.7	20
377	Longâ€term results of singleâ€agent thalidomide as initial therapy for asymptomatic (smoldering or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.0	24
378	Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry. Arthritis Care and Research, 2010, 62, 1787-1795.	1.5	97
379	Bortezomib Plus Thalidomide for Newly Diagnosed Multiple Myeloma in China. Anatomical Record, 2010, 293, 1679-1684.	0.8	7
380	Gammapathie monoclonale de signification indÃ©terminÃ©e, myÃ©lome multiple et ostÃ©oporose. Revue Du Rhumatisme (Edition Francaise), 2010, 77, 144-148.	0.0	0
382	Monoclonal gammopathy in a tertiary referral hospital. Clinical Biochemistry, 2010, 43, 709-713.	0.8	4
383	European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society â€“ first revision. Journal of the Peripheral Nervous System, 2010, 15, 185-195.	1.4	271
384	Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. British Journal of Haematology, 2010, 148, 110-114.	1.2	102
385	Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells. British Journal of Haematology, 2010, 149, 221-230.	1.2	34
386	Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. British Journal of Haematology, 2010, 149, 334-351.	1.2	88
387	Monoclonal gammopathy of undetermined significance: a consensus statement. British Journal of Haematology, 2010, 150, 28-38.	1.2	95

#	Article	IF	Citations
388	Extramedullary plasmacytoma are characterized by a â€˜myelomaâ€‹â€™ immunophenotype and genotype and occult bone marrow involvement. British Journal of Haematology, 2010, 151, 525-527.	1.2	18
389	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia, 2010, 24, 1121-1127.	3.3	677
390	The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3. Annals of the New York Academy of Sciences, 2010, 1192, 298-302.	1.8	14
391	Blood Disorders in the Elderly. , 2010, , 775-790.		0
392	Robert Arthur Kyle, MD: A Conversation with the Editor. Baylor University Medical Center Proceedings, 2010, 23, 400-418.	0.2	0
393	A Case Study Progression to Multiple Myeloma. Clinical Journal of Oncology Nursing, 2010, 14, 419-422.	0.3	0
394	Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells. American Journal of Clinical Pathology, 2010, 133, 694-699.	0.4	11
395	Staging Monoclonal Plasma Cell Disease: Comparison of the Durie-Salmon and the Durie-Salmon PLUS Staging Systems. Radiology, 2010, 257, 195-204.	3.6	53
396	How to Treat Multiple Myeloma: Thoughts on a Multicentre Survey in Germany. Onkologie, 2010, 33, 577-578.	1.1	0
397	Multiple myeloma. Annals of Oncology, 2010, 21, vii313-vii319.	0.6	37
398	Myeloma and the Kidney. , 2010, , 761-769.		2
399	Multiple Myeloma Precursor Disease. JAMA - Journal of the American Medical Association, 2010, 304, 2397.	3.8	48
400	Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Review of Hematology, 2010, 3, 165-174.	1.0	13
401	Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations. Journal of Clinical Oncology, 2010, 28, 690-697.	0.8	101
402	Multiple myeloma presenting as CEA-producing rectal cancer. Rare Tumors, 2010, 2, 10-11.	0.3	4
403	Role of flow cytometry in multiple myeloma and the prognostic significance of CD87 (uPAR) expression. Turkish Journal of Haematology, 2010, 27, 182-189.	0.2	1
404	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v155-v157.	0.6	51
405	Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology. Hematology American Society of Hematology Education Program, 2010, 2010, 295-302.	0.9	25

#	Article	IF	Citations
406	Renal Insufficiency and Failure. Hematology American Society of Hematology Education Program, 2010, 2010, 431-436.	0.9	28
407	A Patient with Chronic Inflammatory Demyelinating Polyneuropathy Associated with an Intracranial Plasmacytoma. American Journal of Physical Medicine and Rehabilitation, 2010, 89, 173-174.	0.7	0
408	Lenalidomide in multiple myeloma: current role and future directions. Expert Opinion on Pharmacotherapy, 2010, 11, 829-842.	0.9	12
409	Plasma Cell Labeling Index in the Evaluation of Smoldering (Asymptomatic) Multiple Myeloma. Mayo Clinic Proceedings, 2010, 85, 300.	1.4	19
410	Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma. Mayo Clinic Proceedings, 2010, 85, 232-238.	1.4	69
411	Heritability of Hematologic Malignancies: From Pedigrees to Genomics. Hematology/Oncology Clinics of North America, 2010, 24, 939-972.	0.9	9
412	Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review. Mayo Clinic Proceedings, 2010, 85, 933-942.	1.4	180
413	Estudio retrospectivo de 1.193 componentes monoclonales detectados en Palma de Mallorca. Revista Del Laboratorio ClÃnico, 2010, 3, 69-75.	0.1	0
414	Interferencias por contrastes yodados en la electroforesis capilar. Revista Del Laboratorio ClÃnico, 2010, 3, 129-135.	0.1	1
415	Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma. Diagnostic Pathology, 2010, 5, 30.	0.9	34
416	The Current Status and Future of Multiple Myeloma in the Clinic. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 28-43.	0.2	21
417	Comparison Among Immunologically Different Subtypes of 595 Untreated Multiple Myeloma Patients in Northern China. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 197-204.	0.2	9
418	Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 248-257.	0.2	18
419	Beyond the CRAB Symptoms: A Study of Presenting Clinical Manifestations of Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 464-468.	0.2	65
420	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. Journal of Clinical Oncology, 2010, 28, 4976-4984.	0.8	358
421	Approaches to Classification of Lymphoma and Leukemia. , 2010, , 3-20.		1
422	Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance. Human Pathology, 2010, 41, 1702-1710.	1.1	31
423	Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide+Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis. International Immunopharmacology, 2010, 10, 487-492.	1.7	2

#	Article	IF	Citations
424	Multiple myeloma presenting as solitary mass in the posterior fossa. Journal of Clinical Neuroscience, 2010, 17, 1457-1459.	0.8	4
427	Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Practice and Research in Clinical Haematology, 2010, 23, 433-451.	0.7	101
428	Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. European Journal of Cancer, 2010, 46, 420-429.	1.3	65
429	Survival of cancer patients with prior monoclonal gammopathy of undetermined significance. European Journal of Internal Medicine, 2010, 21, 564-568.	1.0	3
430	The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. Thrombosis Research, 2010, 125, 216-219.	0.8	20
431	A large radiolucent lesion of the posterior maxilla. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 110, 423-429.	1.6	6
432	Light-chain MGUS: implications for clinical practice. Lancet, The, 2010, 375, 1670-1671.	6.3	6
433	Presentation and risk stratification â€“ improving prognosis for patients with multiple myeloma. Cancer Treatment Reviews, 2010, 36, S12-S17.	3.4	17
434	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet, The, 2010, 375, 1721-1728.	6.3	313
435	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leukemia and Lymphoma, 2010, 51, 1424-1443.	0.6	49
436	Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma. Journal of Clinical Oncology, 2010, 28, 1606-1610.	0.8	329
437	Extramedullary plasmacytoma with a t(11;14)(q13;q32) and aggressive clinical course. Leukemia and Lymphoma, 2010, 51, 1360-1362.	0.6	3
438	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood, 2011, 117, 4701-4705.	0.6	377
439	Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood, 2011, 118, 2985-2987.	0.6	35
440	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood, 2011, 117, 5573-5581.	0.6	161
441	85-Year-Old Man With Epistaxis. Mayo Clinic Proceedings, 2011, 86, 344-347.	1.4	0
442	Review of Physiologic and Pathophysiologic Sources of Fluorodeoxyglucose Uptake in the Chest Wall on PET. PET Clinics, 2011, 6, 339-364.	1.5	6
443	A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 336-341.	0.2	2

#	Article	IF	Citations
444	Comparison of Skeletal Complications and Treatment Patterns Associated With Early vs. Delayed Zoledronic Acid Therapy in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 326-335.	0.2	4
445	Staging disease with ProtÃ©gÃ© 4: Example of multiple myeloma. Irbm, 2011, 32, 329-331.	3.7	1
446	Multiple Myeloma. Annual Review of Medicine, 2011, 62, 249-264.	5.0	121
447	Ocular manifestations of multiple myeloma: Three cases and a review of the literature. Optometry - Journal of the American Optometric Association, 2011, 82, 224-230.	0.6	43
448	IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering WaldenstrÃ¶m's Macroglobulinemia (SWM). Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 74-76.	0.2	37
449	Factors Predicting Transformation of Asymptomatic IgM Monoclonal Gammopathy. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 77-79.	0.2	11
450	The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 2011, 117, 5019-5032.	0.6	1,681
451	Imaging in Multiple Myeloma. Recent Results in Cancer Research, 2011, 183, 133-147.	1.8	15
452	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Review of Hematology, 2011, 4, 51-60.	1.0	23
453	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews, 2011, 37, 266-283.	3.4	66
454	The presence of amyloid in abdominal and oral mucosal tissues in patients initially diagnosed with multiple myeloma: a pilot study. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2011, 111, 326-332.	1.6	12
455	Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Review of Molecular Diagnostics, 2011, 11, 593-603.	1.5	35
456	Myelomagenesis: Capturing Early Microenvironment Changes. Seminars in Hematology, 2011, 48, 13-21.	1.8	7
457	Role of Flow Cytometry of Peripheral Blood and Bone Marrow Aspirates in Early Myeloma. Seminars in Hematology, 2011, 48, 32-38.	1.8	12
458	Multiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities. Seminars in Hematology, 2011, 48, 1-3.	1.8	8
459	Abnormalities in immunoglobulin synthesizing cells. , 2011, , 451-469.		0
460	Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Man with Fragile X-associated Tremor/Ataxia Syndrome. Case Reports in Genetics, 2011, 2011, 1-5.	0.1	2
461	Amiloidose-mieloma mÃºltiplo apresentando-se como pseudomiopatia. Revista Brasileira De Reumatologia, 2011, 51, 651-654.	0.8	0

#	Article	IF	Citations
462	Myelomatous Pleural Effusion: A Case Series in a Single Institution and Literature Review. Annals of Laboratory Medicine, 2011, 31, 225-230.	1.2	27
463	Multiple Myeloma Presenting as Acute Renal Failure. Baylor University Medical Center Proceedings, 2011, 24, 302-305.	0.2	5
464	Uncertainty in Clinical Medicine. , 2011, , 299-356.		42
465	Fractal Characteristics of May-GrÃ¼nwald-Giemsa Stained Chromatin Are Independent Prognostic Factors for Survival in Multiple Myeloma. PLoS ONE, 2011, 6, e20706.	1.1	50
466	Computational Modeling of Interactions between Multiple Myeloma and the Bone Microenvironment. PLoS ONE, 2011, 6, e27494.	1.1	37
467	Monoclonal Gammopathy of Undetermined Significance Does Not Affect Outcomes in Patients Undergoing Solid Organ Transplants. Transplantation, 2011, 92, 570-574.	0.5	32
468	Type 1 Cryoglobulinemia. Journal of Clinical Rheumatology, 2011, 17, 145-147.	0.5	12
469	Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. Therapy: Open Access in Clinical Medicine, 2011, 8, 415-429.	0.2	4
470	Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma. Blood Coagulation and Fibrinolysis, 2011, 22, 260-263.	0.5	10
471	Free Light Chains of Immunoglobulin as a Prognostic Factor for Some Plasmaproliferative Diseases. Journal of Medical Biochemistry, 2011, 30, 293-301.	0.7	1
472	Polychromatic flow cytometry in the clinical laboratory. Pathology, 2011, 43, 580-591.	0.3	20
473	Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood, 2011, 117, 3836-3846.	0.6	93
474	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood, 2011, 117, 4696-4700.	0.6	285
475	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 2011, 117, 6063-6073.	0.6	282
476	Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood, 2011, 118, 2702-2707.	0.6	23
477	Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood, 2011, 118, 1763-1765.	0.6	59
478	Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1Î± levels in patients with MGUS. Blood, 2011, 118, 6529-6534.	0.6	62
479	Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood, 2011, 118, 5901-5904.	0.6	63

#	Article	IF	Citations
481	Immunoglobulin D-Lambda Type Multiple Myeloma Presenting with FDG-PET/CT Negative Bone Marrow Involvement. Internal Medicine, 2011, 50, 1483-1487.	0.3	4
482	Successful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy. Internal Medicine, 2011, 50, 2653-2657.	0.3	3
485	CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica, 2011, 96, 1557-1559.	1.7	31
487	Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 2011, 154, 32-75.	1.2	252
488	Diffusionâ€weighted imaging for nonâ€invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. British Journal of Haematology, 2011, 153, 721-728.	1.2	132
489	Epigenetic silencing of MIR203 in multiple myeloma. British Journal of Haematology, 2011, 154, 569-578.	1.2	63
490	Healthcare costs of multiple myeloma: an Italian study. European Journal of Cancer Care, 2011, 20, 330-336.	0.7	15
491	Neuropathy and paraproteins: review of a complex association. European Journal of Neurology, 2011, 18, 1291-1298.	1.7	65
492	Hypergammaglobulinemia in an SIV-Infected Rhesus Macaque with a B-cell neoplasm with plasma cell differentiation. Journal of Medical Primatology, 2011, 40, 200-204.	0.3	0
493	Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia, 2011, 25, 697-706.	3.3	75
494	Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Annals of the New York Academy of Sciences, 2011, 1237, 19-23.	1.8	77
495	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalanâ€“prednisone vs. melphalanâ€“prednisone in the phase III VISTA trial in multiple myeloma. European Journal of Haematology, 2011, 86, 372-384.	1.1	77
496	Monoclonal Gammopathy of Undetermined Significance Versus Smoldering Myeloma: Is Active Surveillance Enough?. Seminars in Oncology, 2011, 38, 327-334.	0.8	0
497	A rare case of nonâ€secretory multiple myeloma without bone marrow involvement. Pathology International, 2011, 61, 390-393.	0.6	0
498	Lack of increased prevalence of immunoregulatory disorders in hereditary angioedema due to C1-inhibitor deficiency. Clinical Immunology, 2011, 141, 58-66.	1.4	25
499	Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach. Journal of Clinical Oncology, 2011, 29, 3805-3812.	0.8	302
500	Extramedullary Relapse in a Case of Multiple Myeloma Involving the Thyroid Cartilage: Case Report and Review of Literature. Indian Journal of Surgical Oncology, 2011, 2, 313-315.	0.3	8
501	Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma. Investigational New Drugs, 2011, 29, 175-181.	1.2	3

#	Article	IF	Citations
502	The Relationship Between Hypogammaglobulinemia, Monoclonal Gammopathy of Undetermined Significance and Humoral Immunodeficiency: a Case Series. Journal of Clinical Immunology, 2011, 31, 737-743.	2.0	15
503	Living with multiple myeloma: experiences of patients and their informal caregivers. Supportive Care in Cancer, 2011, 19, 101-111.	1.0	84
505	Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms. Strahlentherapie Und Onkologie, 2011, 187, 114-119.	1.0	39
506	Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1046-1053.	3.3	79
507	The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skeletal Radiology, 2011, 40, 843-847.	1.2	57
508	Renal disorder preceding multiple myeloma. Medical Oncology, 2011, 28, 199-201.	1.2	3
509	EBV-Positive Plasmacytoma of the Submandibular Glandâ€"Report of a Rare Case with Molecular Genetic Characterization. Head and Neck Pathology, 2011, 5, 389-394.	1.3	14
510	Primary plasma cell leukemia followed by testicular plasmacytoma. International Journal of Hematology, 2011, 93, 224-227.	0.7	7
511	Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma. International Journal of Hematology, 2011, 93, 257-259.	0.7	4
512	Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. International Journal of Hematology, 2011, 93, 351-360.	0.7	19
513	Primary plasmacytoma of the testicle: a case report. Journal of Medical Case Reports, 2011, 5, 494.	0.4	8
514	Multiple myeloma: 2011 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2011, 86, 57-65.	2.0	137
515	Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients. American Journal of Hematology, 2011, 86, 475-478.	2.0	38
516	A GEIL flow cytometry consensus proposal for quantification of plasma cells: Application to differential diagnosis between MGUS and myeloma. Cytometry Part B - Clinical Cytometry, 2011, 80B, 176-185.	0.7	22
517	Plasma cell leukemia. Blood Reviews, 2011, 25, 107-112.	2.8	81
518	Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: A single center experience. Critical Reviews in Oncology/Hematology, 2011, 79, 31-42.	2.0	35
519	Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis. Leukemia Research, 2011, 35, 44-48.	0.4	6
520	Unusual localizations of plasmacytoma. Leukemia Research, 2011, 35, e104-e105.	0.4	1

#	Article	IF	Citations
521	Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study. Nephrology Dialysis Transplantation, 2011, 26, 3627-3633.	0.4	19
522	Abnormal radiological features in a multiple myeloma patient: a case report and radiological review of myelomas. Dentomaxillofacial Radiology, 2011, 40, 513-518.	1.3	26
523	Current and future imaging modalities for multiple myeloma and its precursor states. Leukemia and Lymphoma, 2011, 52, 1630-1640.	0.6	27
524	Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes. Clinics, 2011, 66, 2055-2061.	0.6	14
525	Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer Journal, 2011, 1, e27-e27.	2.8	113
526	Imaging of Unusual Perineal Masses. American Journal of Roentgenology, 2011, 196, W412-W420.	1.0	22
527	The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells. Clinical Cancer Research, 2011, 17, 1692-1700.	3.2	128
528	Contributors to Secondary Osteoporosis and Metabolic Bone Diseases in Patients Presenting with a Clinical Fracture. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1360-1367.	1.8	110
529	The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future. Oncologist, 2011, 16, 651-662.	1.9	62
530	Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Annals of Oncology, 2011, 22, 411-416.	0.6	40
531	A Case of Monoclonal Lymphoplasmacytosis of the Bone Marrow with IgM-Positive Russell Bodies. Bone Marrow Research, 2011, 2011, 1-3.	1.7	1
532	A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence. Acta Haematologica, 2011, 126, 163-168.	0.7	15
533	Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Annals of Oncology, 2011, 22, 1628-1635.	0.6	65
534	Progression From Precursor Disease to Multiple Myelomaâ€"Reply. JAMA - Journal of the American Medical Association, 2011, 305, 1094.	3.8	0
535	Crescentic Glomerulonephritis in IgA Multiple Myeloma: A Case Report. Nephron Extra, 2011, 1, 69-72.	1.1	3
536	Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma. Clinical Cancer Research, 2011, 17, 1935-1946.	3.2	75
537	MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin. Clinical Cancer Research, 2011, 17, 4309-4319.	3.2	83
538	Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leukemia and Lymphoma, 2011, 52, 771-775.	0.6	86

#	Article	IF	Citations
539	Case 29-2011. New England Journal of Medicine, 2011, 365, 1129-1138.	13.9	6
540	A case of light chain (AL) amyloidosis associated with IgD multiple myeloma (MM): clinical features, laboratory findings and outcome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 117-118.	1.4	0
541	Maintaining Bone Health in Patients With Multiple Myeloma. Clinical Journal of Oncology Nursing, 2011, 15, 9-23.	0.3	28
543	Diagnosis of Smoldering Multiple Myeloma. New England Journal of Medicine, 2011, 365, 474-475.	13.9	155
544	The Role of Serum Protein Electrophoresis in the Detection of Multiple Myeloma: An Experience of a Corporate Hospital. Journal of Clinical and Diagnostic Research JCDR, 2012, 6, 1458-61.	0.8	19
545	Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Annals of Clinical Biochemistry, 2012, 49, 242-256.	0.8	71
546	Investigating an incidental finding of a paraprotein. BMJ, The, 2012, 344, e3033-e3033.	3.0	0
547	Assessing response of myeloma bone disease with diffusion-weighted MRI. British Journal of Radiology, 2012, 85, e1198-e1203.	1.0	128
548	Emerging Strategies for Targeting Cell Adhesion in Multiple Myeloma. Advances in Pharmacology, 2012, 65, 143-189.	1.2	11
549	Genomic analysis of high-risk smoldering multiple myeloma. Haematologica, 2012, 97, 1439-1443.	1.7	43
550	Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia, 2012, 26, 1091-1097.	3.3	85
551	CD29 expressed on plasma cells is activated by divalent cations and soluble CD106 contained in the bone marrow plasma: refractory activation is associated with enhanced proliferation and exit of clonal plasma cells to circulation in multiple myeloma patients. Leukemia, 2012, 26, 1098-1105.	3.3	5
552	SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia, 2012, 26, 2521-2529.	3.3	100
553	Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia, 2012, 26, 609-614.	3.3	88
554	Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia, 2012, 26, 2286-2296.	3.3	33
555	Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Annals of Oncology, 2012, 23, 1499-1502.	0.6	68
556	CD200 Expression in Plasma Cells of Nonmyeloma Immunoproliferative Disorders. American Journal of Clinical Pathology, 2012, 138, 867-876.	0.4	11
557	Increased Numbers of T Helper 17 Cells and the Correlation with Clinicopathological Characteristics in Multiple Myeloma. Journal of International Medical Research, 2012, 40, 556-564.	0.4	38

#	Article	IF	Citations
558	The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Evaluating the Response to Treatment in Patients with Multiple Myeloma. International Journal of Molecular Imaging, 2012, 2012, 1-6.	1.3	21
559	Laryngeal Involvement of Multiple Myeloma. Case Reports in Oncological Medicine, 2012, 2012, 1-3.	0.2	6
560	Plasmacytoma of the Nasolacrimal Duct Simulating Dacryocystitis: An Uncommon Presentation for Extramedullary Relapse of Multiple Myeloma. Case Reports in Oncology, 2012, 5, 119-124.	0.3	4
561	Bilateral hip pain as presentation of multiple myeloma: Figure 1. Emergency Medicine Journal, 2012, 29, 181-181.	0.4	1
563	Chameleon-like Appearance of Immunotactoid Keratopathy. Cornea, 2012, 31, 55-58.	0.9	37
564	Initial Finding of Mandible Mass in Multiple Myeloma. Journal of Craniofacial Surgery, 2012, 23, e599-e600.	0.3	5
565	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?. Haematologica, 2012, 97, 1608-1611.	1.7	17
566	2. Advances in the Diagnosis and Treatment of Multiple Myeloma. The Journal of the Japanese Society of Internal Medicine, 2012, 101, 128b-129a.	0.0	0
568	A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 2012, 120, 1801-1809.	0.6	393
569	How I treat plasma cell leukemia. Blood, 2012, 120, 2376-2389.	0.6	115
570	Extramedullary involvement in multiple myeloma. Haematologica, 2012, 97, 1618-1619.	1.7	77
571	Dysproteinemias or light chain diseases. , 2012, , 251-264.		1
572	The role of imaging techniques in the management of multiple myeloma. British Journal of Haematology, 2012, 159, 499-513.	1.2	108
573	Serum <scp>B</scp>â€cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. British Journal of Haematology, 2012, 158, 727-738.	1.2	199
574	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. British Journal of Haematology, 2012, 158, 805-809.	1.2	19
575	A phase 1 study of lucatumumab, a fully human antiâ€<scp>CD</scp>40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 2012, 159, 58-66.	1.2	101
577	Combined analysis using extended renal reference range of serum free light chain ratio and serum protein electrophoresis improves the diagnostic accuracy of multiple myeloma in renal insufficiency. Clinical Biochemistry, 2012, 45, 740-744.	0.8	11
578	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego na rok 2012. Acta Haematologica Polonica, 2012, 43, 7-47.	0.1	5

#	Article	IF	Citations
579	The Role of Radiation Therapy in the Management of POEMS Syndrome. International Journal of Radiation Oncology Biology Physics, 2012, 84, S622.	0.4	0
580	AktywnoÅ›Ä‡ proteasomu 20S w osoczach pacjentÃ³w z nowo rozpoznanym szpiczakiem plazmocytowym. Acta Haematologica Polonica, 2012, 43, 155-159.	0.1	1
582	Emerging biological insights and novel treatment strategies in multiple myeloma. Expert Opinion on Emerging Drugs, 2012, 17, 407-438.	1.0	13
583	Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Review of Hematology, 2012, 5, 51-68.	1.0	30
584	Multiple myeloma. BMJ: British Medical Journal, 2012, 344, d7953-d7953.	2.4	6
585	Current Concepts of Clinical Management of Multiple Myeloma. Disease-a-Month, 2012, 58, 195-207.	0.4	15
586	Prevalence and type of monoclonal gammopathy of undetermined significance in an apparently healthy Nigerian population: a cross sectional study. BMC Blood Disorders, 2012, 12, 7.	0.9	4
587	NF-Î¹B2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors. BMC Cancer, 2012, 12, 203.	1.1	4
588	First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. The Cochrane Library, 2012, 10, CD004626.	1.5	24
589	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia, 2012, 26, 1862-1869.	3.3	73
590	18F-FAMT in patients with multiple myeloma: clinical utility compared to 18F-FDG. Annals of Nuclear Medicine, 2012, 26, 811-816.	1.2	19
591	Valor diagnÃ³stico del cociente de cadenas ligeras libres de inmunoglobulinas en suero en las gammapatÃas monoclonales de significado incierto. Revista Del Laboratorio ClÃnico, 2012, 5, 111-115.	0.1	0
592	Can Whole-body Low-dose Multidetector CT Exclude the Presence of Myeloma Bone Disease in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)?. Academic Radiology, 2012, 19, 89-94.	1.3	23
593	Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma?. International Journal of Hematology, 2012, 96, 685-691.	0.7	22
594	The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer Journal, 2012, 2, e96-e96.	2.8	70
595	Effects of Epstein-Barr virus infection on the development of multiple myeloma after liver transplantation. Science China Life Sciences, 2012, 55, 735-743.	2.3	3
596	Myeloma and Leukemia. , 2012, , 509-529.		1
597	Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?. Hematology/Oncology Clinics of North America, 2012, 26, 383-393.	0.9	8

#	Article	IF	Citations
598	Parametric Histogram Analysis of Dynamic Contrast-enhanced MRI in Multiple Myeloma. Academic Radiology, 2012, 19, 100-108.	1.3	11
599	Monoclonal Gammopathy of Undetermined Significance: An Update for Nephrologists. Advances in Chronic Kidney Disease, 2012, 19, 291-296.	0.6	10
600	The Role of Immunological Assessment in Patients With Acute Kidney Injury and Possible Myeloma. Advances in Chronic Kidney Disease, 2012, 19, 287-290.	0.6	0
601	Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2012, 53, 1820-1823.	0.6	109
602	Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation. International Medical Case Reports Journal, 2012, 5, 39.	0.3	0
603	Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study. Journal of Surgical Oncology, 2012, 105, 679-686.	0.8	43
604	Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, doubleâ€blind placeboâ€controlled crossâ€over 4g study and an openâ€label 8g extension study. American Journal of Hematology, 2012, 87, 455-460.	2.0	92
605	Trends and outcomes of modern staging of solitary plasmacytoma of bone. American Journal of Hematology, 2012, 87, 647-651.	2.0	69
606	Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progressionâ€free survival in multiple myeloma. American Journal of Hematology, 2012, 87, 948-952.	2.0	63
607	Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood, 2012, 119, 5359-5366.	0.6	68
608	DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis, 2012, 33, 1629-1638.	1.3	62
610	Renal impairment in multiple myeloma: Presenting features in different departments. Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32, 65-68.	1.0	2
611	Pancreatic Involvement by Plasma Cell Neoplasms. Journal of Gastrointestinal Cancer, 2012, 43, 157-167.	0.6	16
612	Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. International Journal of Hematology, 2012, 95, 516-526.	0.7	15
613	Detection of serum tumor markers in multiple myeloma using the CLINPROT system. International Journal of Hematology, 2012, 95, 668-674.	0.7	16
614	Variations in Suppressor Molecule CTLA-4 Gene Are Related to Susceptibility to Multiple Myeloma in a Polish Population. Pathology and Oncology Research, 2012, 18, 219-226.	0.9	28
615	Plasma Cell Leukemia: Case Series From a Tertiary Center with Review of Literature. Indian Journal of Hematology and Blood Transfusion, 2012, 28, 10-14.	0.3	12
616	Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results. European Radiology, 2012, 22, 1114-1121.	2.3	26

#	Article	IF	Citations
617	Extramedullary plasmacytoma of the small intestine: Clinical features, diagnosis and treatment. Journal of Digestive Diseases, 2012, 13, 10-18.	0.7	25
618	Development of MGUS in psoriatic patients: a possible undiagnosed event during antiâ€TNFâ€Î±â€treatment. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1444-1448.	1.3	18
619	Monoclonal gammopathy after liver transplantation: a risk factor for long-term medical complications other than malignancies. Transplant International, 2012, 25, 25-33.	0.8	7
620	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology, 2012, 156, 326-333.	1.2	48
621	Head and neck amyloidosis: clinicopathological features and immunohistochemical analysis of 14 cases. Journal of Oral Pathology and Medicine, 2012, 41, 178-185.	1.4	34
622	Primary plasma cell leukemia in the era of new drugs: Has something changed?. Critical Reviews in Oncology/Hematology, 2012, 82, 141-149.	2.0	18
623	Genetic variations in multiple myeloma II: association with effect of treatment. European Journal of Haematology, 2012, 88, 93-117.	1.1	28
624	Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma. European Journal of Haematology, 2012, 88, 159-166.	1.1	8
625	Preâ€existing diabetes mellitus in patients with multiple myeloma. European Journal of Haematology, 2012, 89, 320-327.	1.1	25
626	Initial survival data of kidney transplant patients with preâ€transplant monoclonal gammopathy. Clinical Transplantation, 2012, 26, 300-304.	0.8	15
627	Multiple myeloma: 2012 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2012, 87, 78-88.	2.0	120
628	Prevalence of monoclonal gammopathy of undetermined significance in Thailand. International Journal of Hematology, 2012, 95, 176-181.	0.7	24
629	International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents. Annals of Hematology, 2012, 91, 93-102.	0.8	5
630	Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Annals of Hematology, 2012, 91, 243-248.	0.8	59
631	Microscopic examination of bone marrow aspirates in malignant disorders of haematopoiesisâ€"a comparison of two slide preparation techniques. Annals of Hematology, 2012, 91, 497-505.	0.8	5
632	Epigenetic inactivation of the MIR129-2 in hematological malignancies. Journal of Hematology and Oncology, 2013, 6, 16.	6.9	59
633	Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine, 2013, 369, 438-447.	13.9	449
634	CXCR4 is a good survival prognostic indicator in multiple myeloma patients. Leukemia Research, 2013, 37, 1083-1088.	0.4	30

#	Article	IF	Citations
636	Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms. Biomarker Research, 2013, 1, 8.	2.8	31
637	Bortezomib, Dexamethasone, and High-Dose Melphalan as Conditioning for Stem Cell Transplantation in Young Japanese Multiple Myeloma Patients: A Pilot Study. Indian Journal of Hematology and Blood Transfusion, 2013, 29, 147-151.	0.3	3
638	Cranial Plasmacytoma: A Case Series and Review of the Literature. Indian Journal of Hematology and Blood Transfusion, 2013, 29, 43-47.	0.3	7
639	Epsteinâ€“Barr virus expression in plasma cell neoplasms and its association with plasmablastic morphologic features. Journal of Hematopathology, 2013, 6, 213-218.	0.2	2
641	Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases. Annals of Hematology, 2013, 92, 1553-1557.	0.8	15
642	â€œIdiopathic Bence-Jones proteinuriaâ€• a new characterization of an old entity. Annals of Hematology, 2013, 92, 1263-1270.	0.8	7
644	Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. Expert Opinion on Biological Therapy, 2013, 13, S55-S68.	1.4	20
645	Managing multiple myeloma patients with renal failure. Hong Kong Journal of Nephrology, 2013, 15, 62-67.	0.0	1
646	Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood, 2013, 122, 4172-4181.	0.6	70
647	Assessment of the diagnostic performances of IgA heavy and light chain pairs in patients with IgA monoclonal gammopathy. Clinical Biochemistry, 2013, 46, 79-84.	0.8	7
648	EvaluaciÃ³n de la inmunofijaciÃ³n sÃ©rica frente al cociente de cadenas ligeras libres Kappa/Lambda en la confirmaciÃ³n de componentes monoclonales de baja concentraciÃ³n. Revista Del Laboratorio ClÃnico, 2013, 6, 32-36.	0.1	0
649	Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. Annals of Pharmacotherapy, 2013, 47, 56-62.	0.9	55
650	Neuroimaging: Intrinsic Lesions of the Central Skull Base Region. Seminars in Ultrasound, CT and MRI, 2013, 34, 412-435.	0.7	31
651	Management of multiple myeloma in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e571-e581.	5.1	37
652	Imaging of Multiple Myeloma: Usefulness of MRI and PET/CT. Seminars in Ultrasound, CT and MRI, 2013, 34, 566-577.	0.7	13
653	t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leukemia Research, 2013, 37, 1251-1257.	0.4	59
654	Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. Bone Marrow Transplantation, 2013, 48, 10-18.	1.3	43
656	New Approaches to Smoldering Myeloma. Current Hematologic Malignancy Reports, 2013, 8, 270-276.	1.2	17

#	Article	IF	Citations
657	Pregnancy and multiple myeloma are not antinomic. Leukemia and Lymphoma, 2013, 54, 2738-2741.	0.6	9
658	Monoclonal gammopathy of undetermined significance: a new proposal of workup. European Journal of Haematology, 2013, 91, 356-360.	1.1	24
659	Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a caseâ€“control study in the context of the IMMEnSE consortium. Journal of Human Genetics, 2013, 58, 155-159.	1.1	5
660	Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia, 2013, 27, 947-953.	3.3	141
661	Diagnosis and Treatment of Multiple Myeloma. , 2013, , 637-663.		2
662	Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations. Clinical Rheumatology, 2013, 32, 115-121.	1.0	3
664	Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma. Leukemia Research, 2013, 37, 1648-1655.	0.4	11
665	Glutathione S-transferase P1 mRNA expression in plasma cell disorders and its correlation with polymorphic variants and clinical outcome. Cancer Epidemiology, 2013, 37, 671-674.	0.8	6
668	Myeloma and MGUS. Medicine, 2013, 41, 295-298.	0.2	1
669	Impacto del tipo de hospital en la supervivencia de pacientes con mieloma mÃºltiple: estudio MICORE. Revista Clinica Espanola, 2013, 213, 330-335.	0.2	2
671	Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides. Experimental Hematology, 2013, 41, 894-902.	0.2	8
672	The impact of the type of hospital on survival of multiple myeloma patients: The MICORE study. Revista Clínica Espanõla, 2013, 213, 330-335.	0.3	0
673	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	1.4	440
674	Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1144-1151.	2.0	15
675	Place actuelle du scanner et de lâ€™IRM corps entier dans le myÃ©lome multiple. Diagnostic and Interventional Imaging, 2013, 94, 175-189.	0.0	0
676	Detecting bony infiltrates in patients with multiple myeloma â€“ Is there a role for computered tomography (CT) as an alternative to the radiographic skeletal survey?. Radiography, 2013, 19, 176-182.	1.1	0
677	A case of IgD myeloma representing a missed biclonal paraproteinemia or isotype switch in a patient previously diagnosed with IgAâ€“lambda myeloma. Clinica Chimica Acta, 2013, 425, 233-235.	0.5	2
678	Multiple myeloma: 2013 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2013, 88, 225-235.	2.0	105

#	Article	IF	Citations
679	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia, 2013, 27, 780-791.	3.3	294
680	Monoclonal Gammopathy of Undetermined Significance. , 2013, , 751-785.		2
681	Proteasome inhibitors in the treatment of multiple myeloma. Expert Review of Anticancer Therapy, 2013, 13, 339-358.	1.1	42
682	Multiple Myeloma and the Kidney. , 2013, , 619-629.		0
683	Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.. Bone Marrow Transplantation, 2013, 48, 1302-1307.	1.3	74
684	Perspectives in the treatment of multiple myeloma. Expert Opinion on Biological Therapy, 2013, 13, S1-S22.	1.4	18
685	Multiple myeloma. BMJ, The, 2013, 346, f3863-f3863.	3.0	64
686	Cytogenetics of extramedullary manifestations in multiple myeloma. British Journal of Haematology, 2013, 161, 87-94.	1.2	81
687	Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Leukemia and Lymphoma, 2013, 54, 1473-1478.	0.6	15
688	Current role of CT and whole body MRI in multiple myeloma. Diagnostic and Interventional Imaging, 2013, 94, 169-183.	1.8	15
689	Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma. Diagnostic and Interventional Imaging, 2013, 94, 629-636.	1.8	32
690	Solitary clival plasmocytomas: Misleading clinical and radiological features of a rare pathology with a specific biological behaviour. Acta Neurochirurgica, 2013, 155, 1849-1856.	0.9	21
691	Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia, 2013, 27, 1738-1744.	3.3	194
692	Optimization of Utilization of Serum Protein Analysis. American Journal of Clinical Pathology, 2013, 139, 793-797.	0.4	12
693	A case of multiple myeloma presenting as scalp swelling with intracranial extension. Journal of Neurosciences in Rural Practice, 2013, 04, 445-448.	0.3	6
694	Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load. Journal of Clinical Oncology, 2013, 31, 4325-4332.	0.8	200
695	Multiple Extramedullary Plasmacytoma with Lytic Bony Lesions: A Rare Case Report. Case Reports in Medicine, 2013, 2013, 1-3.	0.3	5
696	Diagnosis and Treatment of Bone Disease in Multiple Myeloma: Spotlight on Spinal Involvement. Scientifica, 2013, 2013, 1-12.	0.6	61

#	Article	IF	Citations
697	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	0.8	193
698	Precursors to Lymphoproliferative Malignancies. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 533-539.	1.1	15
699	A Male With Progressive Lower Extremity Weakness and Monoclonal Gammopathy. Journal of Clinical Neuromuscular Disease, 2013, 14, 194-203.	0.3	0
700	Multiple myeloma in a kidney transplanted patient primarily diagnosed with monoclonal gammopathy of unknown significance (MGUS)-related nephropathy. CKJ: Clinical Kidney Journal, 2013, 6, 445-446.	1.4	0
701	Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma. Clinical Cancer Research, 2013, 19, 2248-2256.	3.2	78
702	Prevalence of subclinical contributors to low bone mineral density and/or fragility fracture. European Journal of Endocrinology, 2013, 169, 225-237.	1.9	46
703	Posterior Pole Manifestations of Hematologic Diseases. , 2013, , 425-450.		0
704	Kidney Disease and Multiple Myeloma. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 2007-2017.	2.2	125
705	Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. British Journal of Haematology, 2013, 160, 673-679.	1.2	23
706	The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. British Journal of Haematology, 2013, 161, 367-372.	1.2	36
707	Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation. ISRN Hematology, 2013, 2013, 1-7.	1.6	6
708	Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S7764.	0.6	22
709	Multiple Myeloma Mimicking Metastatic Pancreas Cancer. Journal of Clinical Oncology, 2013, 31, e297-e299.	0.8	5
710	Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 283-291.	0.1	12
711	Multiple myeloma in a dog with multiple concurrent infectious diseases and persistent polyclonal gammopathy. Veterinary Clinical Pathology, 2013, 42, 47-54.	0.3	14
712	Myeloma cell morphology and morphometry in correlation with clinical stages and survival. Diagnostic Cytopathology, 2013, 41, 947-954.	0.5	8
713	Tobacco smoking and risk of multiple myeloma: A metaâ€analysis of 40 observational studies. International Journal of Cancer, 2013, 132, 2413-2431.	2.3	23
714	Diagnostic evaluation of monoclonal gammopathy of undetermined significance. European Journal of Haematology, 2013, 91, 561-562.	1.1	8

#	Article	IF	Citations
715	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology American Society of Hematology Education Program, 2013, 2013, 478-487.	0.9	69
716	Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology American Society of Hematology Education Program, 2013, 2013, 496-503.	0.9	26
717	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. British Journal of Haematology, 2013, 163, 223-234.	1.2	7
718	Replacing Urine Protein Electrophoresis With Serum Free Light Chain Analysis as a First-Line Test for Detecting Plasma Cell Disorders Offers Increased Diagnostic Accuracy and Potential Health Benefit to Patients. American Journal of Clinical Pathology, 2013, 140, 890-897.	0.4	35
719	Utilisation of s<scp>FLC</scp> assays â€“ how well do we comply with guidelines?. International Journal of Laboratory Hematology, 2013, 35, 200-210.	0.7	3
720	Comparison of modern and conventional imaging techniques in establishing multiple myelomaâ€related bone disease: a systematic review. British Journal of Haematology, 2013, 162, 50-61.	1.2	178
721	Feasibility study: phospho-specific flow cytometry enabling rapid functional analysis of bone marrow samples from patients with multiple myeloma. , 2013, , n/a-n/a.		7
722	Imaging in myeloma. Imaging, 2013, 22, 20110082.	0.0	0
723	Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17â€‰315 patients. Leukemia, 2013, 27, 1391-1393.	3.3	45
724	Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia, 2013, 27, 941-946.	3.3	201
725	High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia, 2013, 27, 680-685.	3.3	138
726	Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 3696-3703.	0.8	123
727	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. Clinical Cancer Research, 2013, 19, 3130-3142.	3.2	86
728	Revisiting treatment paradigms in high-risk smoldering multiple myeloma: out with the old, in with the new?. Leukemia and Lymphoma, 2013, 54, 2328-2330.	0.6	4
729	Asymptomatic (smoldering) myeloma: treatment strategy. International Journal of Hematologic Oncology, 2013, 2, 445-453.	0.7	0
730	Solitary plasmacytoma of the skull: Two case reports. Oncology Letters, 2013, 5, 479-482.	0.8	8
731	Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood, 2013, 121, 4647-4654.	0.6	128
732	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood, 2013, 122, 2331-2337.	0.6	281

#	Article	IF	Citations
733	Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood, 2013, 122, 3122-3128.	0.6	126
734	Discovering Multiple Myeloma Early in Ambulatory Patients With Chest Pain. Clinical Journal of Oncology Nursing, 2013, 17, 205-207.	0.3	0
735	Multiple Myeloma Masquerades as Rheumatic Diseases. Proceedings of Singapore Healthcare, 2013, 22, 64-69.	0.2	3
736	Acquired Cutis Laxa With an Interstitial Granulomatous Reaction Associated With IgG Lambda Monoclonal Gammopathy. American Journal of Dermatopathology, 2013, 35, e67-e71.	0.3	6
737	The Spectrum of Type I Cryoglobulinemia Vasculitis. Medicine (United States), 2013, 92, 61-68.	0.4	150
738	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. , 0, , 121-133.		2
739	Therapeutic Effects of Lenalidomide on Hemorrhagic Intestinal Myeloma-associated AL Amyloidosis. Internal Medicine, 2013, 52, 1101-1105.	0.3	4
740	Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Management and Research, 2013, 5, 225.	0.9	22
741	BM mesenchymal stromal cellâ€“derived exosomes facilitate multiple myeloma progression. Journal of Clinical Investigation, 2013, 123, 1542-1555.	3.9	661
742	Data quality of the monoclonal gammopathy of undetermined significance diagnosis in a hospital registry. Clinical Epidemiology, 2013, 5, 321.	1.5	5
743	Frequent Occurrence of Highly Expanded but Unrelated B-Cell Clones in Patients with Multiple Myeloma. PLoS ONE, 2013, 8, e64927.	1.1	13
744	Occurrence of multiple myeloma in the head and neck: a report of two cases. Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2013, 39, 139.	0.3	2
745	Monoclonal Gammopathy of Undetermined Significance. , 2013, , .		0
747	Multiple Myeloma: An Update. Oman Medical Journal, 2013, 28, 3-11.	0.3	33
749	Dyscrasies plasmocytaires. , 2013, , 633-647.		0
750	Multiple solitary plasmacytoma with multifocal bone involvement. First clinical case report in a uraemic patient. BMJ Case Reports, 2013, 2013, bcr2013009157-bcr2013009157.	0.2	7
751	Paraneoplastic pemphigus presenting with a single oral lesion. BMJ Case Reports, 2013, 2013, bcr2012007771-bcr2012007771.	0.2	7
752	New Tools for Diagnosis and Monitoring of Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e313-e318.	1.8	8

#	Article	IF	Citations
753	Ilimaquinone and Ethylsmenoquinone, Marine Sponge Metabolites, Suppress the Proliferation of Multiple Myeloma Cells by Down-Regulating the Level of Î²-Catenin. Marine Drugs, 2014, 12, 3231-3244.	2.2	32
754	Letter to the Editor Amyloidosis of the head and neck: a clinicopathological study of cases with long term follow-up. Archives of Medical Science, 2014, 4, 846-852.	0.4	13
755	Clinicopathological significance and potential drug target of p15INK4B in multiple myeloma. Drug Design, Development and Therapy, 2014, 8, 2129.	2.0	12
756	Extramedullary Plasmacytoma of Gingiva and Soft Tissue in Neck. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, ZD16-8.	0.8	2
757	Multiple myeloma: optimal management and long-term disease control. Blood and Lymphatic Cancer: Targets and Therapy, 2014, , 121.	1.2	0
758	Helicobacter pylori-negative Russell body gastritis: does the diagnosis call for screening for plasmacytic malignancies, especially multiple myeloma?. BMJ Case Reports, 2014, 2014, bcr2013202672-bcr2013202672.	0.2	10
759	Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. Nephrology Dialysis Transplantation, 2014, 29, 1894-1902.	0.4	29
761	Next-generation sequencing in multiple myeloma: insights into the molecular heterogeneity of the disease. International Journal of Hematologic Oncology, 2014, 3, 367-376.	0.7	2
762	The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. European Radiology, 2014, 24, 2754-2765.	2.3	54
763	The role of radiotherapy in the management of POEMS syndrome. Radiation Oncology, 2014, 9, 265.	1.2	18
765	Utility of Nine-Color, 11-Parameter Flow Cytometry for Detection of Plasma Cell Neoplasms. American Journal of Clinical Pathology, 2014, 142, 398-410.	0.4	7
766	Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia, 2014, 28, 413-416.	3.3	24
767	Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. Ca-A Cancer Journal for Clinicians, 2014, 64, 422-444.	157.7	85
768	Solitary plasmacytoma of the index finger. Journal of Clinical Pathology, 2014, 67, 828-831.	1.0	0
769	Determination of Prognostic Factors in Japanese Patients With Advanced Gastric Cancer Using the Data From a Randomized Controlled Trial, Japan Clinical Oncology Group 9912. Oncologist, 2014, 19, 358-366.	1.9	54
770	Immune Defects in the Risk of Infection and Response to Vaccination in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Frontiers in Immunology, 2014, 5, 257.	2.2	39
771	Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future. BioMed Research International, 2014, 2014, 1-7.	0.9	17
772	How I treat smoldering multiple myeloma. Blood, 2014, 124, 3380-3388.	0.6	41

#	Article	IF	Citations
773	Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells. BioMed Research International, 2014, 2014, 1-7.	0.9	12
774	Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells. Turkish Journal of Haematology, 2014, 31, 136-142.	0.2	6
775	Pathogenesis of Renal Failure in Multiple Myeloma: Any Role of Contrast Media?. BioMed Research International, 2014, 2014, 1-10.	0.9	14
776	Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica, 2014, 99, 155-162.	1.7	23
777	Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica, 2014, 99, 1365-1372.	1.7	65
778	FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells. Cancer Immunology, Immunotherapy, 2014, 63, 1189-1197.	2.0	65
779	Detecting monoclonal light chains in urine: micro<scp>LC</scp>â€<scp>ESI</scp>â€Qâ€<scp>TOF</scp> mass spectrometry compared to immunofixation electrophoresis. British Journal of Haematology, 2014, 167, 437-438.	1.2	22
780	Smoldering multiple myeloma: present position and potential promises. European Journal of Haematology, 2014, 92, 1-12.	1.1	5
781	Mathematical modelling of the pathogenesis of multiple myelomaâ€induced bone disease. International Journal for Numerical Methods in Biomedical Engineering, 2014, 30, 1085-1102.	1.0	21
782	Pityriasis rotunda as an incidental paraneoplastic finding in two patients with multiple myeloma. Clinical and Experimental Dermatology, 2014, 39, 734-737.	0.6	6
783	Appearance of monoclonal plasma cell diseases in wholeâ€body magnetic resonance imaging and correlation with parameters of disease activity. International Journal of Cancer, 2014, 135, 2380-2386.	2.3	19
784	Treatment with bortezomibâ€based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. American Journal of Hematology, 2014, 89, 145-150.	2.0	56
785	Biology and Treatment of Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S65-S70.	0.2	15
786	Asymptomatic Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S78-S86.	0.2	6
787	Multiple Myeloma Mimicking Spondyloarthritis: a Case Report. Chinese Medical Sciences Journal, 2014, 29, 245-247.	0.2	1
788	Causes of protidemia above 100g/L. European Journal of Internal Medicine, 2014, 25, e123.	1.0	2
789	Common communityâ€acquired infections and subsequent risk of multiple myeloma: A populationâ€based study. International Journal of Cancer, 2014, 134, 1734-1740.	2.3	15
790	Feasibility study: Phosphospecific flow cytometry enabling rapid functional analysis of bone marrow samples from patients with multiple myeloma. , 2014, 86, 139-144.		7

#	Article	IF	Citations
791	Quantification of peptides from immunoglobulin constant and variable regions by LCâ€MRM MS for assessment of multiple myeloma patients. Proteomics - Clinical Applications, 2014, 8, 783-795.	0.8	33
793	The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Expert Review of Hematology, 2014, 7, 55-66.	1.0	17
794	Minimal Change Nephrotic Syndrome Associated With Non-Hodgkin Lymphoid Disorders. Medicine (United States), 2014, 93, 350-358.	0.4	36
795	A Rare Presentation of Myocardial Plasmacytoma Assessed by FDG PET/CT. Clinical Nuclear Medicine, 2014, 39, 643-645.	0.7	7
796	Expression of Lâ€type amino acid transporter 1 (<scp>LAT</scp>1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Science, 2014, 105, 1496-1502.	1.7	54
797	A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target. Clinical Cancer Research, 2014, 20, 5796-5807.	3.2	56
798	Is there any relationship between gene expression of tumor antigens and CD4+T cells in multiple myeloma?. Immunotherapy, 2014, 6, 569-575.	1.0	1
799	Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 261-266.	1.4	21
800	Regular Aspirin Use and Risk of Multiple Myeloma: A Prospective Analysis in the Health Professionals Follow-up Study and Nurses' Health Study. Cancer Prevention Research, 2014, 7, 33-41.	0.7	27
801	The Genetic Architecture of Multiple Myeloma. Advances in Hematology, 2014, 2014, 1-16.	0.6	79
802	Maxillary pain is the first indication of the presence of multiple myeloma: A case report. Molecular and Clinical Oncology, 2014, 2, 59-64.	0.4	12
803	Solitary Bone Plasmacytoma Progressing into Retroperitoneal Plasma Cell Myeloma with No Related End Organ or Tissue Impairment: A Case Report and Review of the Literature. Turkish Journal of Haematology, 2014, 31, 286-289.	0.2	4
804	Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma. BioMed Research International, 2014, 2014, 1-6.	0.9	12
805	HIF-1Î± of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target. Clinical Cancer Research, 2014, 20, 847-858.	3.2	54
806	Monoclonal gammopathy of undetermined significance in pediatric kidney transplant: A possible role of Epsteinâ€Barr virus. Pediatric Transplantation, 2014, 18, 42-46.	0.5	4
807	Management of multiple myeloma in older people. Reviews in Clinical Gerontology, 2014, 24, 173-181.	0.5	0
808	Cancer in Renal Transplant Patients. , 2014, , 271-286.		0
809	Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. Leukemia Research, 2014, 38, 188-193.	0.4	16

#	Article	IF	Citations
810	Secondary Monoclonal Gammopathy of Undetermined Significance Is Frequently Associated with High Response Rate and Superior Survival in Patients with Plasma Cell Dyscrasias. Biology of Blood and Marrow Transplantation, 2014, 20, 319-325.	2.0	12
811	Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia, 2014, 28, 384-390.	3.3	252
812	Percutaneous Vertebroplasty for Pain Management in Patients with Multiple Myeloma: Is Radiofrequency Ablation Necessary?. CardioVascular and Interventional Radiology, 2014, 37, 203-210.	0.9	34
813	How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 303-309.	1.2	10
814	Predictors of plasma cell disorders among African American patients: a community practice perspective. Annals of Hematology, 2014, 93, 1015-1021.	0.8	1
815	A review of 74 patients with newly diagnosed multiple myeloma at a tertiary referral hospital in Nairobi, Kenya. Journal Africain Du Cancer, 2014, 6, 70-74.	0.1	3
816	11C-Acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 41-49.	3.3	38
817	The multiple oral presentations of multiple myeloma. Supportive Care in Cancer, 2014, 22, 259-267.	1.0	28
818	Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukemia, 2014, 28, 174-178.	3.3	66
819	Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia, 2014, 28, 1725-1735.	3.3	221
820	The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy. International Journal of Hematology, 2014, 99, 288-295.	0.7	20
822	Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma. Medical Oncology, 2014, 31, 900.	1.2	2
823	PET/CT studies of multiple myeloma using 18â€‰F-FDG and 18â€‰F-NaF: comparison of distribution patterns and tracersâ€™ pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1343-1353.	3.3	55
824	Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma. Annals of Hematology, 2014, 93, 463-469.	0.8	13
825	Confocal microscopy in a case of crystalline keratopathy in a patient with smouldering multiple myeloma. International Ophthalmology, 2014, 34, 651-654.	0.6	10
826	Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation. British Journal of Haematology, 2014, 165, 777-785.	1.2	30
827	Myeloma in Scar Tissue - An Underreported Phenomenon or an Emerging Entity in the Novel Agents' Era? A Single Center Series. Acta Haematologica, 2014, 132, 39-44.	0.7	15
828	Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains ofJAK1. Leukemia and Lymphoma, 2014, 55, 1176-1180.	0.6	1

#	Article	IF	Citations
829	Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 332-342.	1.1	48
830	Longâ€term outcome of monoclonal (type 1) cryoglobulinemia. American Journal of Hematology, 2014, 89, 156-161.	2.0	59
831	Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology. European Journal of Radiology, 2014, 83, 970-974.	1.2	11
832	Neurologic aspects of plasma cell disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 120, 1083-1099.	1.0	21
833	Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice. Clinical Cancer Research, 2014, 20, 804-813.	3.2	29
834	High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 24-30.	0.2	8
835	Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood, 2014, 123, 338-345.	0.6	105
836	AL amyloidosis or multiple myeloma? An important distinction. British Journal of Haematology, 2014, 164, 748-749.	1.2	8
837	AL amyloidosis or multiple myeloma? An important distinction â€“ response to Falk. British Journal of Haematology, 2014, 164, 749-750.	1.2	0
838	Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in Multiple myeloma patients?. European Journal of Haematology, 2014, 92, 13-18.	1.1	10
839	Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma. British Journal of Haematology, 2014, 164, 752-755.	1.2	10
840	Multiple myeloma: 2014 Update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2014, 89, 998-1009.	2.0	148
841	Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematology,the, 2014, 1, e28-e36.	2.2	40
843	Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica, 2014, 99, 1421-1432.	1.7	50
844	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	5.1	3,343
845	Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 356-369.	0.2	7
846	Severe acute kidney injury and multiple myeloma: Evaluation of kidney and patient prognostic factors. European Journal of Internal Medicine, 2014, 25, 652-656.	1.0	15
847	The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. British Journal of Haematology, 2014, 165, 441-454.	1.2	91

#	Article	IF	Citations
848	Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival. BMC Cancer, 2014, 14, 462.	1.1	30
849	Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 775-790.	0.9	35
850	A Longitudinal Computed Tomography Study ofÂLenalidomide and Bortezomib Treatment for Multiple Myeloma: Trabecular Microarchitecture and Biomechanics Assessed Using Multidetector Computed Tomography. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 485-492.	0.2	1
853	Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: Relationship with bone disease and clinical characteristics. Leukemia Research, 2014, 38, 525-531.	0.4	38
854	Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases. International Journal of Hematology, 2014, 99, 721-725.	0.7	10
856	Coexistence of Myeloproliferative Neoplasm and Plasma-Cell Dyscrasia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 31-36.	0.2	34
857	Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. European Journal of Radiology, 2014, 83, 1222-1230.	1.2	72
858	Expression profile of shelterin components in plasma cell disorders. Clinical significance of POT1 overexpression. Blood Cells, Molecules, and Diseases, 2014, 52, 134-139.	0.6	20
859	Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma. Clinical Cancer Research, 2014, 20, 3254-3260.	3.2	59
860	Whole-Body Diffusion-weighted MR Imaging for Assessment of Treatment Response in Myeloma. Radiology, 2014, 271, 785-794.	3.6	178
861	Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma. Leukemia Research, 2014, 38, 925-930.	0.4	21
862	Does thrombopoiesis in multiple myeloma patients depend on the stage of the disease?. Advances in Medical Sciences, 2014, 59, 166-171.	0.9	6
863	A descriptive study of plasma cell dyscrasias in Egyptian population. Journal of the Egyptian National Cancer Institute, 2014, 26, 67-71.	0.6	4
864	Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells. Cytotherapy, 2014, 16, 278-284.	0.3	6
865	Hematologic manifestations ofHelicobacter pyloriinfection. World Journal of Gastroenterology, 2014, 20, 12818.	1.4	62
866	Imaging of multiple myeloma: Current concepts. World Journal of Orthopedics, 2014, 5, 272.	0.8	67
867	A Case of Laryngo-tracheal Involvement of Multiple Myelomas. Practica Otologica, Supplement, 2014, 138, 88-89.	0.0	0
868	Diffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy. Internal Medicine, 2014, 53, 1809-1812.	0.3	6

#	Article	IF	Citations
869	Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood, 2014, 123, 647-649.	0.6	32
870	Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood, 2014, 123, 78-85.	0.6	173
871	S0120 G.E.M.S.: genomics encounters MGUS and SMM. Blood, 2014, 123, 4-5.	0.6	3
872	CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. Blood, 2014, 124, 2051-2060.	0.6	26
873	A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood, 2014, 124, 899-906.	0.6	73
874	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood, 2014, 124, 907-912.	0.6	111
875	Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood, 2014, 124, 1296-1299.	0.6	48
876	Curing myeloma at last: defining criteria and providing the evidence. Blood, 2014, 124, 3043-3051.	0.6	194
877	Unveiling Skeletal Fragility in Patients Diagnosed With MGUS: No Longer a Condition of Undetermined Significance?. Journal of Bone and Mineral Research, 2014, 29, 2529-2533.	3.1	42
878	Comparing Five Diagnostic Criteria for Multiple Myeloma: A Retrospective Study of 227 Cases. Tumori, 2014, 100, 207-213.	0.6	4
879	Bone Disease in Multiple Myeloma: Pathophysiology and Management. Cancer Growth and Metastasis, 2014, 7, CGM.S16817.	3.5	131
880	Advances in the management of asymptomatic myeloma. Current Opinion in Oncology, 2014, 26, 670-676.	1.1	5
881	The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica, 2014, 99, 629-637.	1.7	61
882	Neuroimaging of Plasmacytoma. Neuroradiology Journal, 2014, 27, 431-437.	0.6	24
883	Prognostic factors and their correlation with staging in patients with multiple myeloma: a single centre study in North India. Memo - Magazine of European Medical Oncology, 2015, 8, 189-193.	0.3	0
884	Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma. Medicine (United States), 2015, 94, e2305.	0.4	43
885	Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. Blood, 2015, 126, 1443-1451.	0.6	78
887	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica, 2015, 100, 1214-1221.	1.7	44

#	Article	IF	Citations
888	CD4+CD25+ cells in multiple myeloma related renal impairment. Scientific Reports, 2015, 5, 16565.	1.6	5
889	Incidental discovery of multiple myeloma, presenting as an amyloid tumor with plasmacytic elements of the thoracic wall. Romanian Journal of Internal Medicine, 2015, 53, 267-272.	0.4	0
890	Myelomatous Pleural Effusion Presenting with Extreme Hyperferritinemia and Severe Inflammatory Response. Case Reports in Oncology, 2015, 8, 349-355.	0.3	2
891	Correlation between microRNA-21 and sprouty homolog 2 gene expression in multiple myeloma. Molecular Medicine Reports, 2015, 11, 4220-4224.	1.1	8
893	Clinicopathological features of plasmablastic multiple myeloma: a populationâ€based cohort. Apmis, 2015, 123, 652-658.	0.9	20
894	Unusual coexistence of extramedullary plasmacytoma and nasopharyngeal carcinoma in nasopharynx. Diagnostic Pathology, 2015, 10, 170.	0.9	9
895	Myeloma cells act as tolerogenic antigenâ€presenting cells and induce regulatory <scp>T</scp> cells in vitro. European Journal of Haematology, 2015, 95, 65-74.	1.1	17
896	18F-FDG PET/CT for Early Postradiotherapy Assessment in Solitary Bone Plasmacytomas. Clinical Nuclear Medicine, 2015, 40, e399-e404.	0.7	16
897	Characterization of monoclonal gammopathy in patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2015, 132, 212-215.	1.0	1
898	Time to redefine Myeloma. British Journal of Haematology, 2015, 171, 1-10.	1.2	18
899	18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma. Clinical Nuclear Medicine, 2015, 40, e300-e307.	0.7	41
900	CHARACTERISTICS AND LONG-TERM OUTCOME OF PATIENTS WITH NONINFECTIOUS RETINAL VASCULITIS. Retina, 2015, 35, 2633-2640.	1.0	19
901	Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e493-e503.	1.8	11
902	Bone Cement Augmentation Procedures for Spinal Pathologic Fractures by Multiple Myeloma. Journal of Korean Medical Science, 2015, 30, 88.	1.1	20
903	Induction Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) in Caucasian Patients with Multiple Myeloma: A Single Center Experience. Journal of Blood Disorders & Transfusion, 2015, 06, .	0.1	0
904	Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors. Turkish Journal of Haematology, 2015, 32, 234-242.	0.2	23
905	A case of solitary plasmacytoma of bone arising in the mandible. Nihon Koku Geka Gakkai Zasshi, 2015, 61, 463-468.	0.0	2
906	The Use of MAGE C1 and Flow Cytometry to Determine the Malignant Cell Type in Multiple Myeloma. PLoS ONE, 2015, 10, e0120734.	1.1	14

#	Article	IF	Citations
907	Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma. PLoS ONE, 2015, 10, e0127022.	1.1	18
908	Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. PLoS ONE, 2015, 10, e0137552.	1.1	7
909	A Rare Case of Nonsecretory Multiple Myeloma in Lagos, Nigeria: A Case Report and Literature Review. Case Reports in Medicine, 2015, 2015, 1-3.	0.3	2
910	Maxillary Swelling as the First Evidence of Multiple Myeloma. Case Reports in Dentistry, 2015, 2015, 1-5.	0.2	7
911	Smoldering Multiple Myeloma. BioMed Research International, 2015, 2015, 1-7.	0.9	3
913	High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity. Tumor Biology, 2015, 36, 8491-8497.	0.8	8
914	The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. JAMA Oncology, 2015, 1, 168.	3.4	93
915	Treatment for IgG and IgA paraproteinaemic neuropathy. The Cochrane Library, 2019, 2019, CD005376.	1.5	23
916	Inter-observer agreement for the evaluation of bone involvement on Whole Body Low Dose Computed Tomography (WBLDCT) in Multiple Myeloma (MM). European Radiology, 2015, 25, 3382-3389.	2.3	5
917	t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer Journal, 2015, 5, e285-e285.	2.8	33
918	Evolving diagnostic criteria for multiple myeloma. Hematology American Society of Hematology Education Program, 2015, 2015, 272-278.	0.9	51
919	Identification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression. Hematology, 2015, 20, 11-17.	0.7	1
920	A voluminous mass as an initial clinical symptom of multiple myeloma: A case report. Experimental and Therapeutic Medicine, 2015, 10, 1689-1691.	0.8	1
921	Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments. Oncology Reports, 2015, 33, 2935-2939.	1.2	15
922	LABORATORIO DE INMUNOLOGÃA EN LA PRÃCTICA CLÃNICA. Revista MÃ©dica ClÃnica Las Condes, 2015, 26, 764-775.	0.2	1
923	Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?. Leukemia and Lymphoma, 2015, 56, 34-41.	0.6	2
924	Dilemmas in Treating Smoldering Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 115-123.	0.8	19
925	Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Annals of Hematology, 2015, 94, 257-264.	0.8	52

#	Article	IF	Citations
926	A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia, 2015, 29, 218-229.	3.3	55
927	GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica, 2015, 100, 377-384.	1.7	64
928	Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. Lancet Haematology,the, 2015, 2, e30-e36.	2.2	54
929	Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument. Annals of Hematology, 2015, 94, 1017-1024.	0.8	9
930	Management of asymptomatic myeloma patients. Expert Review of Hematology, 2015, 8, 19-27.	1.0	0
931	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. Journal of Clinical Oncology, 2015, 33, 657-664.	0.8	330
932	Comparison of 11C-4â€²-thiothymidine, 11C-methionine, and 18F-FDG PET/CT for the detection of active lesions of multiple myeloma. Annals of Nuclear Medicine, 2015, 29, 224-232.	1.2	42
933	Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. , 2015, 88, 101-109.		9
934	Clinical course and prognosis of nonâ€secretory multiple myeloma. European Journal of Haematology, 2015, 95, 57-64.	1.1	50
935	A retrospective study of correlation of morphologic patterns, MIB1 proliferation index, and survival analysis in 134 cases of plasmacytoma. Annals of Diagnostic Pathology, 2015, 19, 117-123.	0.6	13
936	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Resultsâ€“Medicare Database. Biology of Blood and Marrow Transplantation, 2015, 21, 1823-1829.	2.0	30
937	Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney International, 2015, 88, 1135-1143.	2.6	104
938	Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leukemia and Lymphoma, 2015, 56, 1416-1424.	0.6	23
939	Bilateral pleural effusion as an initial manifestation of multiple myeloma: A case report and literature review. Experimental and Therapeutic Medicine, 2015, 9, 1040-1042.	0.8	8
940	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	5.8	38
941	Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 368-376.	0.2	28
942	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. OncoImmunology, 2015, 4, e1008850.	2.1	27
943	Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT. Annals of Hematology, 2015, 94, 1567-1575.	0.8	23

#	Article	IF	Citations
944	Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. Acta Radiologica, 2015, 56, 733-738.	0.5	26
945	Cheâ€1â€induced inhibition of <scp>mTOR</scp> pathway enables stressâ€induced autophagy. EMBO Journal, 2015, 34, 1214-1230.	3.5	66
946	Multiple asymptomatic colon plasmacytomas: a diagnostic and therapeutic dilemma. Annals of Hematology, 2015, 94, 1061-1062.	0.8	1
947	New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies. Nephrologie Et Therapeutique, 2015, 11, 135-143.	0.2	19
948	MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management. European Journal of Endocrinology, 2015, 173, R131-R151.	1.9	215
949	Plasma cell leukemia: Clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases. Hematology/ Oncology and Stem Cell Therapy, 2015, 8, 71-77.	0.6	4
950	The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 2148-2156.	3.2	76
951	BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood Cancer Journal, 2015, 5, e299-e299.	2.8	36
952	MR Imaging and PET/CT in Diagnosis and Management of Multiple Myeloma. Radiographics, 2015, 35, 438-454.	1.4	38
953	A single-center case series of eight patients with the rare plasma cell dyscrasia of acquired Fanconi syndrome secondary to monoclonal gammopathy. Leukemia and Lymphoma, 2015, 56, 3124-3128.	0.6	3
954	Guidelines on the diagnosis and investigation of AL amyloidosis. British Journal of Haematology, 2015, 168, 207-218.	1.2	122
955	The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. Bone Marrow Transplantation, 2015, 50, 822-828.	1.3	17
956	The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. Leukemia, 2015, 29, 1713-1720.	3.3	6
957	Current therapeutic strategies for multiple myeloma. International Journal of Clinical Oncology, 2015, 20, 423-430.	1.0	22
958	High incidence of intact or fragmented immunoglobulin in urine of patients with multiple myeloma. Leukemia and Lymphoma, 2015, 56, 3348-3356.	0.6	5
959	Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. Journal of Molecular Diagnostics, 2015, 17, 669-678.	1.2	36
960	Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients. Pathologie Et Biologie, 2015, 63, 215-221.	2.2	6
961	Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance. Blood Cancer Journal, 2015, 5, e345-e345.	2.8	23

#	Article	IF	Citations
962	Bromodomain inhibition by JQ1 suppresses lipopolysaccharide-stimulated interleukin-6 secretion in multiple myeloma cells. Cytokine, 2015, 71, 415-417.	1.4	11
963	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica, 2015, 100, 1254-1266.	1.7	289
964	Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. Blood Cancer Journal, 2015, 5, e294-e294.	2.8	5
965	Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma. Blood Cancer Journal, 2015, 5, e329-e329.	2.8	23
966	Trends in survival of multiple myeloma: A thirty-year population-based study in a single institution. Cancer Epidemiology, 2015, 39, 693-699.	0.8	24
967	Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 563-577.e3.	0.2	50
968	Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2015, 56, 3320-3328.	0.6	67
969	Case 27-2015. New England Journal of Medicine, 2015, 373, 864-873.	13.9	3
970	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, andÂSoft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1413-1417.	2.0	5
971	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocrine-Related Cancer, 2015, 22, 545-559.	1.6	11
972	The road to cure in multiple myeloma starts with smoldering disease. Expert Opinion on Orphan Drugs, 2015, 3, 653-661.	0.5	6
973	A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents. European Journal of Haematology, 2015, 94, 145-151.	1.1	13
974	Neutrophil Gelatinase-Associated Lipocalin as a Biomarker of Renal Impairment in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 35-40.	0.2	8
975	Multiple Myeloma: 18F-FDG-PET/CT and Diagnostic Imaging. Seminars in Nuclear Medicine, 2015, 45, 16-31.	2.5	21
976	Paraproteinemic neuropathies. Muscle and Nerve, 2015, 51, 1-13.	1.0	33
977	Multiple myeloma maintenance therapy: A review of the pharmacologic treatment. Journal of Oncology Pharmacy Practice, 2015, 21, 36-51.	0.5	19
978	Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal. Hematological Oncology, 2015, 33, 75-79.	0.8	10
979	Perioperative Considerations in the Management of a Patient With Multiple Myeloma Undergoing Aortic Valve Replacement. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 151-155.	0.6	2

#	Article	IF	Citations
980	Classifying ultra-high risk smoldering myeloma. Leukemia, 2015, 29, 751-753.	3.3	37
981	Cancer and Chronic Kidney Disease. , 2015, , 571-584.		1
982	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. International Journal of Cancer, 2015, 136, E351-8.	2.3	30
983	18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clinical and Experimental Medicine, 2015, 15, 1-18.	1.9	60
984	Strategy for Detecting and Following Monoclonal Gammopathies. , 0, , 112-124.		4
985	Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. The Cochrane Library, 0, , .	1.5	0
986	Multiple Solitary Plasmacytomas Arising in the Posterior Mediastinum and Sternum: A Case Report. Journal of the Korean Society of Radiology, 2016, 74, 199.	0.1	0
987	Plasma Cell Disorders. , 2016, , 535-553.		0
988	Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget, 2016, 7, 30876-30891.	0.8	89
989	NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017053.	0.5	18
990	Helicobacter pylori and Hematologic Diseases. , 0, , .		1
991	Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e400-e406.	1.8	2
992	Updated Diagnostic Criteria and Staging System for Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e418-e423.	1.8	199
993	Solitary Bone Plasmacytoma of the Pelvis: A Rare Tumor. Rare Tumors, 2016, 8, 39-41.	0.3	2
994	Two Cases of Heavy Chain MGUS. Case Reports in Oncological Medicine, 2016, 2016, 1-4.	0.2	4
995	Imaging Findings of Plasmacytoma of Both Breasts as a Preceding Manifestation of Multiple Myeloma. Case Reports in Medicine, 2016, 2016, 1-5.	0.3	7
996	Plasma Levels of Monocyte Chemotactic Protein-1 Are Associated with Clinical Features and Angiogenesis in Patients with Multiple Myeloma. BioMed Research International, 2016, 2016, 1-7.	0.9	10
998	The Diagnosis and Treatment of Multiple Myeloma. Deutsches Ärzteblatt International, 2016, 113, 470-6.	0.6	129

#	Article	IF	Citations
999	Non-secretory multiple myeloma: from biology to clinical management. OncoTargets and Therapy, 2016, Volume 9, 7583-7590.	1.0	39
1000	Extramedullary Plasmacytoma in the Mesentery. Japanese Journal of Gastroenterological Surgery, 2016, 49, 746-753.	0.0	3
1001	Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study. PLoS ONE, 2016, 11, e0154993.	1.1	22
1002	Cardiac Amyloidosis Presenting With Cardiogenic Shock. American Journal of Therapeutics, 2016, 23, e1060-e1063.	0.5	1
1003	Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma. Medicine (United States), 2016, 95, e3521.	0.4	24
1004	Increased microcirculation detected by dynamic contrastâ€enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma. British Journal of Haematology, 2016, 174, 127-135.	1.2	25
1005	Multiple myeloma: the quality of care is linked to geographical and organisational determinants. A study in a French registry. European Journal of Cancer Care, 2016, 25, 855-863.	0.7	4
1006	Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers. European Journal of Haematology, 2016, 97, 201-207.	1.1	4
1007	Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?. Genes Chromosomes and Cancer, 2016, 55, 710-718.	1.5	28
1008	Reduction in Câ€reactive protein indicates successful targeting of the ILâ€1/ILâ€6 axis resulting in improved survival in early stage multiple myeloma. American Journal of Hematology, 2016, 91, 571-574.	2.0	75
1009	Abdominal adipose tissue in MGUS and multiple myeloma. Skeletal Radiology, 2016, 45, 1277-1283.	1.2	24
1010	Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1127-1136.	5.1	128
1011	Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agentsâ€™ era. Annals of Hematology, 2016, 95, 1465-1472.	0.8	11
1012	Early mortality in multiple myeloma: the timeâ€dependent impact of comorbidity: A populationâ€based study in 621 realâ€life patients. American Journal of Hematology, 2016, 91, 700-704.	2.0	28
1013	Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers. Internal Medicine, 2016, 55, 1183-1186.	0.3	1
1014	Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head. Journal of International Medical Research, 2016, 44, 1462-1473.	0.4	5
1015	Clinical significance of granuleâ€containing myeloma cells in patients with newly diagnosed multiple myeloma. Cancer Medicine, 2016, 5, 3051-3058.	1.3	3
1016	Pee no more? Urine light chains down the drain. Blood, 2016, 128, 2873-2874.	0.6	2

#	Article	IF	Citations
1017	Monoclonal gammopathy of undeterminated significance and endoneurial IgG deposition. Medicine (United States), 2016, 95, e4807.	0.4	10
1018	The Role of PET/CT in the Assessment of Primary Bone Tumors. Current Radiology Reports, 2016, 4, 1.	0.4	2
1019	The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients. Leukemia Research, 2016, 46, 85-88.	0.4	20
1020	The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma. Pathology Research and Practice, 2016, 212, 509-516.	1.0	10
1021	A man with a short history of lower back pain. BMJ, The, 2016, 353, i1722.	3.0	0
1022	Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma. Surgical Pathology Clinics, 2016, 9, 101-116.	0.7	7
1023	Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single Chinese center. Annals of Hematology, 2016, 95, 901-909.	0.8	22
1024	Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902). Annals of Hematology, 2016, 95, 921-929.	0.8	3
1025	Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica, 2016, 101, 356-362.	1.7	25
1026	Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. Leukemia, 2016, 30, 2026-2031.	3.3	19
1027	Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 335-340.	0.2	16
1028	Presentation of multiple myeloma mimicking bone metastasis from colon adenocarcinoma: A case report and literature review. Molecular and Clinical Oncology, 2016, 4, 31-34.	0.4	4
1030	The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution. Cancer Medicine, 2016, 5, 500-505.	1.3	5
1031	A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or endâ€stage renal disease requiring haemodialysis. British Journal of Haematology, 2016, 174, 748-759.	1.2	48
1032	Prevalence of monoclonal gammopathy of undetermined significance (MGUS) among farmers involved in open field farming and/or cattle breading in France. Leukemia and Lymphoma, 2016, 57, 1727-1730.	0.6	6
1034	IRE1Î±-XBP1 signaling pathway, a potential therapeutic target in multiple myeloma. Leukemia Research, 2016, 49, 7-12.	0.4	42
1035	Multiple myeloma detection based on blood plasma surface-enhanced Raman spectroscopy using a portable Raman spectrometer. Laser Physics Letters, 2016, 13, 105601.	0.6	6
1036	Imaging of Multiple Myeloma. Hematology/Oncology Clinics of North America, 2016, 30, 843-865.	0.9	12

#	Article	IF	Citations
1037	Multiple myeloma epidemiology and survival: A unique malignancy. Seminars in Oncology, 2016, 43, 676-681.	0.8	492
1038	Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma. Cancer Chemotherapy and Pharmacology, 2016, 78, 1237-1244.	1.1	4
1039	Controversies in multiple myeloma: Evidence-based update. Seminars in Oncology, 2016, 43, 666-675.	0.8	6
1040	miR-203 inhibits cell growth and regulates G1/S transition by targeting Bmi-1 in myeloma cells. Molecular Medicine Reports, 2016, 14, 4795-4801.	1.1	20
1041	Labordiagnostik bei der monoklonalen Gammopathie unklarer Signifikanz (MGUS). Laboratoriums Medizin, 2016, 40, .	0.1	0
1042	Multicentered patientâ€based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. European Journal of Haematology, 2016, 96, 119-127.	1.1	8
1043	Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation. International Journal of Laboratory Hematology, 2016, 38, 298-307.	0.7	5
1044	Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer, 2016, 16, 290.	1.1	5
1045	Imaging Manifestations of Hematologic Diseases with Renal and Perinephric Involvement. Radiographics, 2016, 36, 1038-1054.	1.4	30
1046	Cutaneous plasmacytoma adjacent to Bowenoid actinic keratosis on the scalp: Is there a link?. International Journal of Surgery Case Reports, 2016, 21, 52-54.	0.2	3
1047	Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. Cancer Chemotherapy and Pharmacology, 2016, 78, 173-182.	1.1	17
1048	When an Analytical Interference Is a Useful Diagnostic Tool: Finding Monoclonal Gammopathies in Routine Analysis. Journal of Clinical Laboratory Analysis, 2016, 30, 140-144.	0.9	6
1049	Association between hepatitis B virus infection and risk of multiple myeloma: a systematic review and metaâ€analysis. Internal Medicine Journal, 2016, 46, 307-314.	0.5	8
1050	Oligodendroglioma metastasis to the bone marrow mimicking multiple myeloma: A case report. Oncology Letters, 2016, 12, 351-355.	0.8	3
1051	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	2.0	30
1052	18F-FDG PET/CT Metabolic Activity in a Patient With Solitary Extramedullary Plasmacytoma of the Lung. Clinical Nuclear Medicine, 2016, 41, 232-234.	0.7	10
1053	Clinical features and prognostic factors in solitary plasmacytoma. British Journal of Haematology, 2016, 172, 554-560.	1.2	69
1054	Monoclonal gammopathyâ€associated pure red cell aplasia. British Journal of Haematology, 2016, 173, 876-883.	1.2	22

#	Article	IF	Citations
1055	Smoldering multiple myeloma risk factors for progression: a Danish populationâ€based cohort study. European Journal of Haematology, 2016, 97, 303-309.	1.1	54
1056	Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Journal of Oncology Pharmacy Practice, 2016, 22, 289-302.	0.5	21
1057	Implemented myeloma management with whole-body low-dose CT scan: a real life experience. Leukemia and Lymphoma, 2016, 57, 1539-1545.	0.6	10
1058	Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cellular and Molecular Life Sciences, 2016, 73, 1569-1589.	2.4	100
1059	Myeloma. , 2016, , 89-100.		0
1060	The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma. Hematology, 2016, 21, 152-161.	0.7	10
1061	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. Journal of Proteomics, 2016, 136, 89-98.	1.2	68
1062	A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. International Journal of Hematology, 2016, 103, 25-33.	0.7	14
1063	Vertebral lesion distribution in multiple myelomaâ€"assessed by reduced-dose whole-body MDCT. Skeletal Radiology, 2016, 45, 127-133.	1.2	9
1064	To biopsy or not to biopsy, that is the question in myeloma cast nephropathy. Nephrology Dialysis Transplantation, 2016, 31, 1-3.	0.4	62
1065	State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias. Radiologic Clinics of North America, 2016, 54, 581-596.	0.9	11
1066	Minimal tumour burden in haematological diseases: a step forward with quantitative assessment of Bence€Jones in nephelometry?. British Journal of Haematology, 2016, 175, 733-735.	1.2	5
1067	Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma. Clinical Cancer Research, 2016, 22, 3383-3397.	3.2	74
1068	Surgery of the Scalp. , 2016, , 19-30.		0
1069	Cutaneous involvement in multiple myeloma (MM): A case series with clinicopathologic correlation. Journal of the American Academy of Dermatology, 2016, 74, 878-884.	0.6	29
1070	Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR). Leukemia and Lymphoma, 2016, 57, 2330-2341.	0.6	4
1071	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist, 2016, 21, 333-342.	1.9	28
1072	High prevalence of secondary factors for bone fragility in patients with a recent fracture independently of BMD. Archives of Osteoporosis, 2016, 11, 12.	1.0	30

#	Article	IF	Citations
1073	Paraproteinemic neuropathy: a practical review. BMC Neurology, 2016, 16, 13.	0.8	54
1074	An elderly man with a gingival mass that spontaneously regressed. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 121, 348-352.	0.2	5
1075	Improved Follow-Up and Response Monitoring of Thoracic Cage Involvement in Multiple Myeloma Using a Novel CT Postprocessing Software: The Lessons We Learned. American Journal of Roentgenology, 2016, 206, 57-63.	1.0	11
1076	Laboratory guidelines for the diagnosis and follow-up of patients with monoclonal gammopathies. Revista Clínica Espanõla, 2016, 216, 128-134.	0.3	0
1077	Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China. Tumor Biology, 2016, 37, 7893-7900.	0.8	10
1078	CD20-positive multiple myeloma: can conventional chemotherapy still be used to achieve ideal outcome for these patients?. Leukemia and Lymphoma, 2016, 57, 335-340.	0.6	7
1079	GuÃa de laboratorio para el diagnÃ³stico y seguimiento de pacientes con gammapatÃas monoclonales. Revista Clinica Espanola, 2016, 216, 128-134.	0.2	1
1080	Plasma Cell Neoplasms, A Therapeutic Approach. , 2016, , 123-141.		0
1081	Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrology Dialysis Transplantation, 2016, 31, 64-72.	0.4	46
1082	Hematolymphoid lesions of the sinonasal tract. Seminars in Diagnostic Pathology, 2016, 33, 71-80.	1.0	17
1083	Thoracic Bone Tumors Every Radiologist Should Know. Current Problems in Diagnostic Radiology, 2016, 45, 71-79.	0.6	0
1084	Gradual increase of chronic lymphocytic leukemia incidence in Korea, 1999â€“2010: comparison to plasma cell myeloma. Leukemia and Lymphoma, 2016, 57, 585-589.	0.6	12
1085	Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biology of Blood and Marrow Transplantation, 2016, 22, 54-60.	2.0	12
1087	Plasma Cell Neoplasms. , 2016, , .		37
1088	Capillary electrophoresis analysis of Nâ€glycosylation changes of serum paraproteins in multiple myeloma. Electrophoresis, 2017, 38, 2115-2123.	1.3	17
1089	Interferencias por terapia con anticuerpos monoclonales en electroforesis e inmunofijaciÃ³n de proteÃnas sÃ©ricas. Revista Del Laboratorio ClÃnico, 2017, 10, 14-20.	0.1	0
1090	Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study. Journal of the National Cancer Institute, 2017, 109, djw264.	3.0	61
1091	Advances in Clinical Mass Spectrometry. Advances in Clinical Chemistry, 2017, 79, 153-198.	1.8	18

#	Article	IF	Citations
1092	Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma. Blood Cancer Journal, 2017, 7, e530-e530.	2.8	33
1093	Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma. BMC Infectious Diseases, 2017, 17, 33.	1.3	24
1094	Extranodal marginal zone Bâ€cell lymphoma of mucosaâ€associated lymphoid tissue with plasma cell differentiation: Periodic acidâ€schiff reactionâ€positive Dutcher body is a diagnostic clue to distinguish it from plasmacytoma. Diagnostic Cytopathology, 2017, 45, 547-551.	0.5	4
1096	Automated â€œBone Subtractionâ€•Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma. Academic Radiology, 2017, 24, 623-632.	1.3	11
1097	The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study. European Journal of Clinical Pharmacology, 2017, 73, 771-778.	0.8	5
1098	Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathyâ€“associated C3 glomerulopathy. Blood, 2017, 129, 1437-1447.	0.6	120
1099	End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. Future Oncology, 2017, 13, 1181-1193.	1.1	25
1100	Monoclonal gammopathy of undetermined significance and biological treatments: What should we do?. Joint Bone Spine, 2017, 84, 651-653.	0.8	0
1102	A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. European Journal of Haematology, 2017, 99, 80-90.	1.1	7
1103	Corneal Densitometry for Quantification of Corneal Deposits in Monoclonal Gammopathies. Cornea, 2017, 36, 470-475.	0.9	17
1104	Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica, 2017, 102, 1099-1104.	1.7	81
1105	Identification and expression of MMSA-8, and its clinical significance in multiple myeloma. Oncology Reports, 2017, 37, 3235-3243.	1.2	2
1106	How is patient care for multiple myeloma advancing?. Expert Review of Hematology, 2017, 10, 551-561.	1.0	11
1107	Metastatic Intracerebral Plasmacytoma Treated with Radiation and Thalidomide, Dexamethasone with Cyclophosphamide Chemotherapy. World Neurosurgery, 2017, 103, 953.e13-953.e17.	0.7	0
1108	Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. British Journal of Haematology, 2017, 178, 196-208.	1.2	17
1109	Glomerular Diseases Associated with Malignancies. , 2017, , 1-40.		0
1110	Prevalence of Monoclonal Gammopathy of Undetermined Significance in an Apparently Healthy Yixing Population in Mainland China. Acta Haematologica, 2017, 137, 17-19.	0.7	1
1112	Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Populationâ€based data from the Swedish Myeloma Register. European Journal of Haematology, 2017, 99, 216-222.	1.1	48

#	Article	IF	Citations
1113	Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm. European Radiology, 2017, 27, 2969-2977.	2.3	4
1114	Evaluation of pretreatment red cell distribution width in patients with multiple myeloma. Cancer Biomarkers, 2017, 20, 267-272.	0.8	18
1115	Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Annals of Oncology, 2017, 28, 2503-2510.	0.6	45
1116	GammapatÃas monoclonales de significado renal. Nefrologia, 2017, 37, 465-477.	0.2	17
1117	A possible new morphological variant of mantle cell lymphoma with plasma-cell type Castleman disease-like features. Pathology Research and Practice, 2017, 213, 1378-1383.	1.0	5
1118	Monoclonal gammopathies of renal significance. Nefrologia, 2017, 37, 465-477.	0.2	6
1119	Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer Journal, 2017, 7, e599-e599.	2.8	124
1120	Pleural Effusion in Multiple Myeloma: Characteristics and Practice Patterns. Acta Haematologica, 2017, 138, 69-76.	0.7	16
1121	Is long-term particulate matter and nitrogen dioxide air pollution associated with incident monoclonal gammopathy of undetermined significance (MGUS)? An analysis of the Heinz Nixdorf Recall study. Environment International, 2017, 108, 237-245.	4.8	8
1122	Guidelines for the use of imaging in the management of patients with myeloma. British Journal of Haematology, 2017, 178, 380-393.	1.2	101
1123	Long-term Clinical Outcome of Antibody Replacement Therapy in Humoral Immunodeficient Adults With Respiratory Tract Infections. EBioMedicine, 2017, 18, 254-260.	2.7	9
1124	Anti-proliferative activity of CGK012 against multiple myeloma cells via Wnt/Î²-catenin signaling attenuation. Leukemia Research, 2017, 60, 103-108.	0.4	9
1125	Pseudo-monoclonal gammopathy: a report of four cases. Haematologica, 2017, 102, e466-e469.	1.7	11
1126	Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma. Medicine (United States), 2017, 96, e5787.	0.4	8
1127	Efficacy of daratumumabâ€based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	2.0	25
1129	Extra-skeletal plasmablastic myeloma presenting as palatal growth â€“ An unusual entity. International Journal of Surgery Case Reports, 2017, 41, 423-426.	0.2	4
1130	Case report: metastatic infratemporal soft tissue myeloma presenting as a numb lower lip. Dental Update, 2017, 44, 53-54.	0.1	1
1131	Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry. Clinics in Laboratory Medicine, 2017, 37, 821-853.	0.7	20

#	Article	IF	Citations
1132	Expressed fusion gene landscape and its impact in multiple myeloma. Nature Communications, 2017, 8, 1893.	5.8	31
1133	Multiple myeloma of the mandibular condyle: a rare presentation. British Journal of Oral and Maxillofacial Surgery, 2017, 55, 1046-1047.	0.4	2
1134	The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide populationâ€based study. Cancer Medicine, 2017, 6, 1807-1816.	1.3	39
1135	Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma. Strahlentherapie Und Onkologie, 2017, 193, 742-749.	1.0	37
1137	Extramedullary plasmacytoma of the ureter in an HIV-positive patient. International Cancer Conference Journal, 2017, 6, 171-174.	0.2	2
1138	IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report. BMC Immunology, 2017, 18, 32.	0.9	9
1139	Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report. BMC Nephrology, 2017, 18, 127.	0.8	14
1140	Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination. Tropical Diseases, Travel Medicine and Vaccines, 2017, 3, 3.	0.9	23
1141	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. Hematological Oncology, 2017, 35, 432-439.	0.8	8
1142	Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy. Leukemia and Lymphoma, 2017, 58, 1076-1083.	0.6	18
1143	Assessment of Bone Fragility in Patients With Multiple Myeloma Using QCT-Based Finite Element Modeling. Journal of Bone and Mineral Research, 2017, 32, 151-156.	3.1	13
1144	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clinical Cancer Research, 2017, 23, 2665-2672.	3.2	13
1145	Unravelling the immunopathological mechanisms of heavy chain deposition disease with implicationsÂfor clinical management. Kidney International, 2017, 91, 423-434.	2.6	66
1146	The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia, 2017, 31, 853-860.	3.3	72
1147	Observational study of multiple myeloma in Latin America. Annals of Hematology, 2017, 96, 65-72.	0.8	29
1148	Plasma cell leukemia: update on biology and therapy. Leukemia and Lymphoma, 2017, 58, 1538-1547.	0.6	36
1149	Comparison of Fully Automated and Semiautomated Systems for Protein Immunofixation Electrophoresis. Journal of Clinical Laboratory Analysis, 2017, 31, e22027.	0.9	3
1150	The Predictive Role of the Neutrophil/Lymphocyte Ratio in Survival with Multiple Myeloma: A Single Center Experience. Journal of Clinical Laboratory Analysis, 2017, 31, e22032.	0.9	15

#	Article	IF	Citations
1151	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. Radiology, 2017, 282, 484-493.	3.6	81
1152	Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 50-62.	3.3	37
1153	Epidemiology of Hematologic Malignancies. , 2017, , 543-569.		9
1154	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia and Lymphoma, 2017, 58, 639-645.	0.6	11
1155	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia, 2017, 31, 130-135.	3.3	63
1156	Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia, 2017, 31, 136-142.	3.3	50
1157	A Study on Free Light Chain Assay and Serum Immunofixation Electrophoresis for the Diagnosis of Monoclonal Gammopathies. Indian Journal of Clinical Biochemistry, 2019, 34, 76-81.	0.9	0
1160	The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient. Internal Medicine, 2017, 56, 841-846.	0.3	6
1161	AKI in Multiple Myeloma: Paraproteins, Metabolic Disturbances, and Drug Toxicity. Journal of Onco-Nephrology, 2017, 1, 188-197.	0.3	5
1162	An uncommon hip pain. BMJ Case Reports, 2017, 2017, bcr-2017-221717.	0.2	0
1163	Multiple Solitary Plasmacytomas Presenting with Painful Erythematous Swelling of the Upper Eyelid. Journal of Korean Ophthalmological Society, 2017, 58, 216.	0.0	1
1164	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Advances, 2017, 1, 1911-1918.	2.5	37
1165	Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Advances, 2017, 1, 2186-2192.	2.5	47
1166	Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. Oncology Letters, 2017, 14, 4372-4378.	0.8	9
1167	Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases. International Journal of Molecular Sciences, 2017, 18, 804.	1.8	7
1168	Solitary Plasmacytoma of the Mesentery: A Systematic Clinicianâ€™s Diagnosis. Case Reports in Oncological Medicine, 2017, 2017, 1-4.	0.2	4
1169	Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study. PLoS ONE, 2017, 12, e0180562.	1.1	38
1170	High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. PLoS ONE, 2017, 12, e0181487.	1.1	10

#	Article	IF	Citations
1171	Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. PLoS ONE, 2017, 12, e0188988.	1.1	36
1172	N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma. BMC Cancer, 2017, 17, 881.	1.1	14
1173	Strategy for the treatment and follow-up of sinonasal solitary extramedullary plasmacytoma: a case series. Journal of Medical Case Reports, 2017, 11, 219.	0.4	19
1174	Characteristics and Prognosis of Patients with Immunoglobulin M Monoclonal Gammopathy. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 47-53.	0.3	3
1175	Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 438-446.	0.7	22
1176	Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions. Cancer Management and Research, 2017, Volume 9, 189-196.	0.9	13
1178	Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematology Reports, 2017, 9, 16-18.	0.3	20
1179	Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. JCO Clinical Cancer Informatics, 2017, 1, 1-8.	1.0	12
1180	Panoramic and skull imaging may aid in the identification of multiple myeloma lesions. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2017, 23, 0-0.	0.7	5
1181	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. Leukemia, 2018, 32, 2427-2434.	3.3	8
1182	Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 79-85.	1.4	17
1183	Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide. Therapeutic Drug Monitoring, 2018, 40, 301-309.	1.0	9
1184	Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Cancer Science, 2018, 109, 1552-1561.	1.7	10
1185	Short overview on the current standard of treatment in newly diagnosed multiple myeloma. Memo - Magazine of European Medical Oncology, 2018, 11, 59-64.	0.3	8
1186	The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharmaceutica Sinica B, 2018, 8, 539-551.	5.7	141
1187	Risk factors for blood stream infections in multiple myeloma: A populationâ€based study of 1154 patients in Denmark. European Journal of Haematology, 2018, 101, 21-27.	1.1	23
1188	Stem cell mobilization kinetics in elderly patients with multiple myeloma. Transfusion and Apheresis Science, 2018, 57, 204-207.	0.5	0
1189	Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 235-248.	0.2	11

#	Article	IF	Citations
1190	Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient. Academic Radiology, 2018, 25, 904-914.	1.3	31
1191	Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 219-224.	0.2	34
1192	Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma. Leukemia and Lymphoma, 2018, 59, 2546-2556.	0.6	29
1193	Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma. Annals of Hematology, 2018, 97, 851-863.	0.8	5
1194	Nâ€terminal Bâ€type natriuretic peptide (NTâ€proBNP) is associated with disease severity in multiple myeloma. European Journal of Clinical Investigation, 2018, 48, e12905.	1.7	8
1195	Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia, 2018, 32, 1427-1434.	3.3	48
1196	Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013. Cancer Epidemiology, 2018, 53, 105-110.	0.8	21
1197	Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma. Skeletal Radiology, 2018, 47, 351-361.	1.2	10
1198	Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. Journal of Heart and Lung Transplantation, 2018, 37, 611-618.	0.3	66
1199	Nanobody-based dual epitopes protein identification (DepID) assay for measuring soluble CD38 in plasma of multiple myeloma patients. Analytica Chimica Acta, 2018, 1029, 65-71.	2.6	14
1200	Hematologistsâ€™ Preferences for First-line Therapy Characteristics for Multiple Myeloma in Japan: Attribute Rating and Discrete Choice Experiment. Clinical Therapeutics, 2018, 40, 296-308.e2.	1.1	14
1201	A rare case of a minimally secretory plasma cell leukemia with a hemorrhagic gastric plasmacytoma. Leukemia Research Reports, 2018, 9, 23-27.	0.2	0
1202	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer Journal, 2018, 8, 31.	2.8	35
1203	Monoclonal gammopathy in rheumatic diseases. Clinical Rheumatology, 2018, 37, 1751-1762.	1.0	22
1204	Pre-ESRD Care and Mortality in Incident ESRD Patients With Multiple Myeloma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 367-370.	0.6	4
1205	Diagnosis and management of neuropathies associated with plasma cell dyscrasias. Hematological Oncology, 2018, 36, 3-14.	0.8	18
1206	Ageâ€related health care disparities in multiple myeloma. Hematological Oncology, 2018, 36, 224-231.	0.8	8
1207	Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Leukemia and Lymphoma, 2018, 59, 178-186.	0.6	2

#	Article	IF	Citations
1208	Diagnosis and management of smoldering multiple myeloma: the razorâ€™s edge between clonality and cancer. Leukemia and Lymphoma, 2018, 59, 288-299.	0.6	10
1209	Autoantibodies against Î²1-adrenergic receptor: response to induction therapy with bortezomib-containing regimens for multiple myeloma patients. Leukemia and Lymphoma, 2018, 59, 717-724.	0.6	2
1210	Natural history of t(11;14) multiple myeloma. Leukemia, 2018, 32, 131-138.	3.3	67
1211	miRNA meets plasma cells â€œHow tiny RNAs control antibody responsesâ€• Clinical Immunology, 2018, 186, 3-8.	1.4	12
1212	Efficacy of VDT PACEâ€like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	2.0	49
1213	Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines. European Radiology, 2018, 28, 683-691.	2.3	33
1214	Monoclonal gammopathy of undetermined significance as viewed by haematology healthcare professionals. European Journal of Haematology, 2018, 100, 20-26.	1.1	8
1215	Neurologic Complications of Plasma Cell Dyscrasias. , 2018, , 583-595.		1
1216	Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea. Journal of the American Academy of Dermatology, 2018, 78, 471-478.e4.	0.6	22
1217	Role of Plasmapheresis in the Management of Acute Kidney Injury in Patients With Multiple Myeloma: Should We Abandon It?. Therapeutic Apheresis and Dialysis, 2018, 22, 79-86.	0.4	10
1218	Epigenetic silencing of EVL/miR-342 in multiple myeloma. Translational Research, 2018, 192, 46-53.	2.2	14
1219	Epigenetic silencing of LPP/miR-28 in multiple myeloma. Journal of Clinical Pathology, 2018, 71, 253-258.	1.0	15
1220	Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia. Medicine (United States), 2018, 97, e13103.	0.4	3
1221	Serum free light chain-only multiple myeloma associated with multiple bone involvement and the t(11;14)(q13;q32)/<i>CCND1</i>-immunoglobulin heavy chain fusion gene: A report of three cases . Tenri Medical Bulletin, 2018, 21, 56-69.	0.1	0
1222	Hematopoietic Neoplasia. , 2018, , 363-395.		0
1223	Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. Journal of Clinical Oncology, 2018, 36, 2012-2016.	0.8	2
1224	Cutaneous comorbidities in patients with multiple myeloma. Medicine (United States), 2018, 97, e12825.	0.4	2
1225	Organochlorine Levels in Plasma and Risk of Multiple Myeloma. Journal of Occupational and Environmental Medicine, 2018, 60, 911-916.	0.9	8

#	Article	IF	Citations
1226	Increasing therapyâ€related myeloid neoplasms in multiple myeloma. European Journal of Clinical Investigation, 2018, 49, e13050.	1.7	12
1227	Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPinÂ® protein MP0250: a preclinical study. Oncotarget, 2018, 9, 13366-13381.	0.8	37
1228	Lingual liability: macroglossia and dyspnoea as the harbinger of systemic AL (light-chain) cardiac amyloidosis. BMJ Case Reports, 2018, 11, e225923.	0.2	2
1229	CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2722.	2.2	124
1230	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer Journal, 2018, 8, 95.	2.8	59
1231	Multiple Myeloma: Criteria for Diagnosis and Response to Therapy. , 2018, , 651-658.		0
1232	Multiple Myeloma: The Role of Imaging in Staging and Restaging. , 2018, , 659-669.		0
1233	Solitary Extramedullary Plasmacytoma Mimicking Acute Subdural Hematoma. World Neurosurgery, 2018, 120, 521-524.	0.7	2
1234	Biliary Obstruction due to a Pancreatic Plasmacytoma. Case Reports in Gastrointestinal Medicine, 2018, 2018, 1-3.	0.2	2
1235	Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. Cancer, 2018, 124, 4358-4365.	2.0	4
1236	Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies. Journal of Neurology, 2018, 265, 2927-2933.	1.8	12
1237	Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS ONE, 2018, 13, e0206047.	1.1	19
1238	Association of CD117 and HLAâ€'DR expression with shorter overall survival and/or progressionâ€'free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation. Oncology Letters, 2018, 16, 5655-5666.	0.8	7
1239	The Genetic Polymorphisms of NLRP3 Inflammasome Associated with T Helper Cells in Patients with Multiple Myeloma. Journal of Immunology Research, 2018, 2018, 1-13.	0.9	18
1240	Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies. PET Clinics, 2018, 13, 623-634.	1.5	47
1241	Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study. Molecular Medicine, 2018, 24, 30.	1.9	9
1242	The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. Anticancer Research, 2018, 38, 5087-5092.	0.5	6
1243	Clinical significance of cancer-related fatigue in multiple myeloma patients. International Journal of Hematology, 2018, 108, 580-587.	0.7	9

#	Article	IF	Citations
1244	The clinical features and prognosis of the monoclonal gammopathy undetermined significance: A single center study. Blood Cells, Molecules, and Diseases, 2018, 73, 9-13.	0.6	0
1245	Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'. Leukemia, 2018, 32, 2083-2085.	3.3	2
1246	Oral and dental management for people with multiple myeloma: clinical guidance for dental care providers. Dental Update, 2018, 45, 383-399.	0.1	4
1247	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. British Journal of Haematology, 2018, 182, 495-503.	1.2	30
1248	Recurrence of paraproteinemic keratopathy after penetrating keratoplasty and its assessment with confocal microscopy. American Journal of Ophthalmology Case Reports, 2018, 11, 87-91.	0.4	8
1249	Impact of hemodialysis on the prognosis of multiple myeloma: A nationwide populationâ€‘based study and singleâ€‘institute analysis. Oncology Letters, 2018, 16, 1991-2002.	0.8	3
1250	Plasma Cell Neoplasms. , 2018, , 1381-1418.e1.		4
1251	Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma. Annals of Laboratory Medicine, 2018, 38, 160-164.	1.2	1
1252	Multiple Myeloma Index for Risk of Infection. Journal of Cancer, 2018, 9, 2211-2214.	1.2	14
1253	Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma. BMC Cancer, 2018, 18, 650.	1.1	4
1254	Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma. Leukemia Research, 2018, 71, 106-111.	0.4	33
1255	Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells. Cell Death and Disease, 2018, 9, 512.	2.7	25
1256	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplantâ€ineligible multiple myeloma. British Journal of Haematology, 2018, 182, 222-230.	1.2	118
1257	The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. PLoS ONE, 2018, 13, e0202045.	1.1	40
1258	Abnormal Plasma Cell Disorders in Refinery Waste Workers. Journal of Clinical Medicine, 2018, 7, 221.	1.0	4
1259	A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. Experimental Hematology and Oncology, 2018, 7, 18.	2.0	9
1260	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	2.8	171
1261	Tres casos de gammapatÃa monoclonal de significado renal postrasplante renal: nefropatÃa c3 de novo. Nefrologia, 2019, 39, 198-201.	0.2	1

#	Article	IF	Citations
1262	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leukemia and Lymphoma, 2019, 60, 118-123.	0.6	23
1263	Monoclonal Gammopathies. , 2019, , 1079-1093.e1.		0
1264	Five cases of orbital extramedullary plasmacytoma: diagnosis and management of an aggressive malignancy. Orbit, 2019, 38, 218-225.	0.5	13
1265	Solitary Plasmacytoma of Frontal Bone: A Case Report. Indian Journal of Otolaryngology and Head and Neck Surgery, 2019, 71, 1944-1947.	0.3	2
1266	Limitations in daily activities and general perception of quality of life: Long term followâ€up in patients with antiâ€myelinâ€glycoprotein antibody polyneuropathy. Journal of the Peripheral Nervous System, 2019, 24, 276-282.	1.4	5
1267	Primary plasma cell leukaemia in a 20-year young adult male: a rare presentation. Journal of Hematopathology, 2019, 12, 169-170.	0.2	0
1268	Bone Pathology for Hematopathologists. Surgical Pathology Clinics, 2019, 12, 831-847.	0.7	2
1269	Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria. Radiographics, 2019, 39, 1077-1097.	1.4	75
1270	Role of Standard Magnetic Resonance Imaging. , 2019, , 39-72.		0
1271	Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation. International Journal of Hematology, 2019, 110, 447-457.	0.7	1
1272	Challenges in Interpreting Multiple Monoclonal Bands on Serum Protein Electrophoresis and Serum Immunofixation Electrophoresis: An Illustrative Case Report. journal of applied laboratory medicine, The, 2019, 4, 455-459.	0.6	3
1273	Towards quantitative imaging biomarkers of tumor dissemination: A multi-scale parametric modeling of multiple myeloma. Medical Image Analysis, 2019, 57, 214-225.	7.0	6
1274	Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: AÂCase of Unrecognized t(2;11) Structural Variation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 598-602.	0.2	2
1275	PET-Computed Tomography in Myeloma. PET Clinics, 2019, 14, 411-418.	1.5	1
1276	Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 1760-1772.	5.1	109
1277	Liquid Biopsies in Multiple Myeloma. , 0, , .		0
1278	Socioeconomic Position is Positively Associated with Monoclonal Gammopathy of Undetermined Significance in a Population-based Cohort Study. Annals of Hematology, 2019, 98, 2761-2767.	0.8	7
1279	Is urine immunofixation electrophoresis necessary for monitoring myeloma patients who have undergone hematopoietic stem cell transplantation?. Transfusion and Apheresis Science, 2019, 58, 102660.	0.5	1

#	Article	IF	Citations
1280	Multiple myeloma of young adult presented with paraplegia, rare case report in Saudi Arabia. BJR|case Reports, 2019, 5, 20190008.	0.1	0
1281	Monoclonal immunoglobulinâ€“mediated kidney disease: What is beyond amyloidosis in real practice?. Journal of Onco-Nephrology, 2019, 3, 105-112.	0.3	1
1282	Laboratory assessment of multiple myeloma. Advances in Clinical Chemistry, 2019, 89, 1-58.	1.8	23
1283	Concentrations of Serum Free Light Chains in Kappa and Lambda Lesions in Light-Chain Myelomas. Laboratory Medicine, 2019, 50, 189-193.	0.8	11
1284	Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study). International Journal of Hematology, 2019, 109, 409-417.	0.7	3
1285	Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16). Genes Chromosomes and Cancer, 2019, 58, 516-520.	1.5	4
1286	Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature. Journal of Medical Case Reports, 2019, 13, 153.	0.4	9
1287	Low knowledge and awareness of monoclonal gammopathy of undetermined significance (MGUS) among general practitioners. BMC Family Practice, 2019, 20, 61.	2.9	4
1288	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncology, The, 2019, 20, e302-e312.	5.1	290
1289	Multiple Myeloma Guidelines and Their Recent Updates: ImplicationsÂfor Imaging. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2019, 191, 998-1009.	0.7	25
1290	Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e545-e550.	0.2	5
1291	Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 2019, 19, 504.	1.1	25
1292	Presentation and survival of multiple myeloma patients in Ghana: a review of 9 cases. Ghana Medical Journal, 2019, 53, 52.	0.1	17
1293	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2039-2050.	1.3	9
1294	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. Clinical Epigenetics, 2019, 11, 71.	1.8	23
1295	Three cases of monoclonal gammopathy of renal significance after kidney transplantation. De novo C3 glomerulopathy. Nefrologia, 2019, 39, 198-201.	0.2	1
1296	Correlation Between Uptake of 18F-FDG During PET/CT and Ki-67 Expression in Patients Newly Diagnosed With Multiple Myeloma Having Extramedullary Involvement. Technology in Cancer Research and Treatment, 2019, 18, 153303381984906.	0.8	4
1297	Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1397-1405.	1.4	7

#	Article	IF	Citations
1298	Animal mouse models of acute myeloid leukemia. , 2019, , 419-438.		0
1299	Monoclonal gammopathy of undetermined significance. Blood, 2019, 133, 2484-2494.	0.6	57
1300	Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease. Health Science Reports, 2019, 2, e113.	0.6	10
1301	Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Annals of Hematology, 2019, 98, 1703-1711.	0.8	11
1302	Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer Journal, 2019, 9, 36.	2.8	11
1303	Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?. Disease Markers, 2019, 2019, 1-6.	0.6	4
1304	Differential diagnosis between bone relapse of breast cancer and lambda light chain multiple myeloma: role of the clinical biochemist. Tumori, 2019, 105, NP17-NP19.	0.6	2
1305	Glomerular Diseases Associated with Malignancies. , 2019, , 691-734.		0
1306	An update on biology, diagnosis and treatment of primary plasma cell leukemia. Expert Review of Hematology, 2019, 12, 245-253.	1.0	15
1307	Timing treatment for smoldering myeloma: is earlier better?. Expert Review of Hematology, 2019, 12, 345-354.	1.0	5
1308	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	2.8	38
1309	Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution. Annals of Medicine and Surgery, 2019, 41, 11-15.	0.5	6
1310	Health-Related Quality of Life and Satisfaction With Health Care: Relation to Clinical Stage in Mexican Patients With Multiple Myeloma. Cancer Control, 2019, 26, 107327481983128.	0.7	1
1311	Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. Acta Haematologica, 2019, 141, 111-118.	0.7	4
1312	Lymphomas of the head and neck region: an update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 649-665.	1.4	24
1313	Malignancies of theÂBone. , 2019, , 245-261.		0
1314	Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 2055-2061.	1.1	6
1315	PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma. PET Clinics, 2019, 14, 369-381.	1.5	9

#	Article	IF	Citations
1316	Primary plasmablastic plasmacytoma in the stomach of an immunocompetent adult. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.4	7
1317	Solitary Plasmacytoma of Bone of the Spine. Spine, 2019, 44, E117-E125.	1.0	14
1318	Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. Blood Cancer Journal, 2019, 9, 90.	2.8	16
1319	68Ga CXCR-4 PET/CT Imaging in an Atypical Case of Extramedullary Plasmacytoma Mimicking as Renal Cell Carcinoma. Clinical Nuclear Medicine, 2019, 44, e461-e464.	0.7	3
1320	FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. Bone, 2019, 121, 134-138.	1.4	3
1321	Differential Diagnosis and Treatment Modality of Parasellar Plasmacytoma: Clinical Series and Literature Review. World Neurosurgery, 2019, 122, e978-e988.	0.7	7
1322	Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood, 2019, 133, 576-587.	0.6	78
1323	The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo. Annals of Hematology, 2019, 98, 691-703.	0.8	15
1324	Bone marrow endothelial cells sustain a tumor-specific CD8⁺ T cell subset with suppressive function in myeloma patients. OncoImmunology, 2019, 8, e1486949.	2.1	58
1325	Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study. European Journal of Haematology, 2019, 102, 182-190.	1.1	23
1326	Simplified novel prognostic score for real-life older adults with multiple myelomaâ€"registry-based analysis. Annals of Hematology, 2019, 98, 951-962.	0.8	2
1327	Proposal of new clinical diagnostic criteria for POEMS syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 133-137.	0.9	21
1329	Pseudo-monoclonal gammopathy due to autoimmune disease: a case report. Journal of International Medical Research, 2020, 48, 030006051986661.	0.4	0
1330	Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 73-85.	2.7	14
1331	Prediction of bortezomib-induced peripheral neuropathy with the Râ€"R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study. Leukemia and Lymphoma, 2020, 61, 707-713.	0.6	1
1332	Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation. Hematology, Transfusion and Cell Therapy, 2020, 42, 118-124.	0.1	2
1333	Cancer and Chronic Kidney Disease. , 2020, , 899-917.		1
1334	Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 284-291.	0.3	2

#	Article	IF	Citations
1335	Prognostic factor of poor outcome in anti-MAG neuropathy: clinical and electrophysiological analysis of a French Cohort. Journal of Neurology, 2020, 267, 561-571.	1.8	7
1336	Impact of age, sex, ethnicity, socioâ€economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. British Journal of Haematology, 2020, 188, 692-700.	1.2	13
1337	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	2.0	14
1338	Solitary plasmacytoma of the skull vault: A rare case report. Neurochirurgie, 2020, 66, 66-69.	0.6	2
1339	Clinical Features of Head and Neck Solitary Extramedullary Plasmacytoma in Taiwan. In Vivo, 2020, 34, 261-265.	0.6	7
1340	Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT. Annals of Hematology, 2020, 99, 207-209.	0.8	1
1341	Multiple Myeloma and Related Disorders. , 2020, , 1884-1910.e7.		4
1342	1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib. Leukemia and Lymphoma, 2020, 61, 1201-1210.	0.6	15
1343	Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). Journal of Cancer Research and Clinical Oncology, 2020, 146, 749-759.	1.2	9
1344	Outcome and characteristics of nonâ€measurable myeloma: A cohort study with populationâ€based data from the Swedish Myeloma Registry. European Journal of Haematology, 2020, 104, 376-382.	1.1	8
1345	Extramedullary multiple myeloma. Leukemia, 2020, 34, 1-20.	3.3	140
1346	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	3.3	29
1347	Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients. European Journal of Haematology, 2020, 104, 138-144.	1.1	5
1348	CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3 Î² /cyclinD1 signal pathway in Myeloma Bone Disease. Cancer Medicine, 2020, 9, 737-744.	1.3	11
1349	Therapeutic Advances in the Management of Smoldering Myeloma. American Journal of Therapeutics, 2020, 27, e194-e203.	0.5	0
1350	Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma. Cancers, 2020, 12, 12.	1.7	25
1351	Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. Leukemia Research, 2020, 98, 106454.	0.4	8
1352	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood Cancer Journal, 2020, 10, 93.	2.8	13

#	Article	IF	Citations
1353	Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics. BMC Infectious Diseases, 2020, 20, 699.	1.3	15
1354	Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. BioMed Research International, 2020, 2020, 1-9.	0.9	9
1355	Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia, 2020, 34, 3111-3125.	3.3	39
1356	What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?. Frontiers in Oncology, 2020, 10, 538126.	1.3	10
1357	Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients. Journal of Clinical Laboratory Analysis, 2020, 34, e23416.	0.9	9
1358	Multiple Myeloma Associated Bone Disease. Cancers, 2020, 12, 2113.	1.7	35
1359	Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China. Cancer Medicine, 2020, 9, 7819-7829.	1.3	8
1360	Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials. EJHaem, 2020, 1, 262-266.	0.4	1
1361	Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination. Cancer Cell International, 2020, 20, 403.	1.8	11
1362	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer Journal, 2020, 10, 87.	2.8	13
1363	Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria. Cancers, 2020, 12, 2537.	1.7	7
1364	The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis. Cancers, 2020, 12, 2341.	1.7	4
1365	A challenging diagnosis of a nonsecretor plasma cell dyscrasia with pleomorphic plasmablastic morphology. Clinical Case Reports (discontinued), 2020, 8, 3069-3073.	0.2	0
1367	Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study. Oncology Research and Treatment, 2020, 43, 592-604.	0.8	1
1368	DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. Clinical Epigenetics, 2020, 12, 163.	1.8	9
1369	Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies. journal of applied laboratory medicine, The, 2020, 5, 1358-1371.	0.6	19
1370	Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?. Cancers, 2020, 12, 1223.	1.7	9
1371	IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. European Journal of Haematology, 2020, 105, 326-334.	1.1	6

#	Article	IF	Citations
1372	Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma. Journal of Cancer, 2020, 11, 1182-1194.	1.2	24
1373	Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance. Bone, 2020, 137, 115394.	1.4	5
1374	Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?. Cancers, 2020, 12, 1335.	1.7	6
1375	Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications. Cancers, 2020, 12, 1499.	1.7	19
1376	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. Journal of Clinical Oncology, 2020, 38, 2647-2657.	0.8	24
1377	Evolution of diagnostic workup and treatment for multiple myeloma 2013â€2019. European Journal of Haematology, 2020, 105, 434-448.	1.1	2
1378	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 4688-4698.	3.2	30
1379	Septal Nasal Extramedullary Plasmacytoma: A Rare Tumor in an Unusual Area. Ear, Nose and Throat Journal, 2021, 100, 805S-807S.	0.4	2
1380	The Role of Imaging and Systemic Treatments in Myeloma: A Primer for Radiologists. American Journal of Roentgenology, 2020, 214, 1321-1334.	1.0	1
1381	Limitations of Free Light Chain Assays caused by the Matrix Effect. journal of applied laboratory medicine, The, 2020, 5, 311-319.	0.6	3
1382	Rotating Nightshift Work and Hematopoietic Cancer Risk in US Female Nurses. JNCI Cancer Spectrum, 2020, 4, pkz106.	1.4	5
1383	Identification of patients with smouldering multiple myeloma at ultraâ€high risk of progression using serum parameters: the Czech Myeloma Group model. British Journal of Haematology, 2020, 190, 189-197.	1.2	13
1384	Serum free light chain level at diagnosis in myeloma cast nephropathyâ€"a multicentre study. Blood Cancer Journal, 2020, 10, 28.	2.8	31
1385	Mathematical modelling of the role of GADD45Î² in the pathogenesis of multiple myeloma. Royal Society Open Science, 2020, 7, 192152.	1.1	1
1386	Risk and impact of invasive fungal infections in patients with multiple myeloma. Annals of Hematology, 2020, 99, 1813-1822.	0.8	10
1387	Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e652-e659.	0.2	7
1388	Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Journal of Clinical Laboratory Analysis, 2020, 34, e23233.	0.9	15
1389	Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 552.	1.0	40

#	Article	IF	Citations
1390	High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Best Practice and Research in Clinical Haematology, 2020, 33, 101152.	0.7	9
1391	HB-EGFâ€“EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. Cancers, 2020, 12, 173.	1.7	28
1392	Mathematical modelling of the role of Endo180 network in the development of metastatic bone disease in prostate cancer. Computers in Biology and Medicine, 2020, 117, 103619.	3.9	8
1393	The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions. British Journal of Haematology, 2020, 189, 1127-1135.	1.2	17
1394	Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e352-e367.	0.2	23
1395	Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e468-e473.	0.2	4
1396	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.2	15
1397	Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant. Transplantation Proceedings, 2020, 52, 2186-2192.	0.3	3
1398	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer Journal, 2020, 10, 40.	2.8	15
1399	Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains. Laboratory Medicine, 2020, 51, 592-600.	0.8	10
1400	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020, 104, S11-S103.	0.5	306
1401	Clinical Controversies in the Management of Smoldering Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 314-319.	1.8	4
1402	Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). British Journal of Haematology, 2021, 192, 531-541.	1.2	9
1403	Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A populationâ€based study. Cancer Medicine, 2021, 10, 462-470.	1.3	11
1404	Multiple myelomaâ€”A painful disease of the bone marrow. Seminars in Cell and Developmental Biology, 2021, 112, 49-58.	2.3	10
1405	Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy. Kidney International, 2021, 99, 421-430.	2.6	18
1406	Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation, 2021, 56, 368-375.	1.3	8
1407	A realâ€world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematological Oncology, 2021, 39, 41-50.	0.8	22

#	Article	IF	Citations
1408	Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e48-e51.	0.2	1
1409	What Is New in the Treatment of Smoldering Multiple Myeloma?. Journal of Clinical Medicine, 2021, 10, 421.	1.0	7
1410	Solitary plasmacytoma of mandible: an unusual bilateral presentation. Autopsy and Case Reports, 2021, 11, e2021298.	0.2	1
1411	Smoldering multiple myeloma 40 years later: a story of unintended disease. Expert Review of Hematology, 2021, 14, 149-153.	1.0	3
1412	The Value of Body Mass Index in Evaluating the Occurrence of Peripheral Neuropathy in Patients with Multiple Myeloma Treated with Bortezomib. Advances in Clinical Medicine, 2021, 11, 542-546.	0.0	0
1413	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications, 2021, 12, 293.	5.8	54
1414	A Case of Extraosseous Plasmacytoma that Developed in the Sinonasal Cavity. Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology), 2021, 60, 13-20.	0.0	0
1415	A case of solitary plasmacytoma in the mandible. Journal of Japanese Society of Oral Oncology, 2021, 33, 143-149.	0.0	0
1416	Does chemical shift imaging offer a biomarker for the diagnosis and assessment of disease severity in multiple myeloma?. Medicine (United States), 2021, 100, e24358.	0.4	3
1417	Identification of Paraproteins via Serum Immunofixation or Serum Immunosubtraction and Immunoturbidimetric Quantitation of Serum Immunoglobulins in the Laboratory Testing for Monoclonal Gammopathies. Archives of Pathology and Laboratory Medicine, 2021, 145, 1552-1557.	1.2	1
1418	The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Cancers, 2021, 13, 951.	1.7	9
1419	Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells, 2021, 10, 336.	1.8	48
1420	Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers, 2021, 13, 961.	1.7	8
1421	An unusual pattern in serum protein electrophoresis to take in mind: A case report. Practical Laboratory Medicine, 2021, 24, e00200.	0.6	3
1422	Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma. Blood Advances, 2021, 5, 1746-1754.	2.5	10
1423	Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis. Journal of the Neurological Sciences, 2021, 422, 117336.	0.3	0
1424	Management of acute kidney injury in symptomatic multiple myeloma. Kidney International, 2021, 99, 570-580.	2.6	31
1425	The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma. Annals of Hematology, 2021, 100, 1251-1260.	0.8	4

#	Article	IF	Citations
1426	Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation â€“ a case series. British Journal of Haematology, 2021, 193, e36-e38.	1.2	1
1427	Extramedullary multiple myeloma in the spermatic cord: A case report. Current Problems in Cancer Case Reports, 2021, 3, 100051.	0.1	0
1428	Infiltrative Renal Malignancies: Imaging Features, Prognostic Implications, and Mimics. Radiographics, 2021, 41, 487-508.	1.4	12
1429	Prognostic value of the albuminâ€“globulin ratio and albuminâ€“globulin score in patients with multiple myeloma. Journal of International Medical Research, 2021, 49, 030006052199773.	0.4	10
1430	Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. British Journal of Haematology, 2021, 193, 245-268.	1.2	24
1431	Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment. Seminars in Ultrasound, CT and MRI, 2021, 42, 184-193.	0.7	4
1432	Patient's perspectives of living with a precancerous condition: Monoclonal gammopathy of undetermined significance (MGUS). European Journal of Oncology Nursing, 2021, 51, 101901.	0.9	6
1433	Crystalline deposits in the cornea and various areas of the kidney as symptoms of an underlying monoclonal gammopathy: a case report. BMC Nephrology, 2021, 22, 117.	0.8	2
1434	Plasma Cell Dyscrasia of the Calcaneus: A Rare and Unusual Case Presentation. Journal of the American Podiatric Medical Association, 2021, 111, .	0.2	0
1435	Kidney Biopsy in Patients With Monoclonal Gammopathy: A Multicenter Retrospective Cohort Study. Frontiers in Medicine, 2021, 8, 687149.	1.2	4
1436	A Rare Case of Small Bowel Extramedullary Plasmacytomas Presenting With Intestinal Obstruction. Cureus, 2021, 13, e15704.	0.2	2
1437	Ocular Signs and Ocular Comorbidities in Monoclonal Gammopathy: Analysis of 80 Subjects. Journal of Ophthalmology, 2021, 2021, 1-8.	0.6	3
1438	Detection of monoclonal protein by capillary zone electrophoresis can be challenged by iodinated contrast agent interference: a case report. Biochemia Medica, 2021, 31, 359-362.	1.2	2
1439	Possible Therapeutic Potential of Disulfiram for Multiple Myeloma. Current Oncology, 2021, 28, 2087-2096.	0.9	1
1440	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 361-367.	0.2	10
1441	KDOQI US Commentary on the 2020 KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. American Journal of Kidney Diseases, 2021, 77, 833-856.	2.1	7
1442	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation, 2021, 56, 2664-2671.	1.3	9
1443	Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 191-203.	1.2	3

#	Article	IF	Citations
1444	At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China. Leukemia and Lymphoma, 2021, 62, 2992-3001.	0.6	5
1445	Smoldering multiple myeloma â€“ Past, present, and future. Blood Reviews, 2021, , 100869.	2.8	2
1446	Monoclonal gammopathy of undetermined significance. InnovAiT, 0, , 175573802110279.	0.0	0
1447	Long nonâ€‘coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miRâ€‘135bâ€‘5p to target KLF9. Molecular Medicine Reports, 2021, 24, .	1.1	7
1448	Oncologist perspective: role of imaging in myeloma. Skeletal Radiology, 2022, 51, 123-133.	1.2	1
1449	Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients. Indian Journal of Hematology and Blood Transfusion, 0, , 1.	0.3	1
1450	Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients. Journal of Proteome Research, 2021, 20, 4176-4185.	1.8	9
1452	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia and Lymphoma, 2021, 62, 3011-3018.	0.6	2
1453	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 2021, 106, 2799-2812.	1.7	22
1454	Safety of outpatient stem cell mobilization with lowâ€•or intermediateâ€dose cyclophosphamide in newly diagnosed multiple myeloma patients. European Journal of Haematology, 2021, 107, 566-572.	1.1	1
1455	Immune subtraction for improved resolution in serum protein immunofixation electrophoresis and antibody isotype determination in a patient with autoantibody. Practical Laboratory Medicine, 2021, 26, e00240.	0.6	0
1456	To Treat or Not to Treat: A Case of Simultaneous Discovery of Chronic Myelomonocytic Leukemia and Multiple Myeloma. Cureus, 2021, 13, e17505.	0.2	0
1457	Multiple myeloma in Armenia during the period 2006â€“2018: facts and discussion. BMC Cancer, 2021, 21, 941.	1.1	4
1458	Chimeric antigen receptor T-cells (CARs) in cancer treatment. Current Molecular Pharmacology, 2021, 14, .	0.7	1
1459	Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value. Annals of Hematology, 2021, 100, 2979-2988.	0.8	5
1460	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Annals of Hematology, 2021, 100, 2997-3005.	0.8	2
1461	Root Bark of Morus alba L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/Î²-Catenin Pathway. Journal of Microbiology and Biotechnology, 2021, 31, 1559-1567.	0.9	6
1462	LBX2-AS1 as a Novel Diagnostic Biomarker and Therapeutic Target Facilitates Multiple Myeloma Progression by Enhancing mRNA Stability of LBX2. Frontiers in Molecular Biosciences, 2021, 8, 706570.	1.6	3

#	Article	IF	Citations
1463	Outcome data from >10Â000 multiple myeloma patients in the Danish and Swedish national registries. European Journal of Haematology, 2022, 108, 99-108.	1.1	9
1464	Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. American Journal of Hematology, 2021, 96, 1554-1562.	2.0	1
1465	Podocytopathy in patients with monoclonal gammopathy: three patients and literature review. CKJ: Clinical Kidney Journal, 2022, 15, 417-424.	1.4	3
1466	Monoclonal free light chain detection and quantification: Performances and limits of available laboratory assays. Clinical Biochemistry, 2021, 95, 28-33.	0.8	2
1467	Extramedullary plasmacytoma of the ureter. IJU Case Reports, 2022, 5, 19-22.	0.1	2
1468	Protein expression and purification of G-protein coupled receptor kinase 6 (GRK6), toward structure-based drug design and discovery for multiple myeloma. Protein Expression and Purification, 2021, 185, 105890.	0.6	2
1469	The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. Expert Review of Hematology, 2021, 14, 1059-1069.	1.0	1
1470	Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study. Scientific Reports, 2021, 11, 19266.	1.6	2
1471	Association between Kidney Function, Proteinuria and the Risk of Multiple Myeloma: A Population-Based Retrospective Cohort Study in South Korea. Cancer Research and Treatment, 2022, 54, 926-936.	1.3	2
1472	Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma. Leukemia and Lymphoma, 2022, 63, 385-394.	0.6	0
1473	Plasmacytoma of the iliac bone in a seven- year-old girl: A rare tumor with no to ignore. Journal of Pediatric Surgery Case Reports, 2021, 64, 101582.	0.1	0
1474	Artefactual bands on urine protein immunofixation gels. Clinical Chemistry and Laboratory Medicine, 2021, 59, e283-e284.	1.4	0
1475	Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34 + cell monitoring based on the experience from two Japanese university hospitals. Therapeutic Apheresis and Dialysis, 2021, 25, 687-696.	0.4	1
1476	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. Cancer Treatment and Research Communications, 2021, 29, 100444.	0.7	5
1477	Research Progress on Biomarkers in Early Diagnosis of Renal Impairment in Multiple Myeloma. Advances in Clinical Medicine, 2021, 11, 1353-1361.	0.0	0
1478	Myeloma and Related Conditions. , 2021, , 274-305.		0
1479	Macrophages in multiple myeloma: key roles and therapeutic strategies. Cancer and Metastasis Reviews, 2021, 40, 273-284.	2.7	11
1480	Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective realâ€world confirmation. International Journal of Laboratory Hematology, 2021, 43, e244-e247.	0.7	1

#	Article	IF	Citations
1481	Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy. JAMA - Journal of the American Medical Association, 2017, 318, 2099.	3.8	120
1483	Pathologic Fractures. , 2011, , 43-53.		3
1484	Solitary Plasmacytomas and Soft-Tissue Involvement in Multiple Myeloma. , 2018, , 585-593.		1
1485	Firstline Treatment and Maintenance in Newly Diagnosed Multiple Myeloma Patients. Recent Results in Cancer Research, 2011, 183, 189-206.	1.8	20
1487	Plasma Cell Neoplasms. , 2011, , 410-435.		3
1488	Monoclonal gammopathies. , 2013, , 975-986.		3
1489	Plasma cell dyscrasias and leukemias. Cancer Chemotherapy and Biological Response Modifiers, 2005, , 343-389.	0.5	1
1492	Primary Plasma Cell Leukemia Presented as Progressive Paraplegia: A Case Report. Southern Medical Journal, 2009, 102, 101-103.	0.3	2
1493	Amyloidosis: an unusual cause of upper gastrointestinal bleeding. BMJ Case Reports, 2016, 2016, bcr2016217653.	0.2	11
1494	Orbital multiple myeloma: a diagnostic challenge. BMJ Case Reports, 2017, 2017, bcr-2017-220895.	0.2	8
1495	Testicular plasmacytoma misdiagnosed as orchitis. BMJ Case Reports, 2018, 2018, bcr-2017-222046.	0.2	2
1496	Incidence and Risk Factors of Osteonecrosis of Femoral Head in Multiple Myeloma Patients Undergoing Dexamethasone-Based Regimens. BioMed Research International, 2020, 2020, 1-7.	0.9	4
1497	Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. Acta Haematologica, 2021, 144, 264-274.	0.7	2
1498	A case of IgE myeloma transformed into IgE-producing plasma cell leukaemia. Biochemia Medica, 2020, 30, 134-142.	1.2	5
1499	The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. Singapore Medical Journal, 2017, 58, 55-71.	0.3	6
1500	Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma. JCI Insight, 2019, 4, .	2.3	18
1501	Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. Journal of Clinical Investigation, 2016, 126, 1300-1310.	3.9	9
1502	Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology American Society of Hematology Education Program, 2013, 2013, 496-503.	0.9	6

#	Article	IF	Citations
1504	Advances in the understanding of IgM monoclonal gammopathy of undetermined significance. F1000Research, 2017, 6, 2142.	0.8	11
1505	An Integrated Approach to Regression Analysis in Multiple Correspondence Analysis and Copula Based Models. Journal of Statistics Applications and Probability, 2012, 1, 67-87.	0.5	4
1506	Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors. PLoS ONE, 2013, 8, e83905.	1.1	16
1507	Magnetic Resonance Evaluation of Multiple Myeloma at 3.0 Tesla: How Do Bone Marrow Plasma Cell Percentage and Selection of Protocols Affect Lesion Conspicuity?. PLoS ONE, 2014, 9, e85931.	1.1	4
1508	Iterative Decomposition of Water and Fat with Echo Asymmetry and Least-Squares Estimation (IDEAL) Magnetic Resonance Imaging as a Biomarker for Symptomatic Multiple Myeloma. PLoS ONE, 2015, 10, e0116842.	1.1	28
1509	Whole body MRI in multiple myeloma: Optimising image acquisition and read times. PLoS ONE, 2020, 15, e0228424.	1.1	8
1510	NF-KÎ² Activation in U266 Cells on Mesenchymal Stem Cells. Advanced Pharmaceutical Bulletin, 2016, 6, 415-422.	0.6	3
1511	The solitary sellar plasmacytoma: a diagnostic challenge. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 160031.	0.2	7
1512	Biology and Bioinformatics of Myeloma Cell. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2012, 18, 30-41.	1.2	12
1513	Ocular copper deposition associated with monoclonal gammopathy of undetermined significance: case report. Arquivos Brasileiros De Oftalmologia, 2005, 68, 539-541.	0.2	11
1514	mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. Oncoscience, 2015, 2, 382-394.	0.9	10
1515	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget, 2016, 7, 59029-59048.	0.8	16
1516	Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget, 2017, 8, 84847-84862.	0.8	7
1517	Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma. Oncotarget, 2017, 8, 69408-69421.	0.8	15
1518	Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget, 2017, 8, 18792-18801.	0.8	71
1519	Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?. Oncotarget, 2017, 8, 5081-5091.	0.8	14
1520	Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. Oncotarget, 2017, 8, 19427-19442.	0.8	11
1521	Association of VEGF and VDR gene- gene and gene- smoking interaction on risk of multiple myeloma in Chinese Han population. Oncotarget, 2017, 8, 36509-36516.	0.8	8

#	Article	IF	Citations
1522	Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. Oncotarget, 2017, 8, 56243-56254.	0.8	15
1523	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget, 2017, 8, 79517-79526.	0.8	16
1524	Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway. Oncotarget, 2017, 8, 55405-55421.	0.8	13
1525	Multiple myeloma cell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget, 2014, 5, 5686-5699.	0.8	59
1526	Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. Oncotarget, 2018, 9, 20563-20577.	0.8	45
1527	Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget, 2018, 9, 25254-25264.	0.8	15
1528	LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. Oncotarget, 2014, 5, 12950-12967.	0.8	52
1529	Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma. Oncotarget, 2019, 10, 6781-6790.	0.8	2
1530	Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget, 2015, 6, 24205-24217.	0.8	65
1531	Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma. Oncotarget, 2015, 6, 17958-17967.	0.8	13
1532	A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget, 2015, 6, 26129-26141.	0.8	40
1533	Notch signaling deregulation in multiple myeloma: A rational molecular target. Oncotarget, 2015, 6, 26826-26840.	0.8	47
1534	Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget, 2016, 7, 19589-19600.	0.8	45
1535	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evidence, 2010, 4, 215.	4.7	18
1536	Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin's Lymphoma Patients. Cell Journal, 2017, 19, 44-54.	0.2	18
1537	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. Acta Haematologica Polonica, 2018, 49, 157-206.	0.1	4
1538	The Current Status and Future of Multiple Myeloma in the Clinic. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, E1-E16.	0.2	8
1539	Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions. Radiation Oncology Journal, 2016, 34, 59-63.	0.7	17

#	Article	IF	Citations
1540	The role of CT in PET/CT for assessing diffuse infiltration of bone marrow in multiple myeloma using the Durieâ€'Salmon PLUS staging system. Molecular and Clinical Oncology, 2020, 13, 13-18.	0.4	3
1541	Association between left ventricular function and paraprotein type in patients with multiple myeloma. Korean Journal of Internal Medicine, 2017, 32, 459-468.	0.7	5
1542	Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. Korean Journal of Internal Medicine, 2016, 31, 809-819.	0.7	8
1543	Monoclonal gammopathy of undetermined significance: A primary care guide. Cleveland Clinic Journal of Medicine, 2019, 86, 39-46.	0.6	8
1544	Primary plasma cell leukaemia in a 22-year-old woman: A case report. African Journal of Laboratory Medicine, 2015, 4, .	0.2	1
1545	Multiple solitary extramedullary anaplastic plasmacytomas. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 303-304.	0.1	4
1546	Plasmacytoma of the testis in a patient with relapsed and refractory multiple myeloma: Case report and review of the literature. Urology Annals, 2015, 7, 530.	0.3	9
1547	Solitary dural plasmacytoma with parenchymal invasion. Journal of Innovative Optical Health Sciences, 2015, 10, 102-104.	0.5	14
1548	Clinical Profile of Multiple Myeloma in South India. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 62-66.	0.1	7
1549	Light Chain Multiple Myeloma: A Single Institution Series. Journal of Leukemia (Los Angeles, Calif), 2015, 03, .	0.1	2
1550	Comparative Baseline Health-Related Quality of Life in Real-Life Patients with Monoclonal Gammopathies. Journal of Leukemia (Los Angeles, Calif), 2015, 03, .	0.1	1
1551	PET/MR in Relapsed Multiple Myeloma. Journal of Leukemia (Los Angeles, Calif), 2017, 05, .	0.1	1
1552	Gastrointestinal bleeding as initial presentation of extramedullary plasma cell neoplasms: A case report and review of the literature. World Journal of Gastrointestinal Endoscopy, 2019, 11, 308-321.	0.4	9
1553	Solitary Plasmacytoma of the Sternum. Korean Journal of Thoracic and Cardiovascular Surgery, 2013, 46, 482-485.	0.6	5
1554	EVALUATION OF PLASMA CELL PROPIDIUM-IODIDE AND ANNEXIN-V INDICES: THEIR RELATION TO PROGNOSIS IN MULTIPLE MYELOMA. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2005, 149, 271-274.	0.2	5
1555	THE CORRELATION OF SERUM IMMUNOGLOBULIN FREE LIGHT CHAIN LEVELS AND SELECTED BIOLOGICAL MARKERS IN MULTIPLE MYELOMA. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2008, 152, 61-64.	0.2	3
1556	THE RELATIONSHIP BETWEEN SOME SOLUBLE OSTEOGENIC MARKERS, ANGIOGENIC CYTOKINES/OTHER BIOLOGICAL PARAMETERS AND THE STAGES OF MULTIPLE MYELOMA EVALUATED ACCORDING TO THE DURIE-SALMON AND INTERNATIONAL PROGNOSTIC INDEX STRATIFICATION SYSTEMS. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2009, 153, 275-282.	0.2	4
1557	Oncohematological diseases in the Vale do ParaÃba, State of SÃ£o Paulo. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 120-125.	0.7	4

#	Article	IF	Citations
1558	Multifocal Extramedullary and Multiple Solitary Bone Plasmacytoma: A Case Report and Review of the Literature. International Journal of Cancer Management, 2019, 12, .	0.2	2
1559	Extramedullary Plasmacytoma of the Nasal Cavity Report of Three Cases With Review of the Literature. Iranian Red Crescent Medical Journal, 2013, 15, 363-6.	0.5	27
1560	Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435.	2.3	55
1561	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1154-1165.	2.3	113
1562	Hampered influenza-specific IgG B cell responses whereas IgM and IgA responses are maintained in monoclonal gammopathy of undetermined significance. Hematology and Leukemia, 2014, 2, 5.	0.2	1
1563	Clinical and Biochemical Profile of Monoclonal Gammopathies in Caribbean Patients in a Resource-limited Setting. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6501-6504.	0.5	4
1564	Clinical Study of Thalidomide Combined with Dexamethasone for the Treatment of Elderly Patients with Newly Diagnosed Multiple Myeloma. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4777-4781.	0.5	3
1565	No Monoclonal Protein in a Patient with CRAB Features. Clinical Chemistry, 2021, 67, 1584-1588.	1.5	2
1566	Osteoporosis Management with Focus on Spine. , 2021, , 61-92.		0
1568	Smoldering multiple myeloma: biology, clinical manifestations and management. Leukemia and Lymphoma, 2022, 63, 518-529.	0.6	2
1569	Clarifying the molecular mechanism of tomentosinâ€'induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis. International Journal of Molecular Medicine, 2021, 48, .	1.8	2
1570	The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Research, 2021, 11, 100.	1.1	12
1571	Ixazomibâ€based maintenance therapy after bortezomibâ€based induction in patients with multiple myeloma not undergoing transplantation: A realâ€world study. Cancer Medicine, 2021, , .	1.3	7
1572	Realâ€world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45â€year period. British Journal of Haematology, 2022, 196, 649-659.	1.2	6
1573	C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies. Nephrology Dialysis Transplantation, 2022, 37, 2128-2137.	0.4	11
1574	Pathologic Quiz Case: A 39-Year-Old Man With Severe Lower Back Pain. Archives of Pathology and Laboratory Medicine, 2005, 129, e70-e72.	1.2	3
1575	Immunoglobulin Patterns in Health and Disease. , 2005, , 235-267.		0
1576	Lymphoproliferative Neoplasms. Medical Radiology, 2006, , 337-349.	0.0	0

#	Article	IF	Citations
1577	Multiples Myelom und verwandte Plasmazellerkrankungen. , 2007, , 1-12.		0
1578	Plasmazellerkrankungen. , 2007, , 493-510.		0
1579	Mieloma MÃºltiplo neste fascÃculo. Revista Brasileira De Hematologia E Hemoterapia, 2007, 29, .	0.7	0
1580	Multiple Myeloma and Related Disorders. , 2008, , 2323-2351.		1
1581	Anemia and Erythropoeitic Growth Factors in Multiple Myeloma. , 2008, , 455-468.		0
1582	Monoclonal Gammopathy of Undetermined Significance. , 2008, , 625-649.		0
1583	POEMS Syndrome and Other Atypical Plasma Cell Disorders. , 2008, , 571-623.		1
1585	Trogocytosis in Multiple Myeloma.. Blood, 2008, 112, 1681-1681.	0.6	0
1586	A Case of Solitary Plasmacytoma of Bone in the Clivus. Practica Otologica, 2009, 102, 773-779.	0.0	0
1587	Case 35. , 2009, , 218-223.		0
1589	Case 37. , 2009, , 228-233.		0
1590	Case 36. , 2009, , 224-227.		0
1593	Monoclonal Gammopathy of Undetermined Significance Disguised as Chronic Neutrophilic Leukemia. Mediterranean Journal of Hematology and Infectious Diseases, 2010, 2, e2010002.	0.5	4
1594	Multiple Myeloma and Plasma Cell Dyscrasias. , 2010, , 640-666.		0
1595	Plasma Cell Tumors. , 2010, , 1394-1399.		0
1596	Surgical resection of solitary plasmacytoma growing rapidly in the chest wall. The Journal of the Japanese Association for Chest Surgery, 2010, 24, 1032-1036.	0.0	1
1597	Hematologic Issues in Cervical Spine Surgery. , 2010, , 13-27.		0
1600	A case of multiple myeloma rapidly growing in the maxillary tuberosity. Nihon Koku Geka Gakkai Zasshi, 2010, 56, 203-207.	0.0	0

#	Article	IF	Citations
1601	PET-CT Imaging in Multiple Myeloma, Solitary Plasmacytoma, and Related Plasma Cell Dyscrasias. , 2011, , 293-312.		0
1602	Multiple Myeloma and Plasmacytoma. Medical Radiology, 2011, , 811-832.	0.0	0
1603	HÃmatologische und onkologische Erkrankungen. , 2011, , 607-718.		0
1606	Detection of Skeletal Lesions by Whole Body Multidetector Computed Tomography in Multiple Myeloma has no Impact on Long-Term Outcomes Post Autologous Hematopoietic Cell Transplantation. World Journal of Oncology, 2012, 3, 147-157.	0.6	3
1607	A Case of Extramedullary Plasmacytoma of the Paranasal Sinus which Progressed into Multiple Myeloma. Practica Otologica, 2012, 105, 945-950.	0.0	1
1608	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
1609	A resected case of solitary plasmacytoma of the rib. The Journal of the Japanese Association for Chest Surgery, 2012, 26, 085-089.	0.0	0
1610	The Role of Centrosomes in Multiple Myeloma. , 2012, , 255-276.		1
1611	Successful Treatment of Low-Dose Lenalidomide Maintenance Therapy Followed by Second Autologous Peripheral Blood Stem Cell Transplantation in Heavily Treated Multiple Myeloma. International Journal of Clinical Medicine, 2012, 03, 106-109.	0.1	0
1612	Bone Marrow Biopsy and Its Utility in the Diagnosis of AL Amyloidosis and Other Plasma Cell Dyscrasias. , 2012, , 283-290.		0
1613	Plasma Cell Neoplasms and Related Disorders. , 2012, , 612-631.		0
1614	A case of metachronous multiple plasmacytoma involving the mandible. Nihon Koku Geka Gakkai Zasshi, 2012, 58, 302-306.	0.0	2
1615	Plasma Cell Neoplasms, Clinicopathological Characteristics and Immunophenotype of 21 Patients. Open Journal of Pathology, 2012, 02, 127-132.	0.0	0
1616	Tratamiento de primera lÃnea para pacientes con mieloma mÃºltiple no elegibles para trasplante autÃ³logo de cÃ©lulas progenitoras : revisiÃ³n sistemÃ¡tica y meta-anÃ¡lisis (estudio del) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf		
1617	Applying Stochastic Integer Programming to Optimization of Resource Scheduling in Cloud Computing. Journal of Networks, 2012, 7, .	0.4	5
1618	Genomic Strategies Determining Progression from MGUS to Multiple Myeloma. , 2013, , 3-24.		0
1619	Newer IMiDs. , 2013, , 181-213.		0
1620	The Genomics of Multiple Myeloma and Its Relevance in the Molecular Classification and Risk Stratification of the Disease. , 2013, , 543-570.		0

#	Article	IF	Citations
1621	Multiple Myeloma Surveillance Counterpoint: Australia. , 2013, , 493-500.		0
1622	A Case of Laryngo-tracheal Involvement of Multiple Myelomas. Practica Otologica, 2013, 106, 1095-1103.	0.0	0
1623	Treatment Response Monitoring in Patients with Multiple Myeloma: The Role of Positron Emission Tomography-Computed Tomography using Fluorine-18-Fluorodeoxyglucose. Journal of Bone Marrow Research, 2013, 01, .	0.2	2
1625	The World Health Organization Classification of Lymphoid Neoplasms. , 2013, , 1-34.		0
1626	A Case of Primary Lung Cancer with Synchronous Costal Plasmacytoma. Japanese Journal of Lung Cancer, 2013, 53, 47-51.	0.0	1
1627	Multiple Myeloma - A hospital based cross sectional study in Bangladesh. Journal of the Asiatic Society of Bangladesh Science, 2013, 38, 189-198.	0.1	0
1628	Criteria for Diagnosis and Response. , 2014, , 1-15.		0
1629	Solitary Plasmacytoma. , 2014, , 195-210.		0
1630	Management of Treatment Complications and Supportive Care. , 2014, , 159-177.		0
1631	Multipel myeloom. , 2014, , 135-145.		0
1632	Multiple Myeloma and Other Hematological Malignancies. , 2014, , 1335-1354.		0
1633	Multiple Myeloma and the Kidney. , 2014, , 303-310.		1
1634	Primary Extramedullary Plasmacytoma of the Colon. Japanese Journal of Gastroenterological Surgery, 2014, 47, 637-643.	0.0	1
1635	Multiple Myeloma and Related Disorders. , 2014, , 1991-2017.e7.		1
1636	X-Ray in Multiple Myeloma - Not a ï¿½Golden Standardï¿½ any More: Case Series. Journal of Bone Marrow Research, 2014, 02, .	0.2	1
1637	Risk Factors and Reversibility of Renal Failure in Patients with Newly Diagnosed Multiple Myeloma. Korean Journal of Medicine, 2014, 86, 190.	0.1	1
1638	Relapsed plasmacytoma in central nervous system after complete remission of extramedullary plasmacytoma. Yeungnam University Journal of Medicine, 2014, 31, 43.	0.1	0
1639	Gemcitabine in Treating Patients with Refractory or Relapsed Multiple Myeloma. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9291-9293.	0.5	2

#	Article	IF	Citations
1640	Monoclonal Gammopathy in Iran: Prevalence and Isotype Distribution. MOJ Immunology, 2014, 1, .	11.0	0
1641	Multiple Myeloma Presenting with Distal Limb Gangrene: An Odd Case Report. European Journal of Case Reports in Internal Medicine, 2014, 1, .	0.2	0
1642	Pancytopenia in Multiple Myeloma- An Enigma: Our Experience from Tertiary Care Hospital. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, EC04-6.	0.8	5
1643	Extramedullary Relapse of Multiple Myeloma Presenting as Mechanical Small Bowel Obstruction: A Case Report. Korean Journal of Medicine, 2015, 88, 330.	0.1	0
1644	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
1645	MULTIPLE MYELOMA PRESENTING AS THIRD CRANIAL NERVE PALSY: A RARE CASE REPORT. Journal of Evidence Based Medicine and Healthcare, 2015, 2, 2375-2378.	0.0	0
1646	Parietal Plasmacytoma: An Ominous Sign of Disease Recurrence. American Journal of Medical Case Reports, 2015, 3, 163-166.	0.1	1
1647	WORSE PROGNOSIS WITH HIGHER SERUM ASPARTATE AMINOTRANSFER ASE AND LACTATEDEHYDROGENASE LEVELS IN MULTIPLE MYELOMA PATIENTS TREATING WITH BOTREZOMIB - DEXAMETHASONE REGIMEN: A RETROSPECTIVE STUDY. Journal of Evidence Based Medicine and Healthcare, 2015, 2, 3864-3869.	0.0	0
1648	Plasma Cell Neoplasms: Morphology and Immunohistochemistry. , 2016, , 43-64.		1
1651	SkelettverÃnderungen bei hÃmatologischen Systemerkrankungen. , 2016, , 297-328.		0
1652	II. The Diagnosis of Multiple Myeloma. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1209-1215.	0.0	0
1654	Extramedullary Plasmacytoma of Soft Tissue Neck. International Journal of Phonosurgery & Laryngology, 2016, 6, 42-46.	0.0	0
1655	Plasmacytoma and Multiple Myeloma. , 2016, , 306-307.		0
1657	Pulmonary Hypertension Induced by Thalidomide (and Derivatives) in Patients with Multiple Myeloma: A Systematic Review. Journal of Cancer Therapy, 2016, 07, 971-978.	0.1	1
1658	A Case of Pulmonary Plasmacytoma with Amyloid Deposition. Nihon Rinsho Geka Gakkai Zasshi (Journal) Tj ETQq0 0 0 rgBT /Overlock 10	0.0	1
1659	A Comprehensive Approach towards Serum Protein Electrophoresis Reporting with Relative Percentage and Gram as Addendum. Journal of Medical Sciences and Health, 2016, 02, 18-23.	0.1	1
1660	Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance. BMJ Case Reports, 2016, 2016, bcr2016215518.	0.2	0
1661	Amylose AL linguale compliquant un myÃ©lome multipleÂ: cas clinique et revue de la littÃ©rature. Medecine Buccale Chirurgie Buccale, 2016, 22, 253-263.	0.1	0

#	Article	IF	Citations
1662	Bortezomib plus dexamethasone induction followed by autologous stem cell transplantation in multiple myeloma: A study from India. Asian Journal of Medical Sciences, 2016, 7, 44-48.	0.0	0
1663	A RARE CASE OF EXTRAMEDULLARY PLASMACYTOMA MASQUERADING AS JUVENILE NASOPHARYNGEAL ANGIOFIBROMA. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 3898-3901.	0.0	0
1664	Plasma Cell Leukemia. , 2017, , 1-16.		0
1665	CLINICO-PATHOLOGICAL PROFILE AND SURGICAL OUTCOME IN VERTEBRAL COLLAPSE OF NEOPLASTIC ORIGIN. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 5208-5213.	0.1	0
1666	A case of extramedullary plasmacytoma of the tongue. Nihon Koku Geka Gakkai Zasshi, 2017, 63, 374-377.	0.0	1
1667	Role of Capillary Electrophoresis in the Evaluation of Serum Protein Abnormalities: An Experience of a Tertiary Care Teaching Hospital. Journal of Mahatma Gandhi University of Medical Sciences and Technology, 2017, 2, 69-70.	0.0	0
1669	Multiples Myelom beim alten und geriatrischen Patienten. , 2018, , 1-10.		0
1670	A Case of Multiple Extramedullary Plasmacytoma Arising from Both Paranasal Sinuses. Journal of Clinical Otolaryngology, 2017, 28, 261-266.	0.1	0
1671	CLINICAL, HEMATOLOGICAL CHARACTERIZATION AND POLYMORPHISM OF ABO AND Rh BLOOD GROUP SYSTEMS IN PLASMA CELL MYELOMA PATIENTS. Problemy Radiatsiinoi Medytsyny Ta Radiobiolohii, 2018, 23, 410-422.	0.5	0
1672	Multiple Myeloma and Other Plasma Cell Neoplasms. , 2018, , 642-663.e1.		2
1673	Multiples Myelom beim alten und geriatrischen Patienten. , 2018, , 261-270.		0
1674	A case of multiple myeloma with bilateral hydronephrosis due to an extramedullary bladder lesion. Nihon Toseki Igakkai Zasshi, 2018, 51, 517-523.	0.2	0
1675	Extramedullary Plasmacytoma of the Lower Rectum Resected by Laparoscopic Intersphincteric Resection. Japanese Journal of Gastroenterological Surgery, 2018, 51, 154-161.	0.0	0
1676	Tumoren und Knochen. , 2018, , 227-276.		0
1677	å§è…¿éª¨éª¨è…«ç˜¤ã‚’å^ç™ºç—‡ã•ã¥éžå^†æ³Œåž‹åšç™ºæ€§éª¨é«„è…«ã®ï¼‘ä¾‹. Orthopedics & Traumatology, 2018, 67, 185-188.	0.0	0
1678	Mediastinal Extramedullary Plasmacytoma: a Surgical Case. Japanese Journal of Lung Cancer, 2018, 58, 196-200.	0.0	0
1679	EVALUATION OF HUMAN IMMUNOGLOBULIN EFFECTIVENESS IN PATIENTS WITH SENSORYMOTOR POLYNEUROPATHY ASSOCIATED WITH MONOCLONAL GAMMAPATHY OF UNDETERMINED SIGNIFICANCE. Russian Archives of Internal Medicine, 2018, 8, 278-284.	0.0	2
1680	A Case of Primary Cutaneous Diffuse Large B-cell Lymphoma with Localized Cutaneous Nodular Amyloidosis. Nishinihon Journal of Dermatology, 2018, 80, 460-465.	0.0	0

#	Article	IF	Citations
1681	Extramedullary plasmacytoma of the nasal cavity: A case report. Romanian Journal of Rhinology, 2018, 8, 233-234.	0.1	0
1682	Plasmazellneoplasien. , 2019, , 177-193.		0
1683	A Case of Extramedullary Plasmacytoma of the Sigmoid Colon. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 2250-2256.	0.0	0
1684	A Case of Solitary Extramedullary Plasmacytoma of the Spleen. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 1234-1238.	0.0	0
1685	Atraumatic Splenic Rupture in Uncomplicated Multiple Myelomaâ€"A Case Reportâ€". Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 995-1000.	0.0	0
1686	A case of solitary plasmacytoma in the mandible transformed into multiple myeloma. Nihon Koku Geka Gakkai Zasshi, 2019, 65, 110-114.	0.0	1
1687	Telomere dynamics in adult hematological malignancies. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2019, 163, 1-7.	0.2	3
1688	Plasma cell leukemia - one in a million: A case report. World Journal of Clinical Oncology, 2019, 10, 161-165.	0.9	1
1690	Gastrointestinal bleeding as initial presentation of extramedullary plasma cell neoplasms: A case report and review of the literature. World Journal of Gastrointestinal Endoscopy, 2019, 11, 309-322.	0.4	1
1691	A Patient of Multiple Myeloma with Absent M-spike on Serum Protein Electrophoresis and Elevated Serum-Free Light Chains: A Case Report and Literature Review. Cureus, 2019, 11, e5398.	0.2	1
1692	TOTAL SURGICAL RESECTION OF SOLITARY BONE PLASMACYTOMA OF THE SPINAL COLUMN. Acta Medica Medianae, 2019, , 147-152.	0.0	0
1693	Monoclonal Gammopathy of Undetermined Significance. Encyclopedia of Pathology, 2020, , 352-356.	0.0	0
1694	Plasma Cell Myeloma. Encyclopedia of Pathology, 2020, , 404-414.	0.0	0
1696	A rare case of newly diagnosed multiple myeloma presenting to the emergency department with acute paraplegias. Journal of Surgery and Medicine, 0, , .	0.0	0
1697	Diseases of the Hematopoietic and Hemolymphatic Systems. , 2020, , 1151-1196.e11.		0
1698	Prevalence and prognostic value of monoclonal gammopathy in heart failure patients with preserved ejection fraction: A prospective study. Cardiology Journal, 2020, , .	0.5	1
1699	A Case of Anaplastic Plasmacytoma with Rapid Progression. Journal of Clinical Otolaryngology, 2020, 31, 83-87.	0.1	0
1700	Initial manifestation of parotid extraâ€'medullary myeloma in an HIV positive patient on antiâ€'retroviral therapy: A case report and review of the literature. Biomedical Reports, 2020, 13, 28.	0.9	0

#	Article	IF	Citations
1701	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. Journal of Clinical Medicine, 2021, 10, 5028.	1.0	1
1702	Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice via Decreasing Metabolic Ornithine. Frontiers in Oncology, 2021, 11, 779562.	1.3	3
1703	Pathogenesis of Diabetic Neuropathies. , 2020, , 25-46.		0
1704	Algorithm for the screening of Bence Jones proteinury in the laboratory. Revista De Medicina De Laboratorio, 2020, , .	0.0	0
1705	Plasma Cell Leukemia: A Case Report and Literature Review. Open Journal of Blood Diseases, 2020, 10, 71-76.	0.1	0
1706	Bone Tumour Pathology. , 2021, , 69-92.		0
1707	Cancer-testis antigen MAGE-C1/â€ŠCT7 in multiple myeloma: literature review. Oncogematologiya, 2020, 15, 29-37.	0.1	0
1708	Double-Hit Primary Plasma Cell Leukemia with IGH/MYC and IGH/CCND1 Translocations. Case Reports in Hematology, 2020, 2020, 1-5.	0.3	0
1709	HÃmatologische und onkologische Erkrankungen. , 2020, , 329-335.		0
1710	Using time to solve cause and effect dilemmas. , 2020, , 167-199.		0
1711	Identification of glutathione Sâ€‘transferase Ï€ 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling. Oncology Letters, 2020, 19, 2153-2162.	0.8	1
1712	Multiple myeloma with esophageal involvement: A rare case. DEN Open, 2022, 2, e71.	0.5	1
1713	99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma. Nuclear Medicine Communications, 2020, 41, 1081-1088.	0.5	9
1714	Monoklonale Gammopathien. , 2005, , 1148-1162.		0
1717	Concurrent Liver and Mesentery Primary Extraosseous Multiple Myeloma on 18F-FDG PET/CT. Clinical Nuclear Medicine, 2021, 46, e100-e102.	0.7	0
1718	Myeloma-Related Disorders in Cats Commonly Present as Extramedullary Neoplasms in Contrast to Myeloma in Human Patients: 24 Cases with Clinical Follow-up. Journal of Veterinary Internal Medicine, 2006, 20, 1376.	0.6	14
1719	Radiation response of softâ€tissue extramedullary plasmacytoma in multiple myelomaâ€”A case report. Clinical Case Reports (discontinued), 2021, 9, e05084.	0.2	1
1720	Successful treatment with rituximab for central nervous system vasculitis caused by Epstein-Barr virus-associated lymphoproliferative disorder with immunoglobulin M gammopathy. Encephalitis, 2022, 2, 14-18.	0.3	1

#	Article	IF	Citations
1721	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	2.8	8
1722	Diffusion-Weighted MRIâ€"The Way Forward for MRI in Myeloma?. Hemato, 2021, 2, 672-679.	0.2	0
1723	Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow. British Journal of Haematology, 2021, , .	1.2	1
1724	Prognostic Nomogram for Predicting Overall Survival of Solitary Bone Plasmacytoma Patients: A Large Population-Based Study. International Journal of General Medicine, 2021, Volume 14, 8621-8630.	0.8	2
1725	Approach to Neuropathic Pain. Seminars in Neurology, 2021, 41, 744-759.	0.5	0
1726	Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma. European Radiology, 2021, , 1.	2.3	8
1727	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	2.8	62
1728	Solitary bone plasmacytoma as posterior fossa cranial neoplasia, presentation of two clinical cases. , 2022, 13, 7.		1
1729	Outcomes of stem cell mobilization and engraftment in patients with multiple myeloma according to CD56 expression status. Transfusion and Apheresis Science, 2022, , 103351.	0.5	0
1730	Surgical Management of Multiple Myeloma and Plasmocytoma of the Spine. International Journal of Spine Research, 2020, , 054-059.	0.0	0
1731	Light chain amiloydosis: Clinical, laboratory characteristics and treatment approach. Medicinski Podmladak, 2021, 72, 40-44.	0.2	0
1732	Multiples Myelom: Die Therapie ist im Umbruch. , 0, , .		0
1733	Metabolic Volume Measurements in Multiple Myeloma. Metabolites, 2021, 11, 875.	1.3	4
1734	Monoclonal gammopathy in autoimmune diseases: Analysis and follow-up of 160 cases in a tertiary center in China. Clinical Immunology, 2022, 234, 108909.	1.4	0
1735	Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?. Hemato, 2022, 3, 63-81.	0.2	1
1736	The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials. Journal of Cancer Research and Clinical Oncology, 2022, 148, 897-911.	1.2	1
1737	Lucidin 3-methyl ether from Rubia philippinensis suppresses the proliferation of multiple myeloma cells through the promotion of Î²-catenin degradation. Phytomedicine, 2022, 99, 153971.	2.3	0
1738	Polyclonal hypergammaglobulinaemia: towards definition of a threshold. Postgraduate Medical Journal, 2022, , postgradmedj-2021-140591.	0.9	0

#	Article	IF	Citations
1739	Primary Plasma Cell Leukemia Re(de)fined. , 2022, 19, .		0
1740	Two Cases of Solitary (Extramedullary) Plasmacytoma of the Soft Tissue in the Nasal Cavity. Practica Otologica, 2022, 115, 289-294.	0.0	0
1741	The Dynamics of Nucleotide Variants in the Progression from Lowâ€“Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach. Cancers, 2022, 14, 1035.	1.7	0
1742	Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. Cells, 2022, 11, 752.	1.8	4
1743	Corneal Densitometry and In Vivo Confocal Microscopy in Patients with Monoclonal Gammopathyâ€”Analysis of 130 Eyes of 65 Subjects. Journal of Clinical Medicine, 2022, 11, 1848.	1.0	4
1744	Genomics of Plasma Cell Leukemia. Cancers, 2022, 14, 1594.	1.7	3
1745	Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting. Frontiers in Oncology, 2022, 12, 830922.	1.3	12
1746	Hidden in the Eyesâ€”Recurrence of Systemic Hemopathies Reportedly â€œIn Remissionâ€• Six Cases and Review of Literature. Medicina (Lithuania), 2022, 58, 456.	0.8	2
1747	A genetic risk score of alleles related to MGUS interacts with socioeconomic position in a population-based cohort. Scientific Reports, 2022, 12, 4409.	1.6	0
1748	Solitary Plasmacytoma: A Case Report. Journal of Mahatma Gandhi University of Medical Sciences and Technology, 2022, 6, 97-99.	0.0	0
1749	Solitary plasmacytoma of the bone presenting after dental extraction. Diagnostic Histopathology, 2022, , .	0.2	0
1750	Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells. Stem Cells International, 2022, 2022, 1-12.	1.2	3
1751	Multiâ€trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance. Hematological Oncology, 2022, 40, 409-416.	0.8	2
1752	Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. Hematology American Society of Hematology Education Program, 2021, 2021, 673-681.	0.9	7
1753	Risk Stratification and Treatment in Smoldering Multiple Myeloma. Cells, 2022, 11, 130.	1.8	3
1754	An update of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. CKJ: Clinical Kidney Journal, 2022, 15, 1041-1048.	1.4	6
1755	Learning to Detect Monoclonal Protein in Electrophoresis Images. , 2021, , .		4
1756	Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and multiple myeloma. , 0, , 155-183.		0

#	Article	IF	Citations
1761	Echocardiographyâ€defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients. Cancer Medicine, 2022, 11, 4182-4192.	1.3	3
1762	Comparing five diagnostic criteria for multiple myeloma: a retrospective study of 227 cases. Tumori, 2014, 100, 207-13.	0.6	2
1763	The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. Journal of Clinical Medicine, 2022, 11, 2513.	1.0	15
1764	Presence of bone marrow fibrosis in multiple myeloma may predict extramedullary disease. International Journal of Hematology, 2022, 116, 544-552.	0.7	4
1765	Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China. Cancer Epidemiology, 2022, 78, 102168.	0.8	4
1767	Extramedullary plasmacytoma: Tumor occurrence and therapeutic conceptsâ€"A followâ€up. Cancer Medicine, 2022, 11, 4743-4755.	1.3	16
1768	Lenalidomide-Dexamethasone vs. Observation in High-Risk Smoldering Myeloma after 12 Years of Median Follow-Up Time: A Randomized, Open-Label Study. SSRN Electronic Journal, 0, , .	0.4	0
1769	Wholeâ€body magnetic resonance imaging plus serological followâ€up for early identification of progression in smouldering myeloma patients to prevent development of endâ€organ damage. British Journal of Haematology, 2022, 199, 65-75.	1.2	8
1770	Prediction of Solitary Plasmacytoma of Bone in Elderly Patients: A Nomogram and a Risk Classification System for Overall Survival. BioMed Research International, 2022, 2022, 1-20.	0.9	0
1771	Imaging for Multiple Myeloma according to the Recent International Myelom Working Group Guidelines: Analysis of Image Acquisition Techniques and Response Evaluation in Whole-Body MRI according to MY-RADS. Journal of the Korean Society of Radiology, 0, 83, .	0.1	0
1772	Myelomatous Pleural Effusion: A Rare Occurrence in Multiple Myeloma. Cureus, 2022, , .	0.2	1
1773	Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. Leukemia and Lymphoma, 2022, 63, 2403-2412.	0.6	2
1774	18F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma. PET Clinics, 2022, 17, 415-430.	1.5	5
1775	Prevalence and risk factors of monoclonal gammopathy in patients with autoimmune inflammatory rheumatic disease: A systematic review and meta-analysis. Modern Rheumatology, 2023, 33, 792-802.	0.9	1
1776	Myeloma and Leukemia. , 2023, , 503-528.		0
1777	Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis. Skeletal Radiology, 2023, 52, 565-583.	1.2	5
1778	Bone Disease in Multiple Myeloma: Biologic and Clinical Implications. Cells, 2022, 11, 2308.	1.8	13
1779	Posttreatment Persistence of Monoclonal Protein on Immunofixation Electrophoresis but Absence on Serum Protein Electrophoresis in a Case of Solitary Bone Plasmacytoma. Journal of Laboratory Physicians, 0, , .	0.4	0

#	Article	IF	Citations
1780	Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan. EJHaem, 0, , .	0.4	0
1782	Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. European Journal of Cancer, 2022, 174, 243-250.	1.3	13
1783	Diagnostic Applications of Nuclear Medicine: Multiple Myeloma. , 2022, , 475-527.		0
1784	Population-Based Limits of Urine Creatinine Excretion. Kidney International Reports, 2022, 7, 2474-2483.	0.4	2
1785	A Case Report of Non-secretory Multiple Myeloma. Cureus, 2022, , .	0.2	1
1786	Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma. Blood Cancer Journal, 2022, 12, .	2.8	1
1787	Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients. Transfusion Medicine and Hemotherapy, 2023, 50, 39-50.	0.7	1
1788	Spurious laboratory results associated with immunoglobulin M gammopathy in a dog with multiple myeloma. Journal of Veterinary Internal Medicine, 0, , .	0.6	1
1789	Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients. Cancer Medicine, 0, , .	1.3	0
1790	Enrichment of serum IgG4 in MuSK myasthenia gravis patients. Journal of Neuroimmunology, 2022, 373, 577978.	1.1	5
1791	Extramedullary Multiple Myeloma: A Patient-Focused Review of the Pathogenesis of Bone Marrow Escape. World Journal of Oncology, 2022, 13, 311-319.	0.6	2
1792	Two cases of extramedullary plasmacytoma of the small intestine presenting with ileus: A case report. Medicine (United States), 2022, 101, e30842.	0.4	0
1794	Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis. Frontiers in Pharmacology, 0, 13, .	1.6	8
1795	Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation. World Journal of Clinical Cases, 0, 10, 11712-11725.	0.3	0
1796	Pleural plasmacytomas in a patient with multiple myeloma relapse. Respiratory Medicine Case Reports, 2022, 40, 101777.	0.2	2
1797	Multiple Myeloma: Personalised Medicine Based on Pathogenesis. European Medical Journal (Chelmsford, England), 0, , 78-89.	3.0	1
1798	Association of Pulmonary Hypertension and Monoclonal Gammopathy of Undetermined Significance. Advances in Hematology, 2022, 2022, 1-8.	0.6	0
1800	Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma. International Journal of Molecular Sciences, 2022, 23, 14765.	1.8	0

#	Article	IF	Citations
1801	Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study. Frontiers in Immunology, 0, 13, .	2.2	3
1802	Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment. GeroScience, 2023, 45, 727-746.	2.1	7
1803	CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14). Frontiers in Oncology, 0, 12, .	1.3	2
1805	The utility of chest ultrasound-guided fine-needle biopsy in the diagnosis of plasmacytoma. African Journal of Thoracic and Critical Care Medicine, 0, , 167-171.	0.3	1
1806	Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again. Hematology Reports, 2023, 15, 23-49.	0.3	1
1807	COMPLEX ANALYSIS OF THE ROLE OF CYTOKINE GENE POLYMORPHISMS AS PROGNOSTIC FACTOR OF THE RISK OF PLASMA CELL MYELOMA IN PERSONS SUFFERED AFTER THE CHORNOBYL NPP ACCIDENT. Problemy Radiatsiinoi Medytsyny Ta Radiobiolohii, 2022, 27, 374-384.	0.5	0
1808	Use of Clinical Decision Support to Improve the Laboratory Evaluation of Monoclonal Gammopathies. American Journal of Clinical Pathology, 2023, 159, 192-204.	0.4	1
1809	Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma. Cancers, 2023, 15, 430.	1.7	0
1810	Refractory adult-onset Stillâ€™s disease complicated with monoclonal gammopathy of undetermined significance: A case report. Medicine (United States), 2022, 101, e32107.	0.4	1
1811	Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. Blood Cancer Journal, 2023, 13, .	2.8	8
1812	Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice. International Journal of Hematology, 0, , .	0.7	1
1813	Clinical Application and Limitations of Myeloma Response Assessment and Diagnosis System (MY-RADS). Journal of the Korean Society of Radiology, 2023, 84, 51.	0.1	0
1814	Advances in skin-on-a-chip and skin tissue engineering. , 2023, , 123-166.		1
1815	GWAS-Identified Variants for Obesity Do Not Influence the Risk of Developing Multiple Myeloma: A Population-Based Study and Meta-Analysis. International Journal of Molecular Sciences, 2023, 24, 6029.	1.8	2
1816	Extramedullary plasmacytoma of the oral cavity metastasising to both kidneys in a dog. Veterinary Medicine and Science, 2023, 9, 1053-1061.	0.6	2
1818	Increased expression of <scp>CEP72</scp> predicts poor prognosis in multiple myeloma. International Journal of Laboratory Hematology, 0, , .	0.7	0
1819	Preliminary analysis of explainable machine learning methods for multiple myeloma chemotherapy treatment recognition. Evolutionary Intelligence, 2024, 17, 513-533.	2.3	1
1820	Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, e195-e212.	0.2	0

#	Article	IF	Citations
1821	Multiple Myeloma in a Young Adult with Renal Involvement. Clinical Case Reports (discontinued), 2023, 11, .	0.2	0
1822	Improved survival of patients with primary plasma cell leukemia with <scp>VRd</scp> or daratumumabâ€based quadruplets: A multicenter study by the Greek myeloma study group. American Journal of Hematology, 2023, 98, 730-738.	2.0	2
1823	Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study. Cytotherapy, 2023, 25, 773-781.	0.3	1
1824	SOME ASPECTS OF EPIDEMIOLOGY, PATHOGENESIS, DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA. Avicenna Bulletin, 2021, 23, 395-409.	0.0	0
1825	Unraveling the Role of Peroxisome Proliferator-Activated Receptor Î²/Î” (PPAR Î²/Î”) in Angiogenesis Associated with Multiple Myeloma. Cells, 2023, 12, 1011.	1.8	2
1826	The TT Genotype of the KIAA1524 rs2278911 Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma. Cells, 2023, 12, 1029.	1.8	1
1828	Evaluation of laboratory diagnostic tests for light-chain clonality and bone marrow findings in AL amyloidosis. Blood Research, 2023, 58, 71-76.	0.5	0
1829	An Unusual Presentation of Extramedullary Plasmacytoma in the Orbit in a Middle-Aged Woman. Indian Journal of Otolaryngology and Head and Neck Surgery, 0, , .	0.3	0
1830	Primary Plasma Cell Leukemia. , 2023, 1, .		0
1837	Treatment Strategies for Multiple Myeloma Treatment and the Role of High-Throughput Screening for Precision Cancer Therapy. Advances in Experimental Medicine and Biology, 2023, , .	0.8	0
1851	Stem Cell Transplant for Plasma Cell Dyscrasias. , 2023, , 365-395.		0
1869	Plasma Cell Myeloma/Multiple Myeloma. , 2023, , 87-114.		0
1872	Hematologic Cancers. , 2023, , 441-511.		0